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SUMMARY
Follow-up studies of patients with acute HCV infection indicate that up to 50% of them 
develop a chronic infection. Hypervariability of the putative envelope protein E2/NS1 
of HCV suggests that one mechanism by which the virus may persist in the host is by 
the generation of viral escape mutants. By this theory, a predominant population would 
evolve to which antibody is made which neutralises that viral population allowing the 
emergence of a new antigenically different predominant population. A characteristic 
clinical feature of HCV infection is the episodic fluctuating pattern of alanine 
transaminase (ALT) levels in which periods of elevated ALT levels are interspersed 
with periods of normal levels. The emergence of a new genetic variant may be 
expected to coincide with a period of liver dysfunction. Patients on long term renal 
dialysis are more likely to have elevated ALT levels than uninfected patients.
To characterise the emergence of genetic variants of the hypervariable region 
(HVR1) of the E2/NS1 protein and correlate their appearance with periods of liver 
dysfunction, a retrospective study of the HVR1 amplified from multiple serum samples 
taken over several years from three renal dialysis patients was performed. A total of 36 
serum samples serially obtained from three patients with chronic hepatitis C were 
studied. HCV RNA was extracted from patient serum and the E2/NS1 HVR1 was 
amplified by reverse transcription and nested polymerase chain reaction. The amplified 
cDNA was analysed by direct chain termination nucleotide sequencing using the 
Sanger technique. The data indicate nucleotide sequence variation of HVR1 over time 
in each of the three renal dialysis patients but the emergence of a new sequence variant 
could not be linked with to a specific peak in ALT level. However, persistently raised 
ALT levels did appear to be associated with increased rate of change of the HVR1.
The second study presented in this thesis was undertaken to investigate the 
effect serum storage conditions had on the stability of HCV RNA and its detection by 
RT-PCR. Serum taken from a chronically infected patient was stored at 4°C for 14,
17, 19, 25 and 27 weeks and subjected to 1, 3, 5, 7 and 10 successive freeze-thaw 
cycles (-20°C to room temperature). To estimate the titre of HCV RNA, serial 10-fold 
dilutions of the serum were performed and HCV RNA extracted. PCR products were 
detected by agarose gel electrophoresis. Repeated freeze-thawing of serum or storage 
at 4°C did not result in a substantial reduction in HCV RNA levels detectable by RT- 
PCR compared to continuous storage at -20°C, indicating that HCV RNA present in 
serum is relatively resistant to degradation.
To allow quantitative PCR to be performed and to assess the relationship 
between serum HCV RNA levels and the emergence of new genetic variants, an 
attempt was made to synthesis control HCV RNA transcripts. PCR products amplified 
from the 5'NCR and core region of HCV were used as template to introduce a unique 
28 nucleotide scramble sequence using PCR. Primers were designed with a unique 
sequence of bases towards the 5' end of each primer. Within the unique sequence an 
EcoRl restriction enzyme site was incorporated. The first 10 bases of the unique 
sequence of the sense primer (Econl 1) was complementary to the first 10 bases of the 
antisense primer (Econl2). This allowed the cDNA amplified with Econl 1 and Econl2 
to anneal together during amplification, resulting in a PCR product incorporating the 
unique sequence of bases. Unfortunately the final PCR product was contaminated with 
native HCV and was not cut when an EcoRl digest was performed. The result of this 
was that control RNA transcripts were not synthesised and so quantitative PCR could 
not be performed. To overcome this the Econl 1/Econ 12 PCR product would need to 
be cloned into a plasmid containing a T7 promoter sequence and the resultant cDNA 
clones screened for those that contained the unique sequence of bases. Internal control 
HCV RNA could then be transcribed.
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Chapter 1 Introduction
1.1 Hepatitis Viruses: Description and classification
Viral hepatitis is caused by at least five distinct viruses. Hepatitis A virus (HAV) and 
hepatitis E virus (HEV) transmission is by the faecal-oral route and both viruses cause 
acute self-limiting hepatitis. The main route of hepatitis B virus (HBV) transmission is 
by sexual contact or from mother to child. The principal route of transmission for 
hepatitis C virus (HCV) and hepatitis D virus (HDV) is through exposure to 
contaminated blood or blood products. Unlike HAV or HEV, both HBV and HCV are 
associated with chronic liver disease. HCV in particular has a high rate of chronicity. 
Infection with several other viruses, for example cytomegalovirus and Epstein-Barr 
virus can also cause hepatitis (Haldor & Margolis, 1991).
Hepatitis A virus: HAV is the only hepatitis causing virus to have been isolated and 
propagated in cell culture (Purcell, 1994). The hepatitis A virion is a spherical particle, 
consisting of a single stranded positive sense RNA genome approximately 7.5kb long 
which is surrounded by a protein capsid comprising three proteins, VP1, VP2 and 
VP3. The HAV capsid is thought to have icosahedral symmetry. HAV is an enveloped 
virus. The genomic organisation of HAV is similar to viruses belonging to the 
Picomaviridae family of naked positive sense RNA viruses. Initially HAV was 
classified in the genus enterovirus, which includes the polio- and Coxsackieviruses, 
viruses within this genus preferentially inhabit the intestinal tract of the host. HAV has 
now been classified into a separate genus within the Picomaviridae family termed 
hepatovirus. HAV is very distinct in sequence from other entero viruses and has 
unique features, including hepatocyte cell tropism, possibly absence of VP4 protein 
and thermostability (reviewed by Lemon, 1994).
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Hepatitis B virus: HBV is an enveloped virus containing a circular partially double 
stranded DNA genome, approximately 3.2kb long. Unlike many other envelope 
viruses, no knobs or spikes have been observed in the HBV envelope (reviewed by 
Gerlich, 1993). HBV belongs to the family Hepadnaviridae, genus orthohepadnavirus. 
Other viruses included in this family are woodchuck hepatitis virus and ground squirrel 
hepatitis virus (Purcell, 1994). All viruses within this family exhibit narrow host 
ranges, hepatocyte tropism and an ability to cause persistent infection within the host.
Hepatitis C virus: The genome of HCV like that of HAV is a single stranded 
positive sense RNA virus, approximately 9.5kb long (Choo et al., 1991) but unlike 
HAV, HCV is an enveloped virus (Bradley et al., 1985). HCV displays sequence 
homology with pesti- and flaviviruses, small enveloped, single stranded positive sense 
RNA viruses, known to cause disease among animals (Miller & Purcell, 1990; Choo et 
al., 1991). Miller and Purcell also demonstrated that HCV displays sequence 
homology with carmo- and potyviruses, a group of plant viruses. Positive stranded 
RNA viruses have been classified into 3 supergroups based upon analysis of their 
RNA dependent RNA polymerases (Koonin, 1991). HCV was classified into 
supergroup II with pestiviruses and carmoviruses but not with flaviviruses. Therefore, 
HCV has been classified into a separate as yet un-named genus within the family 
Flaviviridae. Evidence to support the classification of HCV as a member of the family 
Flaviviridae is discussed in detail later in this thesis.
Hepatitis D virus: HDV is only found in individuals with ongoing HBV infection. 
HDV is dependent on the presence of HBV for transmission and infection because it 
uses the hepatitis B surface antigen as its virion coat. HDV contains a small circular 
single stranded RNA genome, approximately 1700 nucleotides (nts). No decision has 
yet been reached to the taxonomic status of HDV. Initially HDV was classified as a 
member of the family Hepadnaviridae since it was only found when HBV was present. 
However HDV resembles viroids and plant satellite RNAs, in that the RNA genome is
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circular, displays a high degree of intramolecular base pairing and has a similar mode 
of replication.
Hepatitis E virus: HEV is a spherical, non-enveloped virus containing a single­
stranded, positive sense RNA genome, approximately 7.5kb. Like HDV, HEV is at 
present unclassified. It's genomic organisation resembles that of caliciviruses (Purcell, 
1994), naked RNA viruses associated with respiratory and gastrointestinal infections 
in animals.
Despite diagnostic tests for the detection of known hepatitis viruses being 
available, the etiology of a proportion of post-transfusion (PT) and community- 
acquired hepatitis cases remain unexplained. Deka et al. (1994) reported the isolation 
of virus particles from human stool samples from patients suffering from sporadic 
NANBH. This virus has been provisionally designated hepatitis F virus (HFV). The 
genome of HFV, whose entire sequence is still to be determined, was found to be 
20kb in size. The clinical importance of this virus is not yet known. In addition to the 
discovery of HFV, hepatitis G virus (HGV) a transfusion-transmissible agent isolated 
from the plasma of a patient with chronic PT hepatitis has also been reported. HGV is 
an RNA virus approximately 9.4kb long (Linnen et al., 1996). The frequency with 
which HGV-RNA has been found in the population is similar to that of HCV. HGV is 
frequently found in coinfection with HBV and/or HCV.
Recent work by Simon et al. (1995) has shown the existence of two flavivirus- 
like genomes in plasma from a tamarin infected with the GB hepatitis agent (obtained 
from the serum of a 34 year old surgeon with acute hepatitis). The GB inoculum 
consists of two viruses, GB virus A (GBV-A) and GB virus B (GBV-B). The GBV-B 
agent is thought to have originated from tamarins since it replicates in the liver of these 
animals. GBV-A does not replicate in liver, but is found in lymphoid tissue (Muerhoff 
e ta i, 1995). A third virus, GBV-C, has been isolated from a human specimen. GBV- 
C has been shown to have sequence similarity to GBV-A. Analysis of the genomes of
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GBV-A, B, and C with that of HCV showed the three GB viruses were not genotypes 
of HCV (Schlauder et al., 1995). To assess the clinical relevance of the GB-viruses 
and HGV it will be necessarily to undertake comprehensive studies to investigate their 
prevalence in blood donors and blood recipients, their worldwide distribution, their 
assocition with liver diseases.
1.2 Non-A, non-B hepatitis: Identification of hepatitis C 
virus
1 . 2 .1  Early studies
The discovery in the mid-1960’s of the hepatitis B surface antigen (HBsAg) led to the 
development of diagnostic tests with which to identify infection with HBV. HBV was 
the major cause of post-transfusion (PT) hepatitis prior to the introduction of screening 
for HBsAg. Despite the screening of blood donations for HBsAg, transfusion- 
associated hepatitis persisted. The development of diagnostic tests for HAV in the early 
1970’s indicated that the majority of PT hepatitis cases cases (a major world-wide 
health problem) were not the result of infection by HAV, HBV or by any other known 
hepatotropic viruses. Prince et al. (1974) therefore postulated the existence of another 
agent(s) responsible for PT-hepatitis. They studied 204 patients who had undergone 
cardiovascular surgery, in thirty-six of the fifty-one (71%) patients who developed PT- 
hepatitis there was no evidence of the HBV antigen (HBsAg) or anti-HBsAg. The 
possibility of HAV being responsible was excluded on the basis of the long incubation 
period. CMV was excluded because of equal exposure in those who did not contract 
hepatitis. Similar findings in studies conducted by Alter et al. (1975) and Feinstone et 
al. (1975) supported the existence of a new agent(s) as the cause of PT-hepatitis, this 
agent was termed non-A, non-B hepatitis (NANBH) virus.
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1 . 2 . 2  Transmission studies in chimpanzees
In 1978 two separate studies reported the transmission of the NANBH agent to 
chimpanzees (Alter et al., 1978; Tabor et al., 1978). In that by Alter et al., five 
chimpanzees were inoculated with plasma or serum obtained from patients with acute 
or chronic NANBH or from a blood donor implicated in two cases of NANBH. All 
five chimpanzees developed hepatitis based upon biochemical and histological 
evidence. No evidence of HAV or HBV infection was found in any of them, 
suggesting hepatitis was transmitted by the plasma or serum derived from both acute 
and chronic NANBH patients. In a similar study by Tabor et a l (1978), four 
chimpanzees were inoculated with serum obtained from a chronic NANBH patient or 
from two blood donors whose blood appeared to transmit hepatitis, all four 
chimpanzees developed hepatitis. Both studies demonstrated that the agent responsible 
for PT-NANBH was transmissible and that a chronic carrier state existed. Further 
evidence that the agent responsible for PT-NANBH was transmissible came from 
Bradley et al. (1979), who demonstrated that chimpanzees inoculated with a Factor 
VDI concentrate, implicated in the transmission of NANBH to human recipients, 
developed hepatitis.
The chimpanzee model for NANBH proved invaluable in the absence of specific 
serological assays for the agent responsible. Early cross-challenge and electron 
microscopic studies described the existence of more than one agent responsible for 
NANBH (Bradley etal., 1980; Hollinger et al., 1980). Chimpanzees were inoculated 
with either serum, plasma or Factor XIII concentrates implicated in cases of NANBH, 
after recovery from an episode of hepatitis the chimpanzees were re-challenged with a 
different inoculum and another episode of hepatitis developed. It is possible that the 
second episode of hepatitis was due to recurrence of infection from the first inoculum 
and not as a result of the second since a chronic carrier state existed for the agent(s) 
responsible for NANBH (Alter et al., 1978; Tabor et al., 1978). Bradley et al. (1980), 
in contrast to Shimizu et a l (1979), did not observe nuclear changes in hepatocytes
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from infected chimpanzee livers in the acute phase of infection but did note the 
presence of cytoplasmic tubules. Shimizu et a l (1979) reported two different types of 
ultrastructural changes in infected hepatocytes. Chimpanzees were inoculated with 
plasma obtained from a patient with chronic NANBH (strain F) and from a patient with 
acute NANBH (strain H). Membranous tubular structures were seen in the cytoplasm 
of hepatocytes of chimpanzees infected with strain F, whereas strain H infected 
hepatocytes showed 20-27nm intranuclear particles. These ultrastructural changes were 
originally thought to represent two distinct NANBH agents, subsequent studies 
however have identified nuclear and cytoplasmic changes at the same time in 
experimentally infected chimpanzees (reviewed by Farci & Purcell, 1993). Neither 
HAV or HBV infected hepatocytes displayed such ultrastructural changes, although 
cytoplasmic tubular structures analogous to those observed in NANBH have been 
observed in chimpanzees infected with HDV, in the cytoplasm of mosquito cells 
infected with the flavivirus St. Louis encephalitis and in lymphocytes of patients with 
acquired immune deficiency disease, suggesting these ultrastructural changes are not 
exclusive to NANBH. The feature common to all viruses which cause such 
ultrastructural changes is an RNA genome (reviewed Bradley, 1990).
1 .2 .3  Cloning of non-A, non-B hepatitis infectious agent
In 1982, workers at the Chiron Corporation initiated attempts to clone the NANBH 
genome from infected chimpanzees, reporting the results of this work in 1989 (Choo et 
al., 1989), they believed that the concentration of NANBH-specific nucleic acid in 
samples from infectious chimpanzees was below the limit detectable by existing 
techniques. In order to obtain infectious material with a high enough titre they pooled 
plasmapheresis samples from a chronically infected chimpanzee obtaining a preparation 
estimated to contain approximately 106 chimpanzee infectious doses per ml (CID/ml). 
The plasma was centrifuged until a pellet was obtained which would include even the 
smallest infectious agent. Total nucleic acid was extracted from the pellet, since it was
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not known if the genome was RNA or DNA the extracted nucleic acid was denatured 
resulting in single stranded nucleic acid, cDNA was synthesised using random 
primers, cloned into the bacteriophage vector A,gtl 1 and expressed in Escherichia coli. 
The cDNA library was screened with serum from a chronic NANBH patient and a 
single positive clone, 5-1-1, was identified from a total of about 106 clones.
To investigate the origin of clone 5-1-1, a larger overlapping clone, clone 81, 
was isolated from the same cDNA library using clone 5-1-1 as a hybridisation probe. 
Clone 81 did not hybridise to control human DNA or DNA derived from NANBH 
infected chimpanzees in Southern blot analysis, it did however hybridise to RNA 
extracted from the liver tissue of an NANBH infected chimpanzee, but not to RNA 
derived from an uninfected control. This suggested that a RNA molecule was 
associated with NANBH. Further evidence to support this hypothesis came as a result 
of the observation that the hybridisation signal of total nucleic acid extracted from the 
pellet fraction of NANBH infected chimpanzee ultracentrifuged plasma to clone 81 was 
lost following treatment with ribonuclease but not deoxyribonuclease. Clones 5-1-1 
and 81 therefore appeared to be derived from the RNA genome of a blood-borne virus 
associated with NANBH infection. Further analysis showed it to be a positive single 
stranded RNA genome, approximately lOkb. The virus responsible for NANBH was 
termed hepatitis C virus (Choo et al., 1989, 1991; Kato et al., 1990; Takamizawa et 
al., 1991).
The cloning of the NANBH agent, HCV, subsequently led to the development of 
an assay for HCV antibody detection (Kuo et al., 1989). Using the original HCV 
clone 5-1-1 as a hybridization probe to the original cDNA library (Choo et al., 1989), 
three overlapping clones, 81, 36 and 32, were isolated. Clones 5-1-1, 81, 36 and 32 
were ligated together to re-construct part of the ORF, producing the clone C l00 located 
in the NS4 region of the genome. C l00 was expressed in recombinant yeast as a 
fusion polypeptide with the human gene encoding human superoxide dismutase 
(SOD), the resultant fusion polypeptide C 100-3 was used to coat the wells of a micro­
ti tre plate to capture circulating HCV antibodies in serum or plasma samples.
7
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1 . 2 . 4  Biophysical properties of HCV
The results from cross-challenge experiments in chimpanzees suggested the possibility 
of two agents being responsible for NANBH. Chimpanzee infectivity studies 
conducted by Bradley et al. (1983) demonstrated the existence of chloroform sensitive 
and chloroform resistant NANBH agents. The NANBH agent associated with the 
formation of the cytoplasmic tubules in infected hepatocytes was sensitive to 
chloroform resulting in loss of infectivity in chimpanzees, this suggested the tubule 
forming agent (TFA) contained a lipid structure (virus envelope). Microfiltration 
studies demonstrated the tubule forming, chloroform sensitive agent to have a diameter 
of <80nm. Plasma from a chronically infected chimpanzee was diluted, pelleted and 
resuspended in buffer before being sequentially passed through 450-, 200- and 80nm 
polycarbonate (capillary pore) membrane filters, the resultant filtrate was inoculated 
into a chimpanzee, which subsequently developed hepatitis demonstrating the TFA had 
a diameter of <80nm (Bradley et al., 1985). The agent was also recovered from 
infected plasma by the use of a method commonly used for the purification of small, 
enveloped RNA viruses (Bradley et al., 1983, 1985). Subsequent studies, one using 
PCR to detect the virus in the filtrate suggested the diameter was between 30-38nm 
(He etal., 1987; Yuasa et al., 1991). The existence of a chloroform resistant agent is 
still to be confirmed.
Very little is known about the morphology of the HCV virion. Electron 
microscopy studies suggest the HCV virion it is a spherical particle, 55 to 65nm in 
diameter, with spike-like projections 6 nm in length (Kaito et al., 1994), similar to 
flaviviruses virions. In agreement with these findings are those of Shimizu et al. 
(1996). Using liver tissue from HCV infected chimpanzees and human B-cell and T- 
cell lines which supported HCV replication they performed electon microscopy studies 
and detected virion-like particles, approximately 50nm in diameter, within cytoplasmic 
vesicles. Such particles were not detected in uninfected cells. Putative viral core
Chapter 1
particles 30 to 35nm in diameter and icoshedral in shape have also been identified in 
human plasma (Takahashi etai., 1992a).
Several investigators have determined the buoyant density of HCV virions by 
gradient ultracentrifugation, followed by testing of gradient fractions for infectivity or 
the presence of HCV core antigen or RNA. The density of HCV was first investigated 
by Bradley et al. (1991), and estimated to be between 1.09 and l.llg /m l. Buoyant 
density was determined by inoculating various dilutions of sucrose density gradient 
fractions into chimpanzees and monitoring them for the development of hepatitis. 
Subsequent work has used PCR to demonstrate the presence of HCV RNA in gradient 
fractions, indicating the density to be 1.08g/ml in sucrose, similar to the density of 
pestiviruses (1.09 to 1.16g/ml) rather than flaviviruses (1.19 to 1.20g/ml) (Miyamoto 
et al., 1992). Following treatment with detergents the density increased to 1.25g/ml, 
corresponding to putative viral core particles. Takahaski et al. (1992a, 1992b) 
indicated HCV had a density of l.llg /m l and the putative viral core particles 
1.115g/ml in potassium bromide. The observed difference in density between these 
two groups is probably due to the composition and ionic strength of the gradient 
material used. The density, however, can be affected by the interaction between HCV 
virions and serum p-lipoprotein or immunoglobulins, varying between 1.03 and 
1.20g/ml. (Thomssen et al., 1992; Sato et al., 1993; Hijikata, Minako et al., 1993). 
Complexes of virus and antibody present in the high density fraction (1.17g/ml) were 
associated with low infectivity (taken during chronic phase of infection). In contrast 
such complexes were not found in serum samples with high infectivity (taken during 
acute phase of infection), when the virions were present in the low density fraction 
(Hijikata, Minako e ta i,  1993). HCV virions, banding at a low density were found to 
coprecipitate with p-lipoprotein and those banding at a high density to coprecipitate 
with IgG (Thomssen et al., 1992, 1993). It is unclear why HCV binds to p- 
lipoprotein, Thomssen et al. have suggested p-lipoprotein may mask antibody binding 
sites preventing the binding of neutralising antibodies, resulting in a persistent HCV 
infection or alternatively it may act as a ligand allowing HCV to infect host cells.
9
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Mehdi et al. (1994, 1996) have shown in the case of HBV that recombinant HBsAg 
binds to a 46kDa protein associated with liver plasma membrane, plasma and 
lipoproteins. They have identified this protein as apolipoprotein H (apoH), a serum 
protein often associated with chylomicrons and high density lipoproteins (HDL). Both 
these lipoproteins are targeted to hepatocytes during normal lipid processing. Medhi et 
al. have proposed that a possible mechanism by which HBV can enter hepatocytes is 
via a lipoprotein-bound apoH. HBV binds to apoH on the surface of these lipoproteins 
via it’s surface antigen, and is then taken into hepatocytes along with the lipoproteins, 
via lipoprotein receptors expressed on hepatocytes.
1.3 Viral replication
Evidence from chimpanzee studies suggests viral replication is an early event in HCV 
infection (Shimizu et al., 1990; Negro et al., 1992). The site of replication was found 
to be the cytoplasm of infected hepatocytes. In the study by Shimizu et al., blood and 
liver biopsy samples were obtained from two chimpanzees inoculated with HCV. Sera 
were examined by RT-PCR and HCV RNA was detected as early as three days post­
inoculation after a period during which no HCV-RNA was detected. Cytoplasmic 
antigen and ultrastructural changes (appearance of tubule structures) were detected in 
hepatocytes 3 and 6  days respectively, after HCV RNA was first detected in the serum. 
Circulating anti-HCV appeared between 3 to 33 weeks post-inoculation. The data from 
this study indicate a very early replicative phase for HCV and, potentially, a long 
period of infectivity before the appearance of anti-HCV. The results of this study were 
confirmed by that of Negro et al., who used an in situ hybridization assay to detect 
HCV RNA in hepatocytes. Examination of liver biopsy samples taken from two HCV 
infected chimpanzees showed the presence of HCV RNA 2 days after both 
chimpanzees were inoculated with the virus. Because no suitable in vitro cell culture
10
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system for HCV exists very little is known about the replication cycle of HCV. HCV 
has been cultured with limited success in human T-cell lines (Shimizu et al., 1992).
1.4 Hepatitis C virus: Structure, viral proteins and 
processing of the polyprotein
1.4.1 Genome organisation
HCV contains a positive stranded RNA genome of approximately 9400 nucleotides. 
A large ORF, spanning almost the entire length of the HCV RNA genome, encodes a 
precursor viral polyprotein of 3010 to 3030 amino acids which is flanked at the 5' and 
3' termini by untranslated regions (UTR) (Choo et al., 1989; Choo et al., 1991; 
Takamizawa et al., 1991; Okamoto & Mishiro, 1994a). Comparison of the 
hydrophobicity profiles of the encoded polyproteins of HCV, the flavivirus yellow 
fever virus (YFV) and the pestivirus bovine viral diarrhoea virus (BVDV) suggest 
HCV has a similar genetic organisation to flavi- and pestiviruses (Choo et al., 1991; 
reviewed by Moennig & Plagemann, 1992; reviewed Rice & Strauss, 1990). A 
schematic representation of the genome organisation of HCV is shown in Figure 1.1. 
The HCV precursor viral polyprotein, like that of flavi- and pestiviruses, is 
proteolytically processed to yield both structural and non-structural (NS) proteins. The 
putative structural proteins (core, El and E2/NS1) are located at the 5' terminus of the 
polyprotein, with the remainder of the polyprotein consisting of the non-structural 
proteins (NS2, NS3, NS4a, NS4b, NS5a and NS5b).
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1 . 4 . 2  Classification of HCV as a member of the flaviviridae family
Sequence comparisons between HCV and other known viruses reveals little overall 
homology with any known viral sequence, however, the size of the precursor 
polyprotein of HCV is similar to that of flavi- and pestiviruses. Three regions of the 
HCV polyprotein were found to share amino acid homology with members of the 
flavi virus, pesti virus and plant poty virus genera (Miller & Purcell, 1990). The first 
region of homology, is between amino acids 1230 and 1500 (HCV-1 isolate) and the 
helicase (NS3) domain of plant poty viruses, flavi- and pesti viruses suggesting this 
region of the HCV polyprotein encodes a helicase enzyme. The second region of 
homology lies upstream of the putative helicase region, sharing sequence similarities 
with the putative trypsin-like proteases thought to be encoded by flavi- and 
pestiviruses. The third, existed between amino acids 2703 and 2739, contains the 
amino acid motif Gly-Asp-Asp conserved among all RNA-dependent-RNA 
polymerases of positive stranded RNA viruses (Miller & Purcell, 1990; Choo et al., 
1991; Takamizawa et al., 1991). The similarities displayed between HCV, flavi- and 
pestiviruses has led to its current classification as a separate genus within the family 
Flaviviridae. (Choo etai., 1991; Han eta i, 1991; Takamizawa e ta i,  1991).
1.4.3 The 5'and 3' untranslated regions
Sequence analysis has revealed the 5'UTR is highly conserved among HCV isolates 
(Bukh et al., 1992). This suggests a possible functional role for this region in viral 
replication or gene translation (Han et al., 1991; Houghton et al., 1991; Bukh et al.,
1992). The 5'UTR comprises 341 nts or less, depending on the origin of the HCV 
isolate (Okamoto & Mishiro, 1994a). The precise 5' terminus is difficult to define. The 
5'UTR of HCV appears to resemble that of pestiviruses (45-49% homology) rather 
than that of flaviviruses (Han et al., 1991; Houghton et al., 1991; Bukh et al., 1992). 
The 5'UTR of flaviviruses is shorter (95 to 132nts) and lacks the small ORFs found in
12
Chapter 1
both HCV and pestiviruses upstream of the initiator AUG codon (Han et al., 1991). 
The HCV 5'UTR contains up to five small ORFs, that can encode polypeptides of 
between 12 to 28 amino acids. Different isolates of HCV display different patterns of 
these small ORFs (Bukh et al., 1992). It is not known if there is a cap structure at the 
5' terminus of the genomic RNA.
Experimental evidence indicates the existence of an internal ribosome entry site 
(IRES) within the 5'UTR proximal to the initiator AUG codon. (Tsukiyama-Kohara et 
al., 1992; Wang et al., 1993). Initiation of translation seems to occur in a cap- 
independent manner similar to that observed in picornaviruses. Picornavirus genomic 
RNAs are uncapped and have long 5'UTR (more than 600nts.) which contain silent 
AUG s. Tsukiyama-Kohara et al. (1992) presented evidence that an IRES element 
existed between nucleotides 101 and 332 (HCV-lb isolate). Work by Reynolds et al. 
(1994) however, has mapped the 5' end of the IRES to be between nucleotides 42 and 
71 and the 3' end to nucleotides 354 and 372; thus extending into the coding region 
(starts at nucleotide 341) suggesting the involvement of the initial coding sequence of 
the genome in the function of the IRES. The secondary structures of the 5'UTR of 
HCV, the pestiviruses BVDV and hog cholera virus (HoChV) have been determined 
based upon thermodynamic, phylogenetic and biochemical considerations (Brown et 
al., 1992). The proposed secondary structure of the 5'UTR of HCV is shown in 
Figure 1.2. The 5'UTR shares a large stem-loop structure (domain III) similar to that 
seen in the 5'UTR of pestiviruses. This conserved stem-loop structure is located 
between nucleotides 125 to 323, within the region identified by Tsukyama-Kohara et 
al. (1992) as containing the IRES. A common feature of the IRES of picornaviruses is 
the presence of pyrimidine-rich tracts. Within these tracts short conserved regions 
complementary to 18S ribosomal RNA have been identified. A similar region is found 
within the apical loop of domain III of the HCV 5'UTR (Figure 1.2) but mutational 
analysis has shown this region to be dispensable for IRES function (Wang et al.,
1994). Mutational analysis has also revealed that the primary sequence of the 
pyrimidine-rich tract (nts 120 to 130) (Figure 1.2) is not important but that the helical
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double-stranded specific Rnase. The shaded nucleotides represent the pyrimidine- 
rich tract within the apical loop of domain III which is complementary to 18S 
ribosomal RNA. Domain in  is thought to be essential for internal ribosomal entry. 
Reproduced by permission of Oxford University Press.
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structural element associated with this region is essential for HCV IRES function 
(Wang etai., 1994), this suggests the folding of the 5'UTR is critical for the function 
of the IRES. Based upon current knowledge, it seems likely that initiation of 
translation of the HCV genome occurs in a cap-independent manner via the IRES 
present within the 5'UTR before the initiator AUG codon. Recently, it has been 
suggested that translation initiation of the pestivirus BVDV occurs via an IRES 
contained in the 5'NCR (Poole et al., 1995).
A short untranslated region is located downstream of the stop codon terminating 
translation of the ORF encoding the precursor viral polyprotein. The 3'UTR is variable 
among HCV isolates both in length and in sequence (Okamoto & Mishiro, 1994a). All 
HCV isolates except HCV-1 possess a poly(rU) tail which follows the 3'UTR. Isolate 
HCV-1 is followed by a poly(rA) tail (Han et al., 1991). Recently Tanaka et al. (1996) 
and Kolykhalov et al. (1996) have both described a novel 98 nucleotide sequence 
downstream from the poly(U) stretch in the HCV genome which appears to represent 
the authentic 3’ terminus. This sequence has been shown to be present in several HCV 
isolates and appears to be highly conserved amongst the isolates examined thus far. 
Using computer modeling programs, the 46 bases at the 3’ terminus are predicted to 
form a conserved stem-loop structure. For other positive strand RNA viruses, 
conserved 3’ terminal sequences or structures play a role in intiation of viral replication 
and in packaging of viral RNAs. This suggests that the HCV 3’UTR may play an 
critical role in initiation of viral replication.
1.4.4 HCV structural proteins
The structural proteins of HCV like those of the related flavi- and pestiviruses appear 
to be processed from the amino terminal of the HCV encoded precursor polyprotein 
(Figure 1.1). The putative structural proteins have been expressed both in vitro and in 
vivo, (in cell culture systems) (Takeuchi e ta i,  1990b; Harada et al., 1991; Hijikata et
14
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al., 1991a; Matsuuraetai., 1992; Spaete etai., 1992; Grakoui etai., 1993a; Ralston et 
al., 1993). Three structural proteins have been identified, core, El and E2/NS1.
Core: The first 191 amino acids of the precursor polyprotein are relatively well 
conserved among HCV isolates. Analogy of the HCV polyprotein with flavi- and 
pestiviruses suggests this region encodes the core protein which is probably the 
nucleocapsid component of the HCV virion. This region encodes a 21-22 kilodalton 
(KDa) protein, which lacks N-glycosylation sites and is highly basic (Takeuchi et al., 
1990b; Harada et al., 1991; Hijikata et al., 1991a; Grakoui et al., 1993a). The core 
protein has been observed in the cytoplasm and nucleus of infected cells (Harada et al., 
1991; Matsuura et al., 1992; Lanford et al., 1993). The core protein observed in the 
nucleus of the cell lacked the (20aa) hydrophobic domain present at the C-terminal end 
and was not expressed with El, unlike the core protein observed in the cell cytoplasm. 
Nuclear localisation of core protein has also been reported for flaviviruses. Initially the 
core protein of flaviviruses is produced in a membrane associated form, subsequent 
cleavage of the C-terminal hydrophobic domain converts it to mature core protein 
(Nowak et al., 1989). Thus, the core protein of HCV may be subject to further 
processing events with the C-terminal hydrophobic domain acting as the signal 
sequence required for cleavage by host cell signal peptidases (Takeuchi et al., 1990b). 
Experimental data shows that the core protein binds to ribosomes in vitro and appears 
to have RNA binding activity with the RNA binding domain residing between amino 
acids 1 to 75 in the highly basic N-terminal region of the protein (Santolini et al.,
1994). Antibody against the HCV core protein is found with high frequency in HCV 
infected patients and appears early in infection, but is does not appear to be neutralising 
(Harada etai., 1991).
Envelope proteins: Two putative envelope proteins are located downstream from 
the core protein (Figure 1.1). The El gene comprises 192 amino acids and encodes a 
31-35 kDa protein (gp35) which has 5 or 6  potential glycosylation sites (Hijikata et
15
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al., 1991a; Grakoui et al., 1993a; Ralston et al., 1993). Deglycosylation of the El 
protein results in a size shift of the protein from 35kDa to 21 kDa (Hijikata et al., 
1991a). Antibodies to gp35 are detected in patient sera suggesting that this protein is 
synthesised during infection (Matsuura et al., 1992). The HCV gp35 appears to be 
equivalent to the envelope proteins of flavi- and pestiviruses.
The E2/NS1 gene encodes a 68-72kDa protein (Hijikata et al., 1991a; Grakoui et 
al., 1993a; Ralston etai., 1993). This protein may represent a second envelope protein 
equivalent to the gp53/gp55 of the pestiviruses or represent the first non-structural 
protein equivalent to the flavivirus NS1 protein (Houghton et al., 1991). Comparative 
sequence analyses suggest that the E2/NS1 gene is more closely related to pestiviruses 
rather than flaviviruses (Miller & Purcell, 1990; Choo et al., 1991). The E2/NS1 is a 
glycosylated protein (11 potential glycosylation sites). Half of the mass of this protein 
is due to the mannose sugar residues, deglycosylation results in a 38kDa protein 
(Hijikata etai., 1991a; Spaeteetal., 1992). A hypervariable region (HVR) is found in 
the N-terminus of the E2/NS1 protein (Weiner et al., 1991). This region lacks 
conserved secondary structure and resembles the V3 loop of human immunodeficiency 
virus (HIV). This region of HCV will be discussed in detail later in this thesis.
In transfected mammalian cells both the El and E2/NS1 proteins are cell 
associated remaining anchored to the lumen of the endoplasmic reticulum (ER), unlike 
the flavivirus NS1 protein which is secreted. Removal of the C-terminal hydrophobic 
anchor region of E2/NS1 results in secretion of the protein into the medium (Spaete et 
al., 1992; Ralston et al., 1993). Amino acids 715 to 730 appear to serve as the 
membrane anchor (Selby etai., 1994). For reasons of simplicity E2/NS1 will now be 
referred to as E2.
The expression of El and E2 appear to be associated. Monoclonal antibodies to 
either El or E2 are capable of immunoprecipitating both El and E2, suggesting the 
formation of El :E2 complexes (Grakoui etai., 1993a; Ralston et al., 1993). Grakoui 
etai. (1993a) suggested El was associated with E2 via disulphide bonds based upon 
the reduction in association of the two proteins with dithiothretiol. In contrast to this
16
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report Ralston et al. (1993) and Matsuura et al. (1994) were unable to demonstrate 
association via disulphide bonds. It has been reported that formation of E1:E2 
complexes can occur via two pathways. The predominant pathway involves 
noncovalent interactions between El and E2 leading to the formation of a stable El :E2 
heterodimer, with only a minority of the E1:E2 complexes formed being stabilised via 
disulphide bonds. Dubussion et al. (1994) suggest that these represent misfolded 
complexes. E1:E2 complexes have been shown to confer a degree of immunity in 
experimentally infected chimpanzees (Choo etai., 1994), suggesting vaccines towards 
HCV should incorporate both El and E2.
1.4.5 HCV non-structural proteins
Six proteins presumed to be non-structural (Figure 1.1) all appear to be 
unglycosylated. The NS2 gene encodes a 21 to 23kDa protein and the NS3 a 70kDa 
protein (Grakoui et al., 1993a; Mizushima et al., 1994a). Two different protease 
enzymes are encoded by NS2 and NS3 which are required for processing of the 
nonstmctural region of the precursor polyprotein (see section 1.3.6). The NS3 protein 
contains a serine-like protease domain at the N-terminal and located immediately 
downstream is a helicase domain (Miller & Purcell, 1990; Choo et al., 1991; 
Houghton et al., 1991). The functions of these two domains within NS3 are not 
separated by proteolytic cleavage. The helicase activity of NS3 is presumed to be 
responsible for the unwinding of the RNA template during replication and translation. 
The residues His-1003, Asp-1107 and Ser-1165 found in the N-terminus of NS3 are 
highly conserved among HCV isolates and correspond to the catalytic triad found in 
serine type proteases. (Bartenschlager et al., 1993; Grakoui et al., 1993b; Tomei et al.,
1993). The N-terminal of the active protease of NS3 appears to reside between amino 
acids 1050 to 1083, with the C-terminal residing between amino acids 1115 and 1218 
(Han et al., 1995). Protease activity is inhibited by chymotrypsin-specific inhibitors 
but not by trypsin-like protease or protease inhibitors (Hahm et al., 1995; Han et al.,
17
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1995). A second protease enzyme exists between amino acids 827 to 1233, which 
appears to overlap regions of NS2 and NS3. It encompasses the C-terminal of NS2, 
the NS2/NS3 cleavage site and protease domain of NS3 (Grakoui et al., 1993c; 
Hijikata et al., 1993a). A schematic diagram showing the position of this protease is 
shown in Figure. 1.3. It appears to be a zinc-dependent metalloprotease (Hijikata et 
al., 1993a). The zinc co-ordinate residues are proposed to be His-952 and Cys-993.
Downstream of NS3 are NS4a (4-8kDa) and NS4b (27kDa) (Grakoui et al., 
1993a; Hijikata et al., 1993b). The precise functions of NS4a and NS4b are unknown. 
The NS5A and NS5b encode 56 to 58kDa and 6 6  to 6 8 kDa proteins, respectively 
(Grakoui et al., 1993a; Hijikata et al., 1993b). NS5b contains the amino acid sequence 
motif Gly-Asp-Asp which is highly conserved among RNA dependent RNA 
polymerases encoded by RNA viruses and is presumably responsible for the 
replication of the RNA template (Choo et al., 1991). Unlike HCV and pestiviruses, 
flaviviruses do not process the NS5 region into two distinct domains (reviewed by 
Collett et al., 1988; reviewed by Rice & Strauss, 1990). Immunofluorescent assays 
have shown that apart from NS3 and NS5a all the non-structural proteins appear to be 
associated with membranes of the ER. NS3 and NS5a were detected in the cytoplasm, 
suggesting that they are soluble proteins (Selby et al., 1993) .
1 . 4 . 6  Processing of the HCV polyprotein
The HCV precursor polyprotein appears to be co- and post-translationally processed. 
The N-termini of El and E2 have been sequenced following translation in vitro and 
cleavage sites mapped to Tyr-192 and His-384, respectively (Hijikata et al., 1991a). 
The regions between amino acids 175-191 and 370-383 are hydrophobic and probably 
act as signal sequences for the host signal peptidase. The processing of the structural 
proteins in vitro is dependent upon the presence of microsomal membranes which 
suggests that cleavage of the structural proteins is mediated by host signal peptidases 
(Hijikata etai., 1991a; Santolini e ta i, 1994). Mature core protein appears to terminate
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around amino acid 174, however cleavage between core and El takes place at amino 
acid 191/192. A hydrophobic domain exists between amino acids 174 and 191. 
Experimental data indicates that the core protein is released from the precursor 
polyprotein by two cotranslational endoproteolytic cleavages mediated by host signal 
peptidases which generate the C-terminus of the core and the N-terminus of the El 
protein by removing the hydrophobic domain (Santolini et al., 1994). Thus, from the 
experimental data accumulated so far, the stmctural proteins would appear to be 
cleaved by host signal peptidases.
Host signal peptidases are also believed to mediate cleavage between E2 and NS2 
(Grakoui et al., 1993a; Lin et al., 1994). Three forms of E2 (36, 41 and 62kDa) were 
observed after endoglycosidase treatment (Grakoui et al., 1993a). Grakoui et al. 
suggested the 62kDa protein represented E2 complexed with NS2 and the 36 and 
41 kDa proteins, the deglycosylated forms of E2. Selby et al. (1994) provides evidence 
that three forms of E2 with distinct C-termini occur representing E2 (terminating at 
amino acid 730), E2 complexed with the N-terminal of NS2 (terminates at amino acid 
807) and E2 complexed with NS2 (terminates at amino acid 1026). The E2/NS2 
complexes may be precursors for the E2 and NS2 proteins. The E2/NS2 junction was 
originally estimated to be around amino acid position 740, based upon deletion 
analysis of E2 (Hijikata et al., 1991a). The cleavage site of E2/NS2 has now been 
mapped to amino acid 810 (Mizushima et al., 1994a). The difference between the 
estimated and deduced cleavage site of E2/NS2 suggests that the region between amino 
acid 740 and 810 encodes a small polypeptide (Grakoui et al., 1993a; Mizushima et 
al., 1994a). A small hydrophobic 7kDa (p7) protein comprised of about 60 amino 
acids has been reported to be encoded by this region between E2 and NS2 (Lin et al., 
1994; Mizushima et al., 1994b). A hydrophobic domain at the C-terminus of E2 
preceding p7 may be involved in the translocation of p7 to the ER membrane thus 
allowing cleavage to be mediated by host signal peptidase. This theory is supported by 
the dependence of the cleavage of E2/p7 and p7/NS2 upon the presence of microsomal
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membranes in a cell free system (Lin et al., 1994). The function of this protein and 
whether it is structural or nonstructural is unknown.
The NS2/NS3 cleavage site has been mapped to amino acids 1026/1027 
(Grakoui et al., 1993c) (Figure 1.4). Cleavage occurs in cis by the zinc-dependent 
metalloprotease. Substitution of either of the zinc co-ordinate residues, His-952 and 
Cys-993 (Figure 1.3), with alanine results in cleavage being abolished (Grakoui et al., 
1993c; Hijikata et al., 1993a). The NS3 chymoptrypsin-like protease is responsible for 
cleavage at NS3/NS4a, NS4a/NS4b, NS4b/NS5a and NS5a/NS5b. Cleavage at 
NS3/NS4a (aa 1657/1658) occurs in cis whereas cleavage at NS4a/NS4b (aa 
1711/1712), NS4b/NS5a (aa 1972/1973) and NS5a/NS5b (aa 2420/2421) occur in 
trans (Tomei et al., 1993). The cleavage recognition site for the NS3 protease is 
Asp/Glu -X-X-X-X-Cys/Thr U- Ser/Ala where X is variable (Hijikata et al., 1993b). 
Polar residues (Cys/Thr) are preferred at position 1 (PI) of the cleavage recognition 
site. The residues present at this position appear to be critical for recognition by the 
protease (Bartenschlager et al., 1995). In contrast to this the acidic residue preferred at 
P6  does not appear to be essential for cleavage to occur. Acidic residues found in close 
proximity may compensate for the substitution of the acidic residue at P6  with a non- 
acidic residue (Figure 1.4). Mutational analysis of the NS3-dependent cleavage sites 
shows the NS3/4a cleavage site to have a higher degree of tolerance for amino acid 
substitutions within the cleavage recognition site in comparison to the sites cleaved in 
trans., which suggests cleavage in cis is primarily governed by the structure of the 
polyprotein whereas cleavage in trans is governed by the interaction between the 
protease enzyme and substrate (Bartenschlager et al., 1995a).
NS4a appears to be required for cleavage at the NS3/NS4a, NS4a/NS4b and 
NS4b/NS5a sites, and enhances cleavage efficiency between NS5a and NS5b 
(Bartenschlager et al., 1994; Failla et al., 1994). The NS3 protease and NS4a form a 
stable complex when expressed as a single polyprotein or as separate molecules. 
Deletion mapping experiments have shown that stable formation of the NS3/NS4a 
complex requires the N-terminal 22 amino acid residues of NS3 and the central NS4a
20
Cleavage site P 6  P I p i '
3/4A (1658) AspXXXXThr Ser
4A/4B (1712) AspXXXXCys Ser/Ala
4B/5A (1973) Glu/AspXXXXCys Ser
5A/5B (2421) Glu/AspXXXXCys Ser
Figure 1.4 HCV NS3 serine protease-dependent cleavage sites. The 
cleavage recognition site is shown in boldface type. X is variable. The 
amino acid position of each cleavage site is shown in brackets. Adapted 
from Grakoui et al. (1993b).
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domain between between amino acid residues 1675 and 1686 (Bartenschlager et al., 
1995b; Satoh et al., 1995). A stable NS3/NS4a interaction is important for cleavage at 
the NS3/NS4a, NS4a/NS4b and NS4b/NS5a sites. NS4a may aid in the correct 
folding of the NS3 protease. Alternatively, NS4a may facilitate proteolysis by acting as 
an anchor for the hydrophilic NS3, bringing it into contact with the HCV proteins 
located in the membranes of the ER (Bartenschlager et al., 1994).
Based on what is currently known about the mechanisms involved in processing 
of the non-structural polyprotein precursor the following model is proposed. The 
NS2/NS3 site is cleaved in cis by the NS2/NS3 zinc-dependent metalloprotease. 
Processing between NS3 and NS4a occurs cotranslationally by interaction of the N- 
terminal 22 amino acid residues of NS3 with the central domain of NS4a on the 
nascent polyprotein precursor. Cleavage at the NS3/NS4a site then occurs in cis, and a 
stable NS3/NS4a complex is formed which then mediates cleavage in trans at the 
NS4a/NS4b, NS4b/NS5a and NS5a/NS5b sites.
1.5 Genetic variability of hepatitis C virus
1 . 5 .1  HCV genotypes
Following the discovery of HCV, sequence comparisons of HCV isolates from Japan, 
HCV-J, HCV-BK (Kato et al., 1990; Takamizawa et al., 1991) to the prototype isolate 
HCV-1 (Choo et al., 1991) revealed significant differences in nucleotide sequence. 
HCV-J and HCV-BK showed 91.2% similarity to each other compared to only 78.4% 
and 77.1% similarity to HCV-1 respectively. This suggested that there were at least 
two subtypes of HCV. Analysis of full and partial sequences from different HCV 
isolates indicate HCV could be classified into distinct genotypes, which display 
significant differences in nucleotide sequence and geographic distribution. Each 
genotype can be further divided into subtypes, depending upon the degree of similarity
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of isolates within the group. To date at least nine HCV genotypes are thought to exist 
(Bukh et al., 1992; Chan et al., 1992; Cha et al., 1992; Simmonds et al., 1993a; 
Tokita et al., 1994, 1995). However, the classification of isolates from Vietnam and 
Thailand as types 7, 8  and 9 has been disputed. Tokita et al. (1994, 1995) used the 
unweighted pair-group method with the arithmetic mean (UPGMA) to construct 
phylogenetic trees when classifying the HCV isolates from Vietnam and Thailand. This 
method is not reliable when the nucleotide substitiution rate is not constant over time, 
as is likely in the case of HCV. Both Mellor et al. (1995) and Mizokami et al. (1996) 
suggest that the HCV isolates previously proposed to represent types 7, 8  and 9 should 
be classified as type 6  subtypes. Their findings are based upon re-analysis of the data 
from Tokita et al. (1994, 1995) using the neighbour-joining and Maximum-likelihood 
methods to construct phylogenetic trees. Such methods take into account variation in 
the nucleotide substitution rate in different lineages.
Several authors have proposed systems of nomenclature for classification of 
HCV isolates (Enomoto et al., 1990; Cha et al., 1992; Chan et al., 1992; Okamoto et 
al., 1992a; Simmonds et al., 1993a). Several of these proposed systems do not allow 
for the classification of some variants, namely 4, 5 and 6 , thus a new system of 
nomenclature has been proposed by Simmonds et al. (1993b). Table 1.1 displays the 
proposed systems of HCV nomenclature. Classification of HCV isolates as 2c, 4, 5 
and 6  is based upon only partial sequence analysis of either the 5'UTR, core, E l or 
NS5 regions of the genome. It is therefore possible that if the full genome of such 
isolates is sequenced they may be classified differently. Many authors have used the 
sequence of the 5'UTR successfully to type isolates, however, this region has proved 
to be unsuitable for subtyping isolates. Genotyping HCV isolates is important in 
understanding the natural history, diagnosis and clinical course of HCV infection. 
Evidence exists to suggest infection with different HCV genotypes may lead to a 
different clinical course of infection. Patients with HCV type 1 tend to have more 
severe liver disease (chronic hepatitis, cirrhosis or hepatocellular carcinoma) compared 
to types 2, 3 and 4 (Dusheiko etal., 1994b). Response to interferon treatment appears
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to be better in type 2 infected patients than type 1, especially type lb (Takada et al., 
1992).
1 . 5 . 2  Geographic distribution of HCV genotypes
The genotypes la, lb, 2a, 2b and 3a are found in the USA and Europe (reviewed by 
Dusheiko & Simmonds, 1994). The frequency which each particular genotype is 
found varies among countries. In the Netherlands type lb appears to predominate 
(Cuypers et a l, 1991). In Japan and China the genotypes lb, 2a and 2b predominate. 
In Japan type la is found only in haemophiliacs who received blood or blood products 
produced in the USA (Okamoto & Mishiro, 1994a). The distribution of genotypes in 
Taiwan is similar to that found in Japan.
Countries in the Middle East and Africa display a different distribution. On the 
basis of sequence comparisons in the core, El and NS5 regions, genotype 4 
predominates in Egypt, Cameroon, Burundi and Zaire, with certain subtypes of 
genotype 4 being found only in Egypt. Type 5 appears to be mainly restricted to South 
Africa. Likewise type 6  has been detected in Hong Kong, Macau and Vietnam (Bukh 
et al., 1993; Simmonds et al., 1993a, 1993b; Stuyver et al., 1993; Mellor et al.,
1995).
The different geographic distribution displayed by the genotypes of HCV could 
perhaps be due to the mode of transmission. Predominantly, HCV is transmitted via 
blood or blood products but sporadic cases of HCV infection has occurred where 
transmission by blood has been eliminated.
1 . 5 . 3  Sequence variation in the 5'UTR and putative capsid protein
Sequence comparisons between isolates of HCV shows substantial nucleotide 
sequence variation which is not uniformly distributed across the entire genome. 
Comparisons of the individual HCV isolates show the 5'UTR to be highly conserved
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among different isolates. Table 1.2 shows the degree of nucleotide sequence similarity 
between the 5'UTR from different HCV isolates.
The 5'UTR of HCV consists of highly conserved domains interspersed between 
variable domains. The most variable domain is found between nucleotides -167 to -118 
(numbering according to Choo et al., 1991) (Bukh etal., 1992). This region forms the 
highly stable stem loop structure observed in the HCV 5'UTR (Brown et al., 1992; 
Tsukiyama-Kohara et al., 1992). Nucleotide insertions are observed within this region 
in some isolates (Bukh etal., 1992). Since these nucleotide insertions are found in the 
non-based paired terminal loop (Domain III Figure 1.2) they do not interfere with the 
stem loop structure. Three highly conserved domains were found at positions -263 to - 
246, -199 to -178 and -65 to -3 in 44 HCV isolates studied by Bukh et al. (1992). In 
HBV, sequence here is important for encapsidation. The HBV encapsidation signal 
forms a stable stem-loop structure. Two sets of repeated sequences termed R2 (- 
CACTCC-) and R3 (-CCCGGAG-) are also found in the 5'UTR of reported HCV 
isolates (Inchauspe et al., 1991). These conserved domains and repeated sequences 
may represent regulatory elements important for viral replication. The putative 
nucleocapsid protein appears to the most highly conserved protein between members 
of the same and different genotype (Houghton et al., 1991).
1.5.4 Sequence variation within the envelope region
In contrast to the 5'UTR and nucleocapsid protein, the putative envelope 
glycoproteins, El and E2 display a high degree of variability when HCV isolates are 
compared. Table 1.3 shows the degree of nucleotide and deduced amino acid sequence 
similarity between HCV isolates. Even across the putative envelope proteins variation 
is not uniformly spread, in El a moderately variable domain exists between amino 
acids 215 and 255 and at the N-terminus of E2 a hypervariable region (HVR1) exists 
(Weiner et al., 1991). The precise numbering of the individual amino acids which 
constitute HVR1 appears to vary depending on the genotype of the isolate. HVR1 was
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mapped to amino acids 384 to 414 for type la (Weiner et al., 1991, 1992), this 
hypervariable region (HVR1) represents only 8 % of the total nucleotide sequence but 
accounts for between 30 to 47% of the nucleotide changes and 40 to 63% of the amino 
acid changes observed in the envelope region between HCV isolates (Weiner et al.,
1991). For type lb isolates HVR1 was mapped to amino acids 384 to 410 (Kato et al., 
1992a). Hijikata et al. (1991b) identified a second hypervariable region (HVR2) 
between amino acids 474 to 480 in Japanese type lb isolates. The equivalent region in 
type la isolates seldom shows any sequence variation. The position of the variable and 
hypervariable regions are shown schematically in Figure 1.5.
Despite its high degree of divergence 26 cysteine residues present in the envelope 
region are completely conserved, suggesting they may be important in forming inter- 
and intra- disulphide bonds essential for conformation of the envelope proteins. N- 
glycosylation sites also appear to be conserved (Kato et al., 1992a; Okamoto et al., 
1992a). This conservation of secondary structure does not apply to the hypervariable 
region which lacks both cysteine residues and potential glycosylation sites. The lack of 
secondary stmcture and high degree of variation observed in this region is similar to 
that found in the V3 loop of HIV envelope gpl20, this suggests that HVR1 like the V3 
loop of HIV may be the target of the host's humoral immune system (Weiner et al.,
1992). Within this hypervariable region certain amino acids appear to be well 
conserved among isolates, i.e threonine at position 385, glycine at position 406, 
glutamine at position 409 and leucine at position 413 (Kato et al., 1992a; Lesniewski et 
al, 1993). It is possible these amino acids play a role in receptor recognition.
1 . 5 . 5  Viral Quasispecies
RNA viruses exhibit a high degree of genetic diversity, due to the lack of proof reading 
activity of the RNA polymerase. RNA viruses therefore replicate with limited fidelity 
resulting in the generation of genomic variants which may have a phenotypic selective 
advantage in the host. These variants would then subsequently replicate and become
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dominant in the virus population. The high mutation frequencies of RNA viruses 
results in a mixture of variants existing in the virus population at any given time. 
Evidence indicates that most RNA viruses circulate as a "quasispecies" population 
which evolves due to the high mutation rate per site in the RNA genome (10-3 to 10-6) 
(reviewed by Holland et al., 1992). The term "quasispecies" refers to the 
heterogeneous mixture of circulating closely related genomes. In this complex mixture 
the genomes compete against one another for "survival". The representation of each 
genome is dependent on the rate at which mutation occurs and the relative "fitness" of 
that mutation in the viral genome population. Thus, each quasispecies contains a 
master or predominant sequence (the most frequently represented) and a large spectrum 
of closely related variants. Circulation of RNA viruses as a population of different but 
related variants confers a selective advantage. It allows the virus to adapt to host 
selection pressures by rapid selection of a variant (mutation) with better fitness 
resulting in a change in the distribution of variants within the quasispecies. The 
quasispecies will remain in stable equilibrium if conditions remain unchanged. The 
high degree of sequence variation displayed by HCV, makes it necessary to discuss 
HCV isolates in terms of quasispecies (Martell et al., 1992).
1 . 5 . 6  Sequence variation within an individual
An important feature of HCV infection is that genetic variation exists not only between 
isolates from different individuals, but between isolates from the same individual 
(Ogata et al., 1991; Abe et al., 1992a; Okamoto et al., 1992b; Tanaka et al., 1992). 
The HCV isolate obtained during the acute phase of infection from an experimentally 
infected chimpanzee was found to differ in 111 of the 9412 nucleotides positions 
(1.18%) from the isolate obtained during the chronic phase 8.2 years later (Okamoto et 
al., 1992b). The substitution rate of this isolate was estimated to be about 1.44 x 10' 3 
base substitutions per site per year. The observed sequence heterogeneity observed in 
the sample taken during the acute phase of infection can affect the estimation of the rate
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of sequence change. Ogata et al. (1991) estimated the substitution rate of the HCV 
genome isolated from a human carrier to be approximately 1.92 x 10-3 base 
substitutions per site per year (over a 13 year period). However, only 50% of the viral 
genome was analysed. Both groups found amino acids changes tended to cluster 
within HVR1. The substitution rate of HVR1 has been estimated to be about 4.3 x 10' 3 
base substitutions per site per year (Abe et al., 1992a). Okamoto et a l (1992b) 
analysed both HVR1 and HVR2 at the time of infection and 3.5 and 8.2 years later. A 
homogenous population was found to be present within these regions at the beginning 
of HCV infection. When examined 3.5 years later heterogeneous populations were 
present, the heterogeneity of which was found to have increased when these regions 
were examined 4.7 years later (8.2 years after infection). The diversification of the 
HVR sequences, along with the overall sequence heterogeneity displayed throughout 
the viral genome, suggests variation develops with persistence of infection.
A notable feature of infection with HCV is the high level of chronicity, at least 
50% of acutely infected individuals remain infected and subsequently develop chronic 
hepatitis. Multiple infection of an individual with several HCV isolates may also result 
in sequence diversity (Oshima et al., 1991; Okada et al., 1992). Up to 9.5 and 7.7% 
substitutions in the nucleotide and the amino acid sequence respectively, were found 
between cDNA clones isolated from liver tissue of an infected individual, the cDNA 
clones representing non-structural domains (of NS4 and NS5). This high degree of 
variation within a single patient suggested multiple infection (Oshima et al., 1991). 
This suggests that the immune response to one HCV isolate (type) does not protect the 
host from re-infection by another isolate or alternatively, the individual was initially 
infected with more than one HCV isolate.
Several studies have examined sequential HVR1 sequences isolated from infected 
individuals (Kumar et al., 1993; Kurosaki et al., 1993; Sakamoto et al., 1994). The 
emergence of E2 HVR1 variants was shown to occur during the development of 
chronic infection. The HCV quasispecies appears to change with the appearance of 
HCV isolates with different (new) HVR1 sequence replacing the predominant
27
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population. This suggests alteration of the predominant HVR sequence is caused not 
only by spontaneous mutation of HCV during replication but also by positive selective 
forces. The high rate of sequence variability observed in HVR1 of E2 may result from 
humoral and/or T-cell mediated immune selection, as in the case of the V3 loop of HTV 
gpl20 (Kato et al., 1992b; Weiner et al., 1992).
1 . 5 . 7  Mechanisms of variation
The mechanisms responsible for the high substitution rate of HCV are not fully 
understood. The replacement of one amino acid with another is likely to be dependent 
upon the size, charge and function of the amino acid residue (i.e. part of an antibody 
epitope or enzymatic site). The need to conserve secondary structures involved in viral 
replication or translation (i.e. the stem loop structure within the 5'UTR) may also be 
important (reviewed by Dusheiko & Simmonds., 1994).
The viral E1/E2 proteins are likely to be on the outside of the virus, exposing 
them to attack by the host immune system. Thus, the sequence variability observed in 
the envelope proteins may be humoral immune driven. The E2 HVR may encode the 
part of the envelope protein involved in cellular recognition and so, be under pressure 
to mutate from the host’s humoral immune response. Since antibodies binding to this 
region of HCV would prevent it from recognising and therefore, infecting hepatocytes. 
Antibody-epitope binding studies reveal isolate-specific epitopes located in the E2 
HVR (Weiner et al., 1992). A hypothesis proposed by Weiner et al. suggests the 
envelope sequence variability alters the antigenicity of the protein allowing HCV to 
'escape' the host humoral immune response. The appearance of a new sequence 
variant during infection would be followed by the development of antibodies which 
would specifically recognise and neutralise it (Weiner et al., 1992; Kato et al., 1993a; 
Taniguchi et al., 1993). However, cross challenge experiments in chimpanzees have 
shown a lack of protective immunity. Experimentally infected chimpanzees can be
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reinfected with the same HCV isolate, although, re-infection was seldom symptomatic 
in contrast to primary infection (Farci et al., 1992).
1.6 Natural history of hepatitis C virus
1 . 6 . 1  Acute hepatitis C
Infection with HCV can be divided into two phases, acute and chronic. The incubation 
period between infection and hepatitis onset is on average about 6  weeks, during this 
incubation period HCV RNA can be detected in the serum of infected patients. Farci et 
al. (1991) reported detection of HCV RNA in serum one week after the patient was 
transfused with infected blood, preceding the initial elevation in ALT levels by 5 
weeks. In acute resolving hepatitis C, viraemia is transient and lasts for between 15 to 
38 weeks (Farci etal., 1991; Abe etal., 1992b). The length of time for the appearance 
of antibodies (Abs) to HCV is variable depending on what antibody is measured, Abs 
to the nucleocapsid usually appear first. The majority of patients with acute HCV 
infection are asymptomatic or present with mild symptoms.
1 . 6 . 2  Chronic hepatitis C
HCV infection is characterised by a high incidence of chronicity. The rate of chronicity 
is the same in community-acquired sporadic infection as in parentally-transmitted 
infection (Alter etal., 1992) Chronic hepatitis C may also result in the development of 
hepatocellular carcinoma (HCC) (Saito et al., 1990; Liang et al., 1993).
Di Bisceglie etal. (1991) evaluated hepatitis C infection in patients who received 
blood during heart surgery. Acute post-transfusion (PT) hepatitis developed in 
65/1070 patients (6.1%), becoming chronic in 45 (69%). Antibody to HCV was 
detected in 54 patients (82%) with PT-hepatitis, thirty-nine of these patients were
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followed for between 1 and 24 years cirrhosis developed in 8  patients (20%) between
1.5 and 16 years after transfusion. A characteristic feature of infection with HCV is the 
pattern of fluctuating ALT levels. The course of HCV infection can be divided into 
three phases, 1) acute phase, where ALT levels are high 2) silent phase, which lasts 
for approximately 10 to 15 years, with ALT levels remaining near normal and 3) 
reactivated phase, where ALT levels begin to rise and fluctuate until severe liver 
disease develops (Kiyosawa et al., 1994).
Chronic hepatitis follows one of two patterns; persistent viraemia (duration of at 
least more than one year) or intermittent viraemia (Abe et al., 1992b). In patients with 
persistent viraemia, HCV RNA is detected throughout and can be associated with 
either high or near normal ALT levels. In patients with intermittent viraemia HCV 
RNA is detected during the acute phase becoming undetectable when ALT levels return 
to normal and detectable again when ALT levels increase as the disease becomes active 
(Farci et al., 1991; Abe etal., 1992b).
HCV is believed to be associated with hepatocellular carcinoma (HCC). In Japan 
the incidence of liver carcinoma is higher than in Europe or the USA. Kaneko et al. 
(1994) prospectively followed 158 patients with chronic hepatitis, positive for anti- 
HCV, for the development of HCC. Twenty-two (14%) of these patients developed 
HCC during the follow up period (5-17 years). A higher incidence of HCC was found 
in those patients with chronic active hepatitis (CAH). The development of HCC was 
found to be independent of age, sex, alcohol abuse etc. indicating hepatitis C infection 
is associated with HCC in Japan. The mechanism by which HCV causes HCC is 
unknown.
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1.7 Epidemiology and transmission of HCV
HCV has a worldwide distribution. The prevalence of anti-HCV ranges from 0.3% in 
Canada and northern Europe, to 0.6% in the United States and central Europe, to 1.2% 
to 1.5% in southern Europe and Japan (reviewed by Alter, 1991). HCV may be 
transmitted by parenteral or non-parenteral routes.
Parenteral transmission: The most efficient routes of transmission are through 
blood and blood products, transplantation of organs from infected donors or 
intravenous drug abuse. The introduction of tests for the detection of HCV has reduced 
the frequency of HCV transmission via blood transfusion. Blood transfusion is now 
estimated to account for about 2.1% of cases (reviewed by Lemon & Brown, 1995). 
Anti-HCV is found in 50-90% of haemophiliacs and 70-92% of intravenous drug 
abusers. In haemodialysis patients the prevalence of anti-HCV is between 4-20%. The 
mode of transmission of HCV in renal dialysis units is not yet fully understood since 
not all haemodialysis patients positive for HCV received blood transfusions or shared 
equipment (reviewed by Esteban, 1993; Allander et al., 1994).
Non-parenteral transmission: Sexual transmission has been reported as a 
possible route of infection, however evidence in support of sexual transmission is not 
convincing. In 50 heterosexual partners of individuals with HCV, none were positive 
for anti-HCV or HCV RNA (Bresters et al., 1993). If HCV is spread via sexual 
transmission, the rate of infection is low in comparison to HBV or HIV. Mother to 
child transmission has been demonstrated for HBV and HIV infection. Maternal 
transmission of HCV has been documented (Inoue et al., 1992; Ohto et al., 1994). 
Ohto et al. demonstrated vertical transmission of HCV from mother to child and 
correlated the risk of transmission with the HCV RNA titre of the mother. A higher 
incidence of transmission was found in mothers with high titres of HCV RNA.
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1.8 HCV: Treatment and prevention
1 . 8 . 1  Treatment
Treatment for hepatitis C infection is currently unsatisfactory. Interferon (IFN) is used 
at present to treat hepatitis C infection, but not all patients respond and of those that do, 
about 50% relapse once treatment is stopped. Response to IFN treatment appears to be 
determined by HCV genotype, severity of disease at time of treatment and IFN dosage. 
Individuals infected with genotypes 2 and 3 appear to respond better to IFN treatment 
than those infected with genotype 1 (Duskeiko et al., 1994). In a study by Hino et al. 
(1994) 74 out of 136 (54%) patients with chronic HCV responded to interferon 
treatment. When the HCV genotypes of the patients were examined 34 out of 85 (40%) 
patients infected with genotype lb responded to treatment compared to 2 2  out of 26 
(85%) patients infected with genotype 2a and 7 out of 10 (70%) patients infected with 
genotype 2b. Ribavirin, an analogue of the nucleoside guanosine, is an alternative 
treatment. In a study by Di Bisceglie et a l (1992), ribavirin was administered over a 
period of 6  months, during this period the ALT level decreased in all patients but 
increased again after treatment was stopped. HCV-RNA was detectable throughout 
treatment. The advantage of ribavirin is that it can be administered orally. The use of 
ribavirin as a therapy for hepatitis C requires further evaluation. A pilot study by 
Brillanti et al. (1994, 1995) indicates that combination therapy of ribavirin and IFN 
induces a sustained response in patients who previously responded to IFN treatment, 
but who suffered a relapse after the treatment course was completed. Seventy-five 
percent of IFN relapsers showed sustained normal ALT levels and remained negative 
for HCV RNA 6  months after receiving combination therapy. Larger patient studies to 
investigate the combined effect of IFN and ribavirin to treat HCV infection are 
currently underway.
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1 . 8 . 2  Prevention
There is no vaccine available for the prevention of HCV infection. Re-infection of an 
individual with the same or different HCV isolate, results in the development of a 
second bout of disease which complicates the development of a vaccine (Farci et al., 
1991), as does the high rate of persistence of the virus in infected individuals. Clear 
knowledge of the host's immune response to HCV infection is required for the 
successful development of a vaccine. One study reported the protection of chimpanzees 
against infection with HCV (homologous inoculum) following immunisation with 
recombinant derived HCV envelope glycoproteins (Choo et al., 1994). Until the 
development of a vaccine against HCV the only ways of reducing the incidence of 
HCV infection at present are by careful screening of blood donations, adherence to 
precautions for preventing the spread of blood-borne infections in clinical settings and 
stopping the practice of needle-sharing amongst drug abusers.
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1.9 Aims of this project
The work presented in this thesis had the following objectives :
1. To characterise the emergence of genetic variants of the hypervariable region 
(HVR1) in the 5' terminus of the putative envelope protein E2/NS1 of HCV and 
examine the possible association of periods of liver dysfunction with sequence changes 
in HVR1 in patients on long term dialysis, with the aim of testing the hypothesis that 
the sequence variants that arose in the region during the course of infection in these 
patients represented immune escape mutants.
2. To study the effect of serum storage conditions on the detection of HCV RNA by 
RT-PCR.
3. To construct control HCV RNA transcripts for quantitative RT-PCR analysis in 
order to investigate the relationship between the level of HCV RNA in patient sera and 
the emergence of HVR1 genetic variants.
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2.1 Oligonucleotide synthesis and purification
Acetonitrile, cyanoethy phophoramidites Cruachem Ltd
(dA, dG, dC and T), biotin cyanoethyphoramidite, 
tetrazole/acetonitrile solution, acetic anhydride in 
lutidine and tetrahydrofuran, N-Methylimidazole in 
\tetrahydrofuran, 0.1M Iodine in tetrahydrofuran, 
pyridine and water, 3% Trichloroacetic acid in 
dichlorometane and 0.2 micromol scale Controlled 
Pore Glass (CPG) columns (dA, dG, dC and T).
Acetonitrile (Bioscience grade) and Fisons
ammonium hydroxide solution (high purity grade).
Triethylamine acetate, triflucroacetic acid and Applied Biosystems
oligonucleotide purification cartridges.
2.2 Extraction of RNA
Guandium thiocyanate and B-m ercaptoethanol. BDH Ltd
Sarcosine, antifoam-A and Sigma Chemical Company
transfer-RNA (sheep - fibroblast).
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2.3 Reverse Transcription
Moloney Murine Leukaemia Virus 
Reverse Transcriptase (M-MLV RT),
5x First Strand Buffer and 0.1M Dithiothreitol (DTT).
Random hexamer pd(N)6 .
Rnasin.
2.4 Polymerase Chain Reaction (PCR)
Taq DNA polymerase, lOx PCR Buffer and 
50mM magnesium chloride.
2.5 Electrophoresis
Agarose (catalogue number 9012-36-6).
Nuseive Agarose (genetic technology grade).
Sequagel concentrate, diluent and buffer.
Ammonium persulphate,
N, N, N'N-tetramethylenediamine (TEMED)
DNA molecular weight markers (VI).
Gibco, BRL Ltd
Pharmacia LKB Ltd
Promega Corp.
Gibco, BRL Ltd
Sigma Chemical Company
FMC Bioproducts
National Diagnostics
BioRad Laboratories Ltd
BoehringerMannheim
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2.6 DNA Sequencing
Dynabeads M-280 Streptavidivn. Dynal International
Sequenase Version 2.0 DNA Sequencing kit. United States Biochemical
(USB)
a-3^S dATP >1000Ci/mmol (10 Ci/ml). Amersham International
PLC
2.7 Human sera
Human sera used in the following study were stored by the Virology Section of the 
Clinical Microbiology Department of the Western Infirmary, Glasgow. Informed 
consent for the use of sera taken from patients in the Western Infirmary for diagnostic 
assays was obtained from Dr J D Briggs and physicians of the Renal Unit. Sera was 
defined positive by Second generation Hepatitis C antibody ELISA (Abbott Lab.), 
RIBA (Chiron Corp.) and PCR analysis (5'NCR). Sera stored at -20°C.
Control HCV negative serum was provided by Dr W. Carman, Institute of Virology. 
This serum was defined negative by antibody and PCR analysis. Repeated sera taken 
from the individual have remained negative for HCV antibody and RNA to date 
(October 1996).
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2.8 SSCP
Acrylamide (electran), 
NN'-Methylenebisacrylamide (electran)
Silver nitrate (AgNOs)
Formamide, Formaldehyde
2.9 Micellaneous Materials
Dideoxynucleotides 5'- triphosphates, 
ultrapure dNTP set
AmpliWax PCR Gem 100
X-OMAT S Film
3mm Chromatography paper
Diagnostic Assay kits for Hepatitis B markers, HIV 
and Hepatitis C antibody
Chiron RIBA HCV 3.0 Strip Immunoblot Assay kit 
Geneclean II kit
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BDH Ltd.
Johnson Matthey Ltd. 
Fluka
Pharmacia LKB Ltd
Perkin Elmer Cetus
Kodak Ltd
Whatmann Ltd
Abbott Laboratories 
and Murex Diagnostics
Kindly donated by Othro 
Diagnostic Systems Inc.
Bio 101 Inc.
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Mineral oil Sigma Chemical Company
Biochemical grade water 
Restriction enzymes and buffers.
BDH Ltd
Gibco, BRL Ltd or
Boehringer Mannheim
2.10 Chemicals
All chemicals were obtained from either BDH Ltd., Boehringer Mannheim, Sigma 
Chemical Company, or Prolabo Ltd.
2.11 Commonly used solutions
TE buffer: lOmM Tris-HCL ( pH 7.5 or 8.5), ImM EDTA.
TAE buffer: 40mM Tris-HCL (pH8.0), ImM EDTA.
TBE buffer: 90mM Tris-HCL, 90mM Boric acid, ImM EDTA.
Ligase buffer: 300mM Tris-HCl (pH 7.8), lOOmM MgCl2, lOOmM DTT and lOmM 
ATP.
Phosphate buffered saline (PBS): 170mM NaCl, 3.4mM KC1, lOmM Na2HP04 (pH
7.2) supplemented with 6 .8 mM CaCl2  and 4.9mM MgCl2 -
Sequencing buffer: 0.9M Tris-HCL, 0.9M Boric acid, 0.02M EDTA.
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Solution D: 4M guanidium thiocyanate, 56mM sarcosine, 0.33% antifoam A, 50mM 
Tris-HCl (pH 7.5), 2mM EDTA and 0.7% p-mercaptoethanol.
STET: 0.1M NaCl, lOmM Tris-HCl (pH 8 ), ImM EDTA and 5% Triton X-100.
Dynabead binding and washing buffer: lOmM Tris-HCl (pH 7.5), ImM EDTA,
2.0MmNaCl (final concentration ImM).
Gel loading buffer: 50% sucrose, 0.1M EDTA, 0.05% bromophenol blue
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3.1 Oligonucleotides
3.1.1 Oligonucleotide synthesis
Oligonucleotides were made by cyanoethyl phosphoramidite chemistry, using a 
Cruachem PS250 synthesiser. This involved the sequential addition of a protected 
form of cyanoethyl phosphoramidite monomers. Each protected monomer has a 
labile dimethoxytrityl protecting group which was removed by the detritylating 
agent, 3% trichloracetic acid in dichloromethane, following the addition of each new 
base. When synthesising biotin-labelled oligonucleotides, the last base to be added is 
a biotin-cyanoethyl phosphoramidite monomer, allowing the addition of a biotin 
molecule at the 5’ terminus of the oligonucleotide. The growing DNA molecule is 
covalently linked to an inert support, Controlled Pore Glass (CPG), which is 
contained in a reaction column attached to the machine.
3.1.2 Oligonucleotide cleavage and deprotection
After synthesis, the oligonucleotide was removed from the CPG column by cleavage 
with concentrated ammonia solution. One and a half millilitres of concentrated 
ammonia solution was taken up in a disposable 5ml syringe which was attached to 
one end of the column. The ammonia solution was gently pushed into the column 
until it could be seen at the opposite end, to which a second 5ml disposable syringe 
was attached. The column was then left for 20 minutes at room temperature, after 
which a further column volume of ammonia solution was pushed into the column and 
again the column was left for 20 minutes at room temperature. This action was 
repeated until all the ammonia solution was passed through the column. After the
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final incubation period, the ammonia solution was pushed back and forth through the 
column several times to mix the solution. The solution was then pulled into one 
syringe and transferred to a screw cap eppendorf tube.
After cleavage of the oligonucleotide from the CPG column, deprotection of 
the oligonucleotide to remove the amide protecting groups took place. The microtube 
containing the cleaved oligonucleotide was placed in a water bath, heated to 55°C for 
a minimum period of 5 hours. The eppendorf tube was then removed and placed in a 
refrigerator at 4°C for 10-15 minutes. The deprotected oligonucleotide was then 
stored at -20°C.
3.1.3 Recovery of deprotected oligonucleotide
The ammonia solution containing the deprotected oligonucleotide was divided 
between three eppendorf tubes and evaporated in a centrifugal evaporator (Savant 
"Speedivac" concentrator). The dried oligonucleotide was then resuspended in IOOjllI 
of deionized water for immediate use or stored at -20°C. To avoid contamination, 
oligonucleotides were dried down in a different "Speedivac" to that used for RNA 
preparations and plasmids.
3.1.4 Purification of oligonucleotides
Oligonucleotides used were either purified or unpurified. Those to be purified by 
Applied Biosystems Oligonucleotide Purification cartridges were synthesised with 
their dimethyoxytrityl protecting group still attached to the final base. Deprotected 
oligonucleotides to be purified were not subjected to evaporation (described in 
section 3.1.3) instead, after deprotection a V3  volume of deionized water was added
to the oligonucleotide. A disposable 5ml syringe was attached to the purification 
cartridge. The cartridge was then flushed with 5ml of HPLC grade acetronitrile 
followed by 5ml of 2M triethylamine acetate. The syringe was removed from the
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cartridge prior to removing the syringe plunger. The deprotected oligonucleotide was 
then slowly pushed through the cartridge and collected, the flow rate being kept to 
one or two drops per second. The eluted fraction was then once more pushed slowly 
through the cartridge. The cartridge was then washed three times with 5ml of 1.5M 
ammonium hydroxide, followed twice with 5ml of deionized water. The bound 
oligonucleotide was then detritylated with 5ml of 2% trifluroacetic acid. One 
millilitre of trifluoracetic acid was pushed through the cartridge and 5 minutes were 
allowed to elapse before the remaining acid was pushed through. Once more the 
cartridge was washed twice with 5ml of deionized water. The purified, detritylated 
oligonucleotide was eluted by slowly washing the cartridge with 1ml of 20% 
acetonitrile. The optical density at 260nm was then determined.
3.2 Quantitation of nucleic acids
The concentration of nucleic acids was determined by the optical density (O.D) at 
260nm using a Beckman DU-62 spectrophotometer.
A value of 1 at OD260  is equivalent to: 50mg/ml for double stranded DNA.
40mg/ml for RNA or single stranded DNA. 
20mg/ml for oligonucleotides.
The purity of a nucleic acid preparation was assessed from the ratio of absorbance at 
260nm/280nm, a pure DNA preparation having a ratio of 1.8 and a pure RNA 
preparation having a ratio of 2.
The molar concentration of oligonucleotides was determined directly as 
O.D260/EM (molar extinction coefficient).
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Phenol was melted at 60°C and aliquoted in 5 or 10ml volumes into universals which 
were stored at -20°C. When required, an aliquot of phenol was melted at 60°C and an 
equal volume of deionized water or lx TE buffer (pH 7.5) added at room temperature 
and thoroughly mixed with the phenol. The mixture was allowed to settle into two 
phases. The water saturated or TE saturated phenol solution was stored at 4°C for up 
to two months.
3.4 Human sera
All human sera were stored at -20°C in small sealed aliquots. When required, the 
sera were thawed at 4°C. A fresh aliquot of serum was used in each experiment.
3.5 Extraction of RNA from human sera
The method for extraction of RNA from human sera is adapted from the acid 
guanidium thiocyanate-phenol-chloroform extraction technique devised by 
Chomczynski and Sacchi (1987).
One hundred microlitres of human serum was gently mixed with 300|li1 of 
denaturing solution D and 300fil of water-saturated phenol, to which ljig/ml of 
purified carrier transfer RNA (sheep fibroblast) was added. Fifty microlitres of 
chloroform was added and the mixture incubated on ice for 15 minutes. After 
centrifugation at 1400g at 4°C for 15 minutes the aqueous phase was removed to a 
fresh tube and re-extracted with an equal volume of chloroform. The RNA was 
precipitated with an equal volume of isopropanol at -20°C overnight. RNA was 
pelleted by centrifugation at 14000g at 4°C for 15-20 minutes. The RNA pellet was
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then washed once with 70% ethanol, and centrifuged at 12000g at 4°C for 5 minutes. 
The RNA pellet was allowed to air dry at room temperature or dried under vacuum 
for several minutes, before being resuspended in IOjllI of deionized water. RNA was 
stored at -70°C.
3.6 Amplification of RNA
All reagents for reverse transcription and polymerase chain reaction were aliquoted 
before use and filtered/plugged tips used at all times.
3.6.1 Reverse transcription (RT)
First strand complementary DNA (cDNA) was synthesised from 3fil extracted RNA
using lOOunits of Moloney Murine Leukaemia reverse transciptase (M-MLV RT) in 
50mM Tris-HCL (pH 8.3), 75mM KC1, 3mM MgCl2 , 10mM DTT, ImM each of
dGTP, dATP, dTTP and dCTP, 40pmol of random hexamers or specific antisense 
primer and lunit of RNAsin in a final volume of 20pl Incubation then took place at 
25°C for 10 minutes, followed by 37°C for 55 minutes and 95°C for 5 minutes. After 
incubation was complete, products reaction were stored at 4°C.
3.6.2 Polymerase chain reaction (PCR)
PCR is a rapid procedure for the in vitro enzymatic amplification of a target segment 
of DNA (Saiki et al., 1985; Mullis & Faloona, 1987). Two oligonucleotide primers, 
complementary to and flanking the two strands of the target DNA are synthesised, 
the target DNA denatured and the primers annealed to opposite strands of the DNA, 
oriented with their 3' ends facing one other. DNA synthesis then occurs by the 
extension of the primers at their 3' ends by a thermostable DNA polymerase.
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Successive cycles of denaturation, primer annealing and extension result in an 
exponential accumulation of the target DNA.
The technique of 'nested' PCR was used to amplify HCV DNA from HCV 
cDNA. This involves two rounds of PCR, with product from the first round of 
amplification being subjected to a second round. The set of oligonucleotide primers 
used for the second round of amplification is internal to the set used in the first 
round. The use of nested PCR increases the specificity and amount of HCV DNA 
amplified. In the first round of PCR the reaction was carried out using 0.5 units of 
Taq DNA polymerase in 20mM Tris-HCl (pH 8.4), 50mM KC1, 1.5mM MgCl2 ,
0.2mM each of dGTP, dATP, dTTP and dCTP and 40pmol each of the outer pair 
nested primers in a final volume of 20)il. The reaction mix was then overlaid with 
50jlx1 of mineral oil. Amplification was performed over 35 cycles with an initial 
denaturation step of 95°C for 4 minutes followed by: 94°C/lmin.
55°C/2mins.
72°C/3mins.
One microlitre of first round product was then amplified in a second round of PCR, 
using the same reaction conditions described above except 40pmols each of the inner 
nested primers was used. Amplification was over 25 cycles. The number of cycles, 
reaction times and annealing temperature were varied (see results). Ten microlitres of 
PCR product was run on a 2% agarose gel containing ethidium bromide and 
visualised under shortwave ultraviolet light (UV).
3.7 Analytical agarose gel electrophoresis of DNA
Electrophoresis of DNA was performed on horizontal slab gel (11 x 14 x 0.5 cm) of 
2% (w/v) agarose in lx TBE or lx TAE containing 0.1 mg/ml ethidium bromide 
(EtBr). DNA samples were loaded onto the gel in loading buffer ( 50% sucrose, 
0.1M EDTA, 0.05% (w/v) bromophenol blue). Electrophoresis was performed at
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100-150 volts in lx TBE or lx TAE buffer, except for low melting agarose gels 
where electrophoresis was performed at 50-80 volts, until the dye front had migrated 
the required distance. The gel was then visualised under shortwave UV light and 
photographed.
3.8 Purification of DNA fragments from agarose gels
3.8.1 Extraction of DNA from a low melting agarose gel
Electrophoresis of the DNA of interest was performed using a 2% Nusieve agarose 
lx  TBE gel at 50-80 volts. The DNA bands were visualised under longwave UV 
light and the required DNA band excised from the gel. The excised DNA/gel slice 
was incubated at 60-65°C for 10 minutes until the agarose had fully melted. Two 
hundred microlitres of lx TE buffer (pH 7.5) was added and the mixture vortexed. A 
3/4  volume of TE saturated phenol (phenol saturated with lx TE buffer, pH 7.5, see 
section 3.3) was then added to the gel slice. The mixture was vortexed and the 
aqueous phase recovered by centrifugation (microcentrifuge, high speed) for 5 
minutes and re-extracted twice with an equal volume of lx TE (pH 7.5) saturated 
phenol. A further two extractions of the aqueous phase were performed, with equal 
volumes of chloroform. The DNA was recovered from the aqueous phase by 
precipitation, by adding a Vio volume of 3M sodium acetate and 2.5 volumes of 
ethanol and placing the tube in dry ice/ethanol for 5-10 minutes. The precipitated 
DNA was then pelleted by centrifugation for 10 minutes, washed with 750jil of 70% 
ethanol, dried under vacuum and resuspended in the appropriate volume of deionized 
water. The DNA was stored at -20°C.
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3.8.2 Silica matrix adsorption
A commercial kit, "Geneclean", which contains a specially formulated silica matrix 
called 'Glassmilk', which binds single and double stranded DNA in the presence of 
sodium iodide (Nal), was used for recovering DNA fragments from agarose gels. An 
agarose gel slice (in lx TAE buffer) containing the DNA of interest was mixed with 
3 volumes of Nal solution and incubated at 55°C for 5 minutes, until the agarose was 
completely dissolved. Glassmilk was added at a concentration of 5ml/5mg of DNA 
and the mixture incubated at 4°C for 10 minutes to allow the DNA to bind. 
Following a short spin (about lOsecs.), the pelleted glassmilk/DNA was washed 3 
times with 10-50 volumes of ice-cold 'New Wash' solution ( which contains Tris- 
HCl, EDTA , NaCl and ethanol) by repeated suspension and pelleting. The DNA was 
eluted from the glassmilk by resuspending the pelleted glassmilk/DNA in half the 
final volume of deionized water required and incubating at 55°C for 5 minutes. The 
glassmilk was pelleted by centrifugation (microcentrifuge) and the eluted DNA 
removed to a fresh tube. A second elution step was then performed. The eluted DNA 
was stored at -20°C.
3.9 Preparation of DNA for sequencing
3.9.1 Preparation of double stranded DNA templates derived from PCR 
products
Eighty to one hundred microlitres of second round PCR product was run on a 2% 
low melting point TBE buffered agarose gel, stained with EtBr and the DNA band of 
interest excised. DNA was then extracted from the agarose gel slice as described in 
section 3.8.1 and resuspended in 15-20jil of deionized water. The PCR products were
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cleaned prior to sequencing to remove any excess primer and non-specific amplified 
products.
3.9.2 Generation of single stranded DNA templates derived from PCR products
'Dynabeads' M-280 Streptavidin (Dynal Int.), magnetic beads with streptavidin 
covalently attached to the bead surface, were used to generate single stranded DNA 
from PCR products. Essential for the use of Dynabeads is the biotinylation of the 
PCR oligonucleotide primers. Two 50|il volume second round PCR reactions were 
performed; in the first PCR reaction, biotinylated sense and unbiotinylated antisense 
primers were used and in the second, unbiotinylated sense and biotinylated antisense 
primers were used. PCR reactions were performed using the conditions described in 
section 3.6.2.
A: Preparation of Dynabeads M-280 Streptavidin.
The Dynabeads M-280 were resuspended by pipetting back and forth, the beads were 
never vortexed or centrifuged. The appropriate volume of Dynabeads M-280, 20pl 
per PCR reaction (at concentration of lOmg/ml) was placed into a microtube. The 
tube was then placed in a Dynal' (MPC) magnetic stand for at least 30 seconds and 
the supernatant removed by aspiration. The tube was then removed and an equal 
volume of PBS containing 0.1% BSA was added and the beads gently resuspended. 
Once more the tube was placed in the magnet and the supernatant removed. The 
beads were then resuspended in 2 volumes of 'Binding and Washing' (B&W) buffer, 
to a final concentration of 5mg/ml.
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B: Immobilisation.
Forty microlitres of pre-washed beads were added to 40jll1  of amplified PCR product 
and incubated for 15 minutes at room temperature. The beads were kept resuspended 
during this incubation period by gently rocking the tube. The tube was then placed in 
the magnet and the supernatant removed. The beads were then washed with 40jli1  of 
B&W buffer.
C: Denaturation.
The tube containing the immobilised product was placed in the magnet and the 
supernatant removed. Eight microlitres of freshly prepared 0.1M NaOH solution was 
added to the beads, which were resuspended and incubated for 1 0  minutes at room 
temperature. Once more the supernatant was removed by placing the tube containing 
the beads in the magnet. The beads were washed once with 50 |lU  of 0.1M NaOH, 
followed by 50jli1 of B&W buffer and then 50jll1 of lx TE buffer (pH 7.5). The beads 
were finally resuspended in 10-20|il of lx TE buffer (pH 7.5).
3.10 Dideoxynucleotide sequencing
The dideoxynucleotide chain termination method of Sanger et al. (1977), using the 
Sequenase Version 2.0 DNA Sequencing kit (United States Biochemical) according 
to a modified version of the manufacturers protocol, was used to determine DNA 
sequence. In the original procedure of Sanger et al. (1977), primer extension was 
catalysed by the Klenow fragment of E.coli DNA ploymerase I. The Sequenase 
Version 2.0 kit uses a genetic variant of bacteriophage T7 DNA polymerase (Tabor 
& Richardson, 1989). A list of solutions provided in the kit is provided in Table 3.1.
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Table 3.1 List of reagents contained in the Sequenase
Version 2.0 DNA Sequencing Kit.
Sequenase Buffer (5X concentrate)
Dithiothreitol (DTT) solution 
Labelling Mix (dGTP) (5X concentrate) 
ddGTP Termination Mix
ddATP Termination Mix
ddTTP Termination Mix
ddCTP Termination Mix
Sequence Extension Mix (dGTP)
Stop Solution
Enzyme Dilution Buffer
Sequenase Version 2.0 T7 DNA Polymerase
200mM Tris-HCl (pH7.5), lOOmM 
MgCl2 , 20mM NaCl
0.1M
7.5mM each dGTP, dTTP, dCTP
80mM each dGTP, dATP, dTTP, 
dCTP, 8 mM ddGTP, 50mM NaCl
80mM each dGTP, dATP, dTTP, 
dCTP, 8 mM ddATP, 50mM NaCl
80mM each of dGTP, dATP, dTTP, 
dCTP, 8 mM ddTTP, 50mM NaCl
80mM each dGTP, dATP, dTTP, 
dCTP, 8 mM ddCTP, 50mM NaCl
180mM each dGTP, dATP, dTTP, 
dCTP, 50mM NaCl
95% Formamide, 20mM EDTA 
0.05% Bromophenol Blue,
0.05% Xylene Cyanol FF
lOmM Tris-HCl (pH7.5), 5m DTT, 
0.5mg/ml BSA
13 units/ml in 20mM KPO4  (pH7.4), 
ImM DTT, O.lmM EDTA, 50% 
Glycerol
Chapter 3
A: Annealing reaction.
Seven microlitres of DNA template, either single or doubled stranded DNA, was 
mixed with lpi of the appropriate primer (5pmol/|il). For single stranded DNA the 
annealing reaction was performed at 37°C for 30 minutes. For double stranded DNA, 
the annealing reaction was preceded by incubation at 95°C for 2 minutes, 70°C for 3 
minutes and 95°C for 45 seconds. Annealing was carried out at 37°C for 15 minutes. 
Incubation was briefly interrupted after 2.5 minutes at 70°C to centrifuge the tubes to 
ensure all the template/primer mixture was subjected to annealing at 37°C. After 
annealing was complete the tubes were transferred directly to ice.
B: Labelling reaction.
Before this reaction was carried out, the tubes for the termination reaction were 
prepared (see section C). The labelling mix, supplied in the Sequenase Version 2.0 
kit (Table 3.1), was diluted 10-fold with deionized water. To the tube containing the 
annealed template/primer, 2pl of reaction buffer, 2 pI of 1 0 -fold diluted labelling mix, 
ljil of 0.1M DTT and I jliI of a-^^S dATP (lOmCi) were added and the tube briefly 
centrifuged to mix contents. Two microlitres of an 8 -fold dilution of Sequenase 
Version 2.0 T7 DNA polymerase was added and the tube incubated at 25°C for 2 
minutes.
C: Termination reaction.
Two and a half microlitres (2.5]ll1) of each termination mix for G, A, T and C tracks 
(Table 3.1) were added to individual tubes (one set per template/primer reaction). 
The tubes were pre-incubated at 37°C for at least 1 minute prior to use. Three and a 
half microlitres (3.5jil) of the completed labelling reaction was added and mixed 
with each of the four termination mixes. The tubes were incubated at 37°C for 3-5
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minutes before termination of the reaction by the addition of 4pl of stop solution 
(Table 3.1)
The above termination protocol was used when sequencing PCR products 200- 
500 nucleotides in length. When PCR products greater than 500 nucleotides were to 
be sequenced, the termination mixes were adjusted. A half microlitre (0.5|il) of 
dGTP sequence extending mix (Table 3.1) was added to 2jil of each termination mix 
and the incubation time for the termination reaction was extended to 5-8 minutes.
D: Sequencing gel.
The 'Sequagel' system (National Diagnostics Ltd.) is a 'ready to use' system for the 
preparation of polyacrylamide gels. For DNA sequence analysis a 5% sequencing 
gel, containing a final concentration of 8.3M urea in lx TBE buffer was made from 
mixing 30ml of Sequagel concentrate with 70ml of Sequagel diluent and 10ml of 
Sequagel buffer. Polymerisation of the gel was catalysed by adding 8 0 0 |li1  of 10% 
(w/v) ammonium persulphate and 40pl of TEMED for every 100ml of gel casting 
solution. The BRL model S2 electrophoresis apparatus was used to run the gels. 
Sequencing gels (30 x 40 x 0.4 cm) were prepared as described by Maniatis et al. 
(1992). The sequencing gel was pre-run at 70 watts for 30-60 minutes in lx 
sequencing buffer. Prior to loading onto the gel, single stranded DNA sequencing 
reactions were heated at 72°C for 3 minutes to elute the DNA from the Dynabeads. 
Double stranded DNA sequencing reactions were heated at 90°C for 3 minutes to 
denature the DNA. Two and a half to three and a half microlitres (2 .5 -3 .5 jl l1 )  of each 
termination reaction was loaded into the appropriate well and electrophoresis was 
performed at 70 watts until the dye fronts had migrated the required distance. After 
electrophoresis was complete, one of the glass plates was carefully removed and the 
gel fixed in a solution of 10% methanol/10% acetic acid(glacial) for 10-15 minutes. 
The gel was then transferred to a supporting sheet of Whatman 3MM filter paper,
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covered with 'cling film' and dried for 1-2 hours using a vacuum gel drier. The cling 
film was removed and the gel exposed to X-OMAT S film at room temperature.
3.11 Recombinant Immunoblot Assay (RIBA)
A commercial in vitro qualitative enzyme immunoassay for the detection of 
antibody to HCV, the Chiron RIBA HCV 3.0 Strip Immunoblot Assay, kindly 
donated by Ortho Diagnostics Systems Inc., was used to test patient serum samples 
of interest for the presence of HCV antibodies. In the above mentioned commercial 
kit, HCV recombinant antigens and peptides are immobilised as individual bands on 
a nitrocellulose strip. Solutions provided in the kit are listed in Table 3.2. During 
incubation of the strip with a serum sample, antibodies to HCV, if present, will react 
with the corresponding recombinant antigen and/or peptide band on the strip.
Before beginning the assay, the kit was removed from storage at 4°C and 
allowed to come to room temperature. The desired number of nitrocellulose strips 
were removed and 1ml of specimen diluent was added to each strip contained in own 
individual tube. Twenty microlitres of the appropriate serum sample or control was 
added. The tubes were put into a rack and rocked for 4 hours at room temperature. 
The specimen diluent was aspirated and 1ml of fresh specimen diluent added. The 
tubes were returned to the rocker for a further 30 minutes. Again the diluent was 
aspirated and 1ml of wash buffer added. The wash buffer and the all the strips were 
placed in a wash vessel, containing 30ml of wash buffer. The vessel was agitated 
briefly (5-10mins) and the buffer decanted. A further wash was performed before 
lml of conjugate per strip was added. The wash vessel was then placed on a rotary 
shaker at 110 ± 5 rpm for 10 minutes at room temperature. The conjugate was 
removed and the strips washed three times with wash buffer, lml of substrate per 
strip was added. The strips were agitated, on the rotary shaker for 15 minutes, again 
at room temperature. The substrate was removed by aspiration and the strips washed
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Table 3.2 List of reagents contained in the Chiron RIBA
HCV 3.0 Immunoblot Assay.
Specimen Diluent 
detergent
Conjugate
Substrate Solution 
Substrate Buffer 
Wash Buffer Concentrate 
Positive Control
Negative Control
Phosphate buffered saline with protein stabiliers and
Goat anti-human IgG (heavy and light chain 
specific) conjugated to horseradish peroxide with 
protein stabilizers
4-chloro-l-naphthol in methanol
Buffered hydrogen peroxide
Buffered detergent solution
Source: Heat and psoralen treated human serum 
containing anti-HCV and nonreactive for HBsAg 
and anti-HIV.
Source: Human serum nonreactive for antibody to 
HCV or HIV and to HBsAg.
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twice with deionized water. Using forceps, the strips were transferred to absorbent 
paper and allowed to air dry in the dark at room temperature. The strips were 
interpreted within three hours of them drying (see results).
3.12 Restriction enzyme digestion of DNA
DNA was digested with the appropriate restriction enzyme (normally 1 unit/jLig 
DNA) in the appropriate restriction enzyme buffer, according to manufacturers 
instructions. For the analysis of small scale plasmid DNA preparations, 3|il of DNA 
was digested in a 20jli1 volume reaction containing 25)j,g/ml RNase A at 37°C for 2 
hours. DNA fragments were separated by gel electrophoresis.
3.13 Single stranded conformation polymorphism (SSCP)
Single stranded conformation polymorphism (SSCP) analysis is a method for 
detecting single base differences in PCR products, by detection of mobility 
differences of single stranded (ss) DNA in non-denaturing polyacrylamide gels 
during electrophoresis. It was thought that by employing this technique we would 
have a relatively simple detection method for sequence changes in the HVR of HCV 
from serum samples from a patient over time, detecting minor variants as well as the 
predominant variant, thus decreasing the number of samples needing to be 
sequenced.
PCR reactions on the samples of interest were performed. The PCR products 
were denatured prior to loading onto the polyacrylamide either by heat denaturation 
or alkali denaturation. ljil of loading buffer ( 0.5% bromophenol blue and 0.5% 
xylene cyanol FF in formamide ) was added to lOpl of PCR product and the products 
heat denatured at 95°C for 5 minutes and snap-cooled on dry ice/ethanol.
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Alternatively, 1 jui of 0.5M NaOH and ljxl of lOmM EDTA was added to 10 jil of 
PCR product and heated to 42°C for 5 minutes before adding l|il of loading buffer. 
The PCR products were then loaded onto a non-denaturing polyacrylamide gel, of 
varying composition (Table 3.3). The polyacrylamide gels were poured using vertical 
gel apparatus (Protean II kit from Biorad) and run at 15-30 V cm- 1 (350-600V) for 
1.5-2.5 hours and maintained at 20-22°C by circulating cold water. The gels were 
stained with either by EtBr or silver. Two methods for silver staining the gels were 
used (Table 3.4).
SSCP was also performed using 32P labelled PCR products. 0.2mM of y-32P 
dATP instead of 'cold' dATP was used in the PCR reaction, 2pl of radioactive PCR 
product was mixed with 8 jll1 of 'cold' PCR product and denatured, by one of the 
methods described above. The products were run on a gel along with a radiolabelled 
lOObp marker (GIBCO, BRL) which was labelled according to manufacturers 
instructions. The gel was dried and exposed to X-OMAT S film at -70°C.
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Table 3.3 Composition of polyacrylamide gels used for 
SSCP analysis.
Gel % gel 
(w /v)
Ratio polyacrylamide: Buffer 
bisacrylamide
G lycerol
(w /v)
1. Stacking gel
i) Lower gel 6 49:1 0.5x TBE 5
ii)Upper gel* 8 19:1 0.2x TBE NA
2 . 7 49:1 0.5X TBE 5
3. 5 4:1 0.5X TBE 5
NA. Not applicable
*75% formamide was added to this gel.
Table 3.4 Silver staining methods
Method 1.
Step 1. Fix gel for 2-3hrs in soln. I ( 25% ethanol, 10% acetic acid).
Step 2. Discard soln. I and leave gel overnight in soln. II (10% ethanol, 0.5%
acetic acid).
Step 3. Discard soln. II and add soln. Ill (0.19% silver nitrate, 99.81% ). Leave 
for 2 hrs.
Step 4. Discard soln. Ill and wash gel with deionized water.
Step 5. Add soln. IV (3% sodium hydroxide, 0.009% sodium borohydride,
0.76% formaldehyd). Shake gel gently over a light box until bands 
appear. Approx. 5-15mins.
Step 6 . Discard soln. IV and fix gel in soln. V (5% acetic acid). Fix for lhr.
Method 2.
Step 1. Fix gel in soln. I (7.5% acetic acid) for 5-30mins.
Step 2. Wash gel three times with deionized water. 2-5mins.
Step 3. Add soln. II (0.15% silver nitrate, 0.056% formaldehyde) for 10-
60mins.
Step 4. Discard soln. II and wash gel with deionized water.
Step 5. Add soln. Ill (3% sodium carbonate, 0.056% formaldehyde, 0.04%
sodium thiosulphate) and gently shake gel over light box until bands 
appear. Approx. 2-10mins.
Step 6 . Discard soln. Ill and fix gel in soln. IV (7.5% acetic acid) for 5mins.
Chapter 4 Results: Section 1
Sequence evolution of the HVR1 of the putative envelope 
gene E2 of hepatitis C virus in patients on haemodialysis.
The work presented in this chapter was undertaken to characterise the emergence of 
sequence variants of the hypervariable region (HVR1) at the 5' end of the gene coding 
for the putative envelope protein E2 of HCV and to examine the possible association of 
periods of liver dysfunction with sequence changes in HVR1 in patients on long term 
dialysis. The E2 HVR1 is defined in the work presented here as between nucleotide 
positions 1150 and 1233 and amino acid positions 384 and 411 (numbering according 
to Choo et al., 1991).
A characteristic of the HCV genome is sequence heterogeneity. Comparisons of 
HCV isolates from different infected individuals showed sequence variation between 
isolates (Choo et al., 1991; Kato et al., 1990; Takamizawa et al., 1991). Previous 
studies have shown that the HCV genome is heterogeneous not only between different 
infected individuals but also within the same individual (Ogata et al., 1991; Okamoto et 
al., 1992b). The HVR1 domain in particular undergoes diversification of its sequence 
with time in an individual (Kato et al., 1992a, 1994; Kurosaki et al., 1993; Sakamoto et 
al., 1994). The high substitution rate observed in the viral envelope proteins, especially 
the HVR1, may be driven by the immune system since the envelope proteins, located 
on the surface of the virion, are likely to be the principal target of the host's humoral 
immune response. The emergence of viral escape variants has, therefore, been 
proposed as a possible mechanism by which HCV is able to maintain a persistent 
infection.
A characteristic clinical feature of hepatitis C is the episodic fluctuating pattern of 
alanine transaminase (ALT) and aspartate transaminase (AST) levels. Periods of 
elevated ALTs and ASTs, lasting from weeks to months, are interspersed with periods
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of normal or near normal levels. Since the levels of the two enzymes generally move in 
parallel, in this work only the ALT levels have been studied in detail. ALT levels are 
used as an indicator of liver damage because ALT is primarily found in hepatocytes 
rather than other cell types. When hepatocytes are damaged, ALT is released into the 
bloodstream.
The emergence of a new sequence variant of HCV might be expected to be related 
to a period of liver cell damage in one of two ways, depending on whether damage to 
hepatocytes is due to a direct cytopathic action of HCV or to the destruction of HCV 
infected hepatocytes by the host’s immune system. If an elevation in ALT was the 
result of a direct cytopathic action of HCV, the vims would infect hepatocytes and viral 
replication would take place resulting in hepatocyte damage and the release of infectious 
vims. This in turn would lead to an increase in the number of hepatocytes infected with 
HCV. The net result of this process would be liver damage, seen as an elevation in 
ALT. The appearance of antibodies which could neutralise the infectious vims before it 
is able to infect an hepatocyte would result in a period of lower viral replication and less 
liver damage. With the emergence of a new sequence variant which is not recognised 
by existing antibody there would be an increase in the number of hepatocytes being 
infected, resulting in an increase in liver damage. In this model the level of viral 
replication would be high during an elevation in ALT and the new sequence variant 
would emerge before the ALT peak.
Alternatively, liver damage might result from the destmction of infected 
hepatocytes by the host's immune system. HCV infected hepatocytes which are 
recognised by the host's immune system would be destroyed, resulting in an elevation 
in ALT and fewer infected hepatocytes. Hence, there would be a decrease in the level of 
viral replication. This would give a selective advantage to other HCV variants which 
caused the infected hepatocytes to display different epitopes leading to the emergence of 
a new predominant variant. This leads to an increase in the number of infected 
hepatocytes and so, an increase in the level of viral replication. In this model, the level
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of viral replication would be low during an elevation in ALT and a new sequence 
variant would appear some time after the ALT peak.
Although elevations of ALT are not uncommon in patients on long-term renal 
dialysis, HCV infected patients are more likely to have elevated ALT levels than 
uninfected patients (McIntyre et al., 1994). To characterise the emergence of genetic 
variants and examine their possible association with periods of liver dysfunction, the 
HVR1 domain was studied retrospectively in three renal haemodialysis patients.
4 .1  Study patients
Three haemodialysis patients chronically infected with hepatitis C were studied. Sera 
from all three patients were positive by second generation ELISA (Abbott Lab.), 
confirmed by third generation RIBA (Ortho Diagnostic Systems Inc.) and for HCV 
RNA by RT-PCR using primers derived from the 5'NCR. Previous work in the 
laboratory had shown changes in the RIBA pattern over time in renal dialysis patients 
from either indeterminate result to a positive result or positive to an indeterminate 
(McIntyre et al., 1994). However, the results of the third generation RIBA for these 
three patients (Figure 4.1) showed no loss of antibody to any of the expressed antigens 
over time.
Patient KR a 53 year old male (when the first sample was examined). HCV RNA 
was detected by RT-PCR using primers amplifying the 5'NCR of the genome in July 
1990 but no antibody was detected by either ELISA or RIBA until October 1990. He 
had been on regular haemodialysis since 1989 after two failed transplants and had a 
third kidney transplant in April 1990 which failed immediately. The source of the virus 
infecting this patient is not known. Sera from the kidney donor in 1990 and donors of 
blood cross matched for transfusion between April 1990 and the first RT-PCR positive 
result were all PCR and antibody negative for HCV.
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Patient SF a 43 year old female (when the first sample was examined). The first 
available serum taken in December 1982 was antibody positive for HCV. Both the 'time 
and source of infection for this patient are unknown. SF has been on haemodialysis 
since 1976 and has had two transplants which both failed.
Patient FAL a 43 year old female (when the first sample was examined). The first 
available serum taken in January 1986 was antibody positive for HCV. Both the time 
and source of infection are unknown. FAL was on regular haemodialysis from 1976 
until she was successfully transplanted in 1992.
Patients KR and FAL are infected with HCV genotype la  and patient SF with 
HCV genotype lb. This information was kindly provided by Dr June Munro and was 
determined by sequence comparison of the NS5 "V3" region (amino acids 2356 to 
2379) with reference sequences (Kato etal., 1990; Choo et al., 1991; Inchauspe et al., 
1991; Takamizawa et al., 1991) as part of a molecular epidemiological study.
The serum samples were taken for ordinary diagnostic purposes and not 
specifically for this study. Because of this, it is likely that the samples, especially the 
earlier ones, had been thawed several times and may have been subject to adverse 
conditions e.g. left at room temperature which leads to a reduction in RNA titre (Busch 
et al., 1992) or exposure to bacterial and fungal contamination. To address this, once 
the study was underway, aliquots of the sera were stored at -20°C until needed, to 
reduce the number of freeze-thaw cycles and chance of becoming contaminated.
Serum samples taken at regular intervals were available for the study from 1990 
to 1994 for patient KR, from 1986 to 1994 for patient SF and from 1986 to 1992 for 
patient FAL. Thirteen sera were obtained from patient KR over a three year period from 
1991-1994, eleven from patient SF over a six year period from 1988-1994 and eleven 
sera from patient FAL over a four year period from 1988-1992, after a successful 
transplant in (August) 1992 no further samples were taken until 1994 when a further
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sample was obtained for the purpose of this study, making twelve in total. These 
samples are listed in Tables 4.1 to 4.3.
4 .2  Amplification of the hypervariable region
HVR1 sequence variants which emerged during the course of infection in each patient 
were detected by RT-PCR. Viral RNA extracted from patient sera was reversed 
transcribed to give cDNA copies of the virus genomes. For the majority of samples, 
random hexamers were used for reverse transcription of RNA; for a few samples 
reverse transcription was performed with antisense primer (c48 or SF4). Table 4.4 
shows the sequence and position of primers used. Nested PCR was then performed. 
(See Chapter 2 section 3.6.2.)
A difficulty arose in that a single primer combination would not amplify the 
HVR1 from all samples. The original intention was to amplify both envelope genes, El 
and E2 using the primers SF1/SF4 in the first round of amplification and SF3/SF4 in 
the second, but this proved unsuccessful. It was then decided to amplify only the E2 
HVR1 using primers described in the literature (Weiner et al., 1992). The combination 
of primers of X14/X18 for the first round of amplification and X4/X19 for the second 
proved unsuccessful. On each occasion the X19 primer was used, no product was 
amplified. Using SF3/SF4 as the outer set of primers with X14/X18 as the inner set 
proved successful. It was felt, however, the PCR would be more efficient if the outer 
and inner set of primers were closer together. For this reason primers based upon those 
published by Cha et a l (1992), c48/c58, were synthesised (Table 4.4) to be used in 
conjunction with SF3/SF4 instead of X14/X18; however, not all the samples would 
amplify using this combination. A third primer combination was tried; c48/c58 as the 
outer primers and X14/X18 as the inner primers. This combination amplified some, but 
not all, of the samples which the other two primer combinations had failed to amplify. 
The final primer combination tried was c48/SF4 and X14/X18 which amplified some of
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Table 4.1 Sera studied from patient KR
Sample Diagnostic laboratory Date sample taken 
Number
A 127/91 01-01-91
B 1532/91 05-03-91
C 6495/91 10-10-91
D 6110/92 14-08-92
E 8235/92 26-10-92
F 8657/92 04-11-92
G 87/93 06-01-93
H 3216/93 14-04-93
I 3955/93 07-05-93
J 8215/93 10-10-93
K 9122/93 08-11-93
L 631/94 24-01-94
M 2771/94 06-04-94
Table 4.2 Sera studied from patient SF
Sample Diagnostic laboratory Date sample taken 
Number
A H2070/88 09-06-88
B H2393/89 07-07-89
C H3887/89 09-11-89
D 2505/90 04-04-90
E 5020/90 11-07-90
F 173/91 09-01-91
G 6552/91 02-10-91
H 9614/92 ' 02-12-92
I 110/93 06-01-93
J 6494/93 04-08-93
K 636/94 24-01-94
Table 4.3 Sera studied from patient FAL
Sample Diagnostic laboratory Date sample taken 
Number
A H767/88 02-03-88
B H2373/88 06-07-88
C HI 599/89 03-05-89
D 3203/90 01-05-90
E 8475/90 04-12-90
F 158/91 08-01-91
G 2198/91 02-04-91
H 6537/91 01-10-91
I 8283/91 08-11-91
J 129/92 07-01-92
K 5111/92 07-07-92
L No code assigned 12-09-94
Ta
bl
e 
4.4
 
O
lig
on
uc
le
ot
id
e 
pr
im
er
s
V
I/}
p
<N CM
tg tg
CM
H
w
04 CM CM CM CM CM
CMw
P4w w 3  W W W W W Q
U U h U U U U U H
V
' S * 
+* s  
© © «  r
a  *
5  °  £  &
o r - VO CM
00 SO O i—H so 1-H
CM co Tt O ■^H OS CM SO
O CO 4-H i—1 CM OO
in wo o O o 1—1 o Os O
o o 4—> -4-4 -4— 4 O - 4 - 4 O -4— 4
■4— > +-> VO 00 -4— 4 CO ■4— 4 CO
oo CM m 00 r ^ Os
c - 1 -H O o r - CM so CO
m r —H CM 1—* Ov
m
t
IT)
(VV 
©V 
© cr v
c»
V
s•mmu
3 U O u  o
o  o
o  o
U o o  o
3 o  u
u  o
<  H
u  o
C/3 C/3
C/3 / — \ccj Vi ca
0/3
H to ' t  ^  M ©s no 00
ft f t r i S  r ;  CJ ”  »n
00 CO 00 X X X X O O
ON
ON
OO.G
u
o•<-»
bOc
'SI-Hoo0
00
g
• Vh<u
1  
£
C/3 *
<D
G 
O ’-»—> o 
'C
P<oo
W
P i
C/3
<D
-4— 4o
G<D
Q
=a= f 
Ba
se
d 
on 
the
 
W
ein
er
 e
t 
al.
 (
19
92
) p
ri
m
er
s. 
$ 
Ba
se
d 
on 
the
 
Ch
a 
et 
al
. 
(1
99
2) 
pr
im
er
s.
Chapter 4
the missing samples. Figure 4.2 shows an example of the products amplified. There 
were still some samples in which HCV RNA was detected by RT-PCR of the 5 'NCR 
but in which the HVR1 could not be amplified using any of the above primer 
combinations. Table 4.5 summarises the successful primer combinations and 
amplification conditions. Different annealing temperatures and magnesium 
concentrations were also investigated. The conditions used in this study were those 
found to give the optimal results.
RNA was extracted from two separate aliquots of the original serum samples to 
ensure there had been no mix up in samples and to detect any potential artefacts that 
might arise from misincorporation of bases by Taq polymerase during amplification. 
Therefore, two independent sequences for each serum sample were obtained.
Amplification of HVR1 from early serum samples from the patients proved 
difficult, especially for patient KR around the time he became infected (1990). A 
previous worker within the laboratory in 1991 had successfully amplified the 5 'NCR 
from sera taken from this patient from July 1990 onwards. Possibly subsequent storage 
and handling conditions of the semm had affected the stability of the HCV RNA.
4 .3  Direct sequencing
The PCR products were purified and directly sequenced as described in Chapter 2 
sections 3.8.3, 3.9 and 3.10. The primers used for sequencing were X4, X14, X I 8 , 
c48 and c58. The majority of samples were sequenced using primers X4 and X I8 . As 
each serum was sampled twice, four sequencing reactions were performed; two in the 
sense and two in the antisense direction. A consensus sequence was then derived. At 
some positions on the gel, a sequence ambiguity was observed. Direct sequencing can 
identify both the predominant sequence and minor sequences, resulting in a mixture of 
bases (i.e. two bases) at the same position on the sequencing gel, see Figure 4.3.
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Table 4.5 Amplification conditions
Primer
combination
No. amplification 
cycles
PCR conditions
SF3/SF4 2 t 94°C/1 min
45°C/2 mins
72°C/3 mins followed by
28t 94°C/1 min 
55°C/2 mins 
72°C/3 mins
X14/X18 25t 94°C/1 min 
60°C/2 mins 
72°C/3 mins
c48/c58 35t 94°C/1 min 
55°C/2 mins 
72°C/3 mins
251: 94°C/1 min 
55°C/2 mins 
72°C/3 mins
C48/SF4 30t 94°C/1 min 
55°C/2 mins 
72°C/3 mins
t  Denotes first round amplification.
$ Denotes second round amplification.
Figure 4.3 Direct DNA sequencing of a PCR amplified HVR1 cDNA 
fragment. The gel identified heterogeneity in the sample. Both the sense and 
antisense sequencing direction are shown. Mixed base positions present in the 
sample are indicated by arrows 1 to 3. At position 1, a mixture of thymine and 
cytosine are seen, since the thymine base displays the strongest signal intensity 
between the two bases in both directions it is recorded as the predominate base at 
that position; at position 2 , a mixture of adenine and thymine are seen, in the sense 
direction the adenine base displays the strongest signal intensity but in the antisense 
direction the bases are of equal intensity, this would be recorded as a mixed base 
position; and at position 3, a mixture of thymine and cytosine of equal signal 
intensity are seen in the antisense direction whereas only thymine is seen in the 
sense direction. The thymine at position 3 in the sense direction is seen more clearly 
on other gels of the same sequence and so, the thymine is recorded as the 
predominate base at this position.
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Chapter 4
To distinguish between the predominant sequence and minor sequences and derive the 
consensus sequence, the following criteria were used :
1) If the sequencing gel showed two bases at a given position and one base displayed 
the strongest signal intensity in at least three of the four sequences it was recorded as 
the predominant base.
2) If at least two sequences showed a mixture of bases in both the sense and antisense 
direction of equal signal intensity, a mixed base position was recorded.
3) If two of the four sequences showed a mixture of bases but were the same sense, 
the predominant base was recorded as the base displayed in the sequence of the 
opposite strand.
HVR1 sequences were aligned using the programs PILEUP and PRETTY for 
nucleotide comparisons and TRANSLATE, PILEUP and PRETTY for derived amino 
acid sequence comparisons. These are programs in the Genetic Computer Group 
sequence analysis package version 7. The sequence data was also analysed using the 
computer program PHYLIP version 3.5 (Felsentein., 1993) and the MEGA, Molecular 
Evolutionary Genetics Analysis, package version 1.01 (Kumar.S et al., 1993).
4 .4  Emergence of HVR1 sequence variants in Patient KR
ALT levels were normally measured at least twice a month. Unfortunately due to 
difficulties experienced with amplifying HCV RNA from patient sera and because 
samples were not sent to the Virology Laboratory every time ALTs were performed, 
HCV sequences could not be obtained at each time for which an ALT level is available. 
The ALT profile of patient KR is shown in Figure 4.4. The graph depicts the highest 
ALT value recorded each month. The arrows depict the times at which HCV sequences
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Chapter 4
were detected. Until 1990, the ALT levels were normal (<40 U/L). In April of 1990 the 
ALT level peaked at 134 U/L after KR received his kidney transplant. The ALT level 
returned to normal before peaking again in July (186 U/L), the month during which 
HCV RNA was detected for the first time. Between July and October the ALT level 
was normal or near normal before increasing in October to levels above 200 U/L at 
which time antibody to HCV (by 3rd generation RIBA) appeared. ALT levels remained 
elevated (above 100 U/L) until April 1991 after which they fluctuated, with peak values 
of between 124 to 380 U/L.
The predominant HVR1 nucleotide and deduced amino acid sequences are shown 
in Figures 4.5 and 4.6, respectively. The predominant HVR1 sequence found on 
sequencing sample A (Jan'91) changed within a period of 63 days with a new variant 
emerging, with a T to C transition at position 1204, (Phe-402 to Leu). Discounting 
mixed based positions, a total of nineteen nucleotide changes occurred in the HVR1 
over a period of three years, summarised in Table 4.6. All nineteen nucleotide changes 
were non-silent and occurred in either the first or second codon position. Transitions 
were; six G to A, three A to G, one T to C and one C to T. The transversions were, 
two A to T , two C to A and one each of T to G, C to G, T to A and A to C.
The first double band A/G (mixed base position) appeared at position 1211 in 
sample G (April 1993). This denoted two populations, one with Lys and one with Arg 
at position 404. Lys appeared at this position in the predominant HVR1 sequence in 
sample D (August 1992) changing to Arg in sample E (October 1992). Arg was found 
at this position in all subsequent sequences until sample M (April 1994), when an Arg 
to Ser change occurred. All of the mixed based positions resulted in the presence of two 
amino acids, one of which was present at that position in either a previous or a 
subsequent HVR1 variant sequence. The exception to this was the appearance of a G/T 
double band at position 1219 in samples H and I (April and May 1993) denoting Ala 
and Ser at position 407; Ala was found at this position in all other sequences. The 
predominant sequence found in sample M (April 1994) had a mixture of two bases 
(A/G) at nucleotide position 1340 (Figure 4.5) outside HVR1, predicting an asparagine
11
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Consensus VLLLFAGVDA-T— TGGAA— ST-Q----F-PG--QNVQL-NTN
Figure 4.6 Alignment of the derived amino acid sequences for HCV isolates from 
patient KR between residues 374 and 417. Consensus sequence for HVR (residues 
384-411) shown in red type face and underlined. Blue type face denotes an amino 
acid change, magenta type face denotes a second and green type face denotes a third 
change. Italics indicate the possibility of the presence of both amino acids, because 
of nucleotide sequence ambiguity. ^Numbering according to Choo et al. (1991).
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residue at amino acid position 420 (Figure 4.6) resulting in a potential N-linked 
glycosylation site. Figure 4.7 shows sequencing gels from isolates from KR. Arrows 
denote mixed base positions. When the mixed base positions are taken into account the 
ratio of transitions to transversions was 1. 1 to 1 ; without taking them into account the 
ratio was 1.4 to 1 (Table 4.6).
4 .5  Emergence of HVR1 sequence variants in Patient SF
The ALT profile of patient SF is shown in Figure 4.8. Persistently high ALT levels (up 
to 272 U/L) are observed from 1983 to 1986, after which normal or near normal levels 
prevailed apart from the occasional peak. During the observation period the ALT levels 
ranged between 11 and 49 U/L, apart from two peaks of 99 and 79 U/L in July 1990 
and 1991, respectively.
HVR1 nucleotide and amino acid sequences are shown in Figures 4.9 and 4.10, 
respectively. No changes are observed between June 1988 and April 1990. After this 
there is continuous change except in December 1992 and January 1993. The first 
sequence change observed occurs at the point where the ALT level has risen above 
normal in sample E (July 1990). A double band, C/T appears at position 1214 denoting 
the presence of Thr and He at amino acid position 405; previously only Thr was found 
at this position. Amino acid position 405 appears to be very variable. At the nucleotide 
level the changes which occur are A to T to C/T to G to A/C to C to A and back again to 
C. The result of these changes in terms of amino acid change is Thr to Thr/He to Ala to 
Thr/Pro to Pro to Thr to Pro. The double band, A/G, which appears at position 1167 
(sample F) and 1173 (sample G) does not lead to a change in amino acid (Figure 4.9 
and 4.10). A further silent mutation, C to T, occurs at position 1158 (sample H and I). 
The predominant HVR1 sequence obtained in sample J (August 1993) has Arg at 
position 400; Ser is at this position in all the other samples. Six amino acid changes 
occur between January and August 1993 with no peak in ALT being observed. The
64
Figure 4.7 Direct DNA sequencing of the PCR amplified cDNA fragments of 
the HVR1 from patient KR sera. Arrows ( ^ )  denote the HVR1. The regions of 
nucleotide changes between the four sequential samples are indicated by arrows 1 , 2  
and 3. At position 1 (sense strand) the sequence reads AAGAGAA in Jan'91 and 
Mar' 91 but ATGAGAA in Oct'91 and Aug'92, thymine having replaced adenine; at 
position 2 (sense strand) the sequence reads TTTCTTT in Jan'91 but TCTCTTT in 
Mar'91, Oct'91 and Aug'92, cytosine having replaced thymine; at position 3 (sense 
strand) the sequence reads GGAAA in Jan'91, Mar'91 and Oct'91 but GAAAA in 
Aug’92, adenine having replaced guanine.
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Figure 4.10 Alignment of the derived amino acid sequences of HCV isolates 
from patient SF between residues 378 and 417. Consensus sequence for HVR 
(residues 384-411) shown in red type face and underlined. Blue type face denotes an 
amino acid change, magenta type face denotes a second and green type face denotes a 
third change. Italics indicate the possibility of the presence of both amino acids, 
because of nucleotide sequence ambiguity. *Numbering according to Choo et cd. 
(1991).
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ratio of transitions to transversion is 1 .8  to 1 and 1 .2  to 1 , when mixed base positions 
are excluded.
4 .6  Emergence of HVR1 sequence variants in Patient FAL
The ALT profile of patient FAL is shown in Figure 4.11. FAL displays normal or near 
normal ALT values apart from the occasional peak, the highest of which is 102 U/L in 
August 1986. Figures 4.12 and 4.13 show the HVR1 nucleotide and derived amino 
acid sequences. Between sample A (March 1988) and sample G (April 1991) there are 
nine amino acid changes and between sample G and sample I (November 1991) there is 
only one change. At position 1156, a C to C/T change occurs. The resulting amino acid 
change is His to the combined presence of His and Tyr. At position 1198 a T/A to T 
change occurs, the result of which is the presence of Thr alone at amino acid position 
400. At position 1224 a T to T/G to a T change occurs, denoting the presence of Ser 
and Arg respectively, at position 408 in sample G. This is the only sequence difference 
between samples G and I. Base changes at positions 1180 and 1181 result in Arg being 
replaced by Tyr at amino acid position 394, resulting in a polar charged amino acid 
being replaced with a polar uncharged amino acid. At position 404 Ala, a hydrophobic 
amino acid is replaced by Ser, a hydrophilic amino acid. Ser-405 is replaced by Pro, 
the result of a T to C change at position 1213. Only one silent change occurs, G to G/A 
to A , at position 1534. When the mixed base positions are taken into account the ratio 
of transitions to transversions is 1.6 to 1. When they are excluded, the ratio is 6  to 1.
Although the HVR1 from twelve serum samples from patient FAL were 
amplified, the results of nucleotide sequencing of the PCR products could be read 
clearly for only the three samples described above. Figure 4.14 shows an example of a 
sequencing gel for patient FAL. Two regions, denoted by arrows, proved to be the 
most difficult to read. This inability to read the gels could be explained by the presence 
in vivo of a virus population consisting of a heterogeneous mixture of genetically
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Mar*88 A
1120
r
1165
c
Apr* 91 G g y
Nov* 91 I g y
HCV-1
Consensus
g c
GTGC TGC TGC TAT T TGCCGGCGTCGACGC - GAAACC - ACGTCACCG
Mar*88
1166
A t eg c w at
1212
g
Apr* 91 G c ta t a gk t
Nov* 91 I c ta t a gk t
HCV-1 ag c g ca actgt t g at gt gc c eg
Consensus GGGGAGCTG-CGCC— CCACACGGCTAGC-TT-CTA--CTCTTT-CA
1213 1258
Mar* 88 A t  t g a
Apr* 91 G c k r r
Nov* 91 I c t a a
HCV-1 c ag g g c a
Consensus -CAGGCGCCAG-CA-AAGATCCAGTTG-TCAACACCAACG
Figure 4.12 Alignment of HCV isolates from patient FAL between nucleotide 
residues 1120 and 1258. Consensus sequence for HVR (residues 1150-1233) shown 
in red type face and underlined. Green type face denotes a mixed nucleotide position. 
Blue type face denotes a nucleotide change. *Nucleotide numbering according to 
Choo etal. (1991).
374 417
Mar188 A h v r ltn as s i
s
Aprf 91 G h a y ft s sp s i
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Nov191 I h a y ft s sp s i
y r
HCV-1 h saghtvsgfvs lap k v i
Consensus VLLLFAGVDAE T-VTGGA-A-HTAS-- LF--GA-QNIQL-NTN
Figure 4.13 Alignment of the derived amino acid sequences from residues 374 
to 417 of HCV isolates from patient FAL. Consensus sequence for HVR (residues 
384-411) shown in red type face and underlined. Blue type face denotes first 
amino acid change. Magenta type face denotes second amino acid change. Italics 
indicate the possibility of the presence of both amino acids, because of nucleotide 
sequence ambiguity. *Numbering according to Choo et al. (1991).
Figure 4.14 Direct DNA sequencing of the PCR amplified cDNA fragments of 
the HVR1 from patient FAL sera. Arrows denote the HVR1. The gels identified 
heterogeneity in patient FAL within this region.
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different but related variants termed ‘quasispeciesone of which has an insertion or a 
deletion in its HVR1 nucleotide sequence. To test this, one would need to either clone 
the PCR products, perform limiting dilutions or single stranded conformation 
polymorphism (SSCP) gel electrophoresis before sequencing, to allow detection of 
both the major population and minor populations present.
4.7 SSCP analysis
To try and resolve the problem presented by a mixed virus population when direct 
sequencing of PCR products was used, SSCP gel electrophoresis was attempted. This 
has the advantage of detecting minor HCV quasispecies populations present as well as 
the major one. The technique of SSCP allows the detection of a single base change in 
short DNA fragments based on differences in mobility of single-stranded DNA in non­
denaturing polyacrylamide gels. Second round PCR products amplified from the HVR1 
of the HCV genome from three different serum samples from the same individual were 
subjected to SSCP analysis. Double-stranded DNA PCR products were denatured prior 
to electrophoresis in a non-denaturing gel. The products were separated into bands of 
different mobility in the gel. The mobility of the DNA single strands within the gel is 
dependent on the conformation adopted by each single strand, which is determined by 
its nucleotide sequence.
An example of typical SSCP gel is shown in Figure 4.15. Samples were heat 
denatured and alkali denatured to determine which method gave better separation into 
single-stranded DNA. The SSCP band profiles (pattern and intensity of the band) was 
better for heat denatured (lanes 6  to 1 0 ) products compared to alkali denatured products 
(lanes 1 to 5). Since it was not known if the SSCP would be sensitive enough to detect 
a one or two nucleotide difference in sequence between the three HVR1 PCR products, 
products amplified from the 5’NCR of the HCV genome were included. The two 
5’NCR products each represent a different genotype of HCV, type 1 (lanes 1 and 6 )
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Figure 4.15 SSCP gel . Discontinuous gel electrophoresis was used.
DNA was denatured by passage through a ‘stacking’ gel, 8% (w/v) 
polyacrylamide:bisacrylamide (19:1 ratio) containing formamide and assumed 
sec o n d a ry  c o n fo rm a t io n  in a ‘r e s o lv in g ’ ge l ,  6% (w /v )
polyacrylamide:bisacrylamide (49:1 ratio). 10|il of PCR product was run in
each lane. Lanes: (1 ,6 )  type 1 isolate 5’NCR; (2, 7) type 3 isolate 5 ’NCR; 
(3, 8) patient KR HVR1 sample C; (4, 9) patient KR HVR1 sample I; (5, 10) 
patient KR HVR1 sample G. Lanes 1-5 samples alkali denatured and lanes 6- 
10 samples heat denatured. Gel run at 600 volts.
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and type 3 (lanes 2 and 7), respectively. The number of nucleotide differences between 
these two genotypes in the 5’NCR is at least twenty. However, both the type 1 and 
type 3 isolates migrate with the same mobility in the gel; despite base differences in 
their nucleotide sequence. The two bands seen in each lane represent the sense and 
antisense strands. A difference in the mobility of one or both of the single strands 
reflects sequence differences. The double stranded DNA fluoresces more intensely than 
the single strands. An undenatured double stranded control should have been included, 
giving an indication of product size. The resolution (separation) of the 5’NCR products 
was better than that of the HVR1 products. Instead of being clear like the 5’NCR 
bands, the bands are smeared and difficult to see. The HVR1 products appear to 
migrate with different mobility, indicating the presence of different quasispecies. Due to 
poor resolution, the number of coexisting quasispecies cannot be determined.
4 .8  Phylogenetic analysis of patient HVR1 sequences
The MEGA computer package was originally used to construct phylogenetic trees for 
each of the three patients under study. However, the MEGA package does not 
recognise ambiguities in IUPAC single-letter codes, thus a mixed base position is not 
recognised. Because of this, two or more sequences have to be entered to represent 
each base present at a mixed base position. Therefore, patient sequences with more than 
two mixed base positions cannot be entered. To overcome this problem the PHYLIP 
computer package was used instead. This programme will accommodate mixed base 
positions as given in the IUB code (Nomenclature Committe, 1985). Phylogenetic trees 
were constructed from Maximum Likelihood distances using the neighbour joining 
method for each of the three patients under study. Evolutionary relations of the HVR1 
sequences in each individual patient are shown in Figures 4.16 to 4.18. Horizontal 
lines indicate the distance between each HVR1 sequence. Analysis of the trees suggest 
that in patient KR the 1991 HVR1 sequences are from a different lineage to those that
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Figure 4.16 Phylogenetic analysis of HVR1 sequences from Patient KR. 
Sequentially recovered predominant HCV HVR1 sequences were analysed for their 
evolutionary relationship. The sequence of isolate HCV-1 (Choo et al., 1991) was 
used as a reference group. Horizontal lines represent the evolutionary distances 
between the HVR1 sequences. The numbers at the forks are the bootstrap values 
(%). TheHVRl sequences are Kr91a (Jan‘91), Kr91b (Mar’91), Kr91c (Oct’91), 
Kr92a (Aug’92), Kr92b (Oct’92), Kr92c (Nov’92), Kr93a (Jan’93), Kr93b 
(Apr’93), Kr93c (May’93), Kr93d (Oct’93), Kr93e (Nov’93), Kr94a (Jan’94) and 
Kr94b (Apr’94).
K r 9 2 b
Kr92c53
1— Kr92a
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Kr93e
Kr93b
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Kr94b
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Kr93c
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Figure 4.17 Phylogenetic analysis of HVR1 sequences from Patient SF. 
Sequentially recovered predominant HCV HVR1 sequences were analysed for their 
evolutionary relationship. The sequence of isolate HCV-1 (Choo et al., 1991) was 
used as a reference group. Horizontal lines represent the evolutionary distances 
between the HVR1 sequences. The numbers at the forks are the bootstrap values 
(%). The HVR1 sequences are Sf8 8  (Jun’8 8 ), Sf89a (Jul’89), Sf89b (Nov’89), 
Sf90a (Apr’90), Sf90b (Jul’90), Sf91a (Jan’91), Sf91b (Oct’91), Sf92 (Dec’92), 
Sf93a (Jan’93), Sf93b (Aug’93) and Sf94 (Jan’94).
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Figure 4.18 Phylogenetic analysis of HVR1 sequences from Patient FAL. 
Sequentially recovered predominant HCV HVR1 sequences were analysed for their 
evolutionary relationship. The sequence of isolate HCV-1 (Choo et al., 1991) was 
used as a reference group. Horizontal lines represent the evolutionary distances 
between the HVR1 sequences. The numbers at the forks are the bootstrap values 
(%). The HVR1 sequences are Fal8 8 a (Mar’8 8 ), Fal91b (Apr’91) and Fal91d 
(Nov’91).
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emerge in and after 1992. Thus, it appears that the strains which emerge and become 
predominate in 1992 do not arise by continuous mutation of the 1991 strains. Bootstrap 
testing of the tree shows that the divergence between the 1991 and 1992 HVR1 
sequences is significant, the bootstrap value was 95%. The HVR1 sequences detected 
after 1991 appear to be continuously evolving, with newly emerging HVR1 variants 
being similar to previously dominant populations. Although the 1993 and 1994 HVR1 
sequences appear to diverge from the 1992 sequences, the bootstrap value was only 
53%, therefore this divergence is not significant. The 1993 variants could have equally 
evolved from the 1992 variants. In patient FAL the divergence shown between the 
HVR1 sequence detected in 1988 and that detected in 1991 was significant, the 
bootstrap value was 74%. The distances observed in patient SF were not significant for 
the majority of sequences, the highest bootstrap value was being 57%. The exception 
was the 1992 and 1993 (sample I) samples where the bootstrap value was 98%. This 
suggests that the HVR1 sequence variant detected in December 1992 and January 1993 
was previously present as a minor population in the viral quasispecies and due 
disequilbrium it became predominant. Interpretation of such results is controversial, 
since for one to truly know whether continuous or discontinuous evolution has taken 
place it will be necessary to analysis other regions of the genome.
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4.9 Discussion
4 . 9 . 1  The effectiveness of direct sequencing in analysing HCV  
sequence variants
To analyse the nucleotide sequence change in the E2 HVR1 of renal dialysis patients 
infected with HCV, direct sequencing of amplified PCR products without limiting end 
point dilution was employed. Direct sequencing was used in preference to sequencing 
cloned PCR products because there is the advantage that PCR derived errors due to the 
misincorporation of nucleotides by Taq polymerase (estimated to incorporate an 
inaccurate nucleotide once every 9000 nucleotides polymerised) during amplification of 
the product are not detected. Such errors usually occur infrequently and at random 
positions in the amplified product, therefore, sequencing a large population of 
molecules present in the amplified product reduces the chances of detecting such an 
error. When sequencing cloned PCR products several recombinants have to be 
sequenced to generate a consensus sequence to eliminate any errors which may have 
been introduced during amplification, since each recombinant is the product of a single 
DNA molecule from the PCR product. The other disadvantage of generating sequence 
data by this approach is that more manipulation steps are required to produce the 
recombinants for sequencing. Cloning can be a relatively inefficient technique, 
therefore the frequency at which a particular recombinant is found may not relate to the 
frequency at which that sequence is present in the population in the amplified product.
RNA viruses are prone to mutations due to the lack of proof-reading activity of 
RNA-dependent RNA polymerases. As a result, RNA viruses form quasispecies 
populations that contain a predominant or master sequence and a swarm of closely 
related genetic variants (reviewed by Steinhauer and Holland (1987); Holland et a l., 
1992). Possible consequences of a quasispecies virus population are antigenic change 
allowing evasion of the host immune system and the development of resistance to 
antiviral drugs through genomic change. Martell et al. (1992) described the
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quasispecies nature of HCV and suggested that it may account for the tendency of 
infection with this virus to become persistent.
In the work presented here, the nucleotide sequence of the HVR1 of HCV 
genomes are those detected in the serum from each of the three patients studied. It could 
be argued that this sequence may not be the same as that causing disease in the liver 
though Sakamoto et al. (1995) has provided evidence that the HCV quasispecies 
detected in the plasma and liver of patients with chronic hepatitis C at the same time 
point are the same in terms of population and diversity. Plasma and liver samples from 
each patient were obtained simultaneously. By nucleotide sequencing and SSCP 
analysis they showed that in all eight patients studied, the predominant HVR1 sequence 
and quasispecies detected in the plasma was identical to that detected in the liver. The 
study only examined plasma and liver samples at a single time point in each patient. To 
provide evidence that a change in the quasispecies population in the plasma (or serum) 
is reflected in that infecting the liver and causing damage, it is necessary to examine 
serial samples from each patient. To do this would have required several liver biopsies 
being obtained from each individual patient, but in performing a liver biopsy there is an 
element of risk to the patient. Therefore, from an ethical viewpoint such a study may 
not be feasible.
From sequence data obtained from the three patients in this study, the 
quasispecies nature of HCV was observed by the presence of mixed base positions on 
the sequencing gels. Direct sequencing distinguishes the predominant sequence from 
minor sequences according to the relative intensity of each base signal (band) on the 
sequencing gel. However, the sensitivity of detection of minor species is poor. So, 
although the predominant sequence at the second or third time point was not 
demonstrated previously, this does not mean it did not pre-exist as a minor population. 
The HVR1 variant sequence found to be predominant could have evolved directly from 
the previous predominant sequence through continuous mutation or could have been 
present previously as a minor population, outgrowing the previously predominant 
sequence because it had a selective advantage.
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The use of SSCP gel electrophoresis analysis allows the detection of minor HCV 
quasispecies populations as well as the major one. SSCP analysis is based on the 
principle that the electrophoretic mobility of a molecule in a gel is sensitive to the size, 
charge and shape of the molecule. In non-denaturing conditions single-stranded DNA 
has a folded structure that is determined by the intramolecular interactions and hence, its 
sequence. The technique allows the detection of a single base change in short DNA 
fragments, since any change in sequence which affects the folding of the DNA is 
detected as a mobility difference on electrophoresis. A quasispecies virus population 
can therefore be separated into different bands by SSCP with each band representing a 
different quasispecies. The usefulness of SSCP in the analysis of HCV quasispecies 
has been shown in papers by Enomoto et al. (1994) and Kurosaki et a l (1994). In both 
experiments the authors used asymmetric PCR to generate single stranded products, 
avoiding the need to denature double stranded products.
When SSCP was attempted in this work it was unsuccessful. The HVR1 
products analysed appeared to migrate with different mobilities but due to poor 
resolution of the bands, the number of coexisting quasispecies in each sample could not 
be determined. The sensitivity of SSCP can be affected by several factors, such as 
polyacrylamide concentration, degree of gel cross-linking ratios, temperature at which 
gel electrophoresis is performed and the presence or absence of glycerol. Time did not 
allow for experimentation to discover optimal conditions for SSCP analysis of HVR1 
PCR products. Interestingly, when the 5’NCR products were subjected to SSCP the 
single stranded DNA bands migrated with the same mobility for both the type 1 and 
type 3 isolates. One would have expected them to migrate with different mobilities due 
to nucleotide differences in their sequence. However, the mobility of single-stranded 
DNA is dependent upon the folded structure adopted by it in non-denaturing 
conditions. Therefore, if both type 1 and type 3 isolates adopt the same folded 
structure, regardless of differences in nucleotide sequence, they should migrate with the 
same mobility in the gel. The 5’NCR of HCV is predicted to form an extended stem- 
loop structure for the region between nucleotides -208 and -58 which is conserved
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among the HCV genotypes (Brown etal., 1992; Smith et al., 1995). It is this region of 
the 5’NCR which has been amplified. An alternative explanation for the results 
obtained is that the method failed to work because the optimum conditions were not 
used.
4 . 9 . 2  Emergence of HVR1 sequence variants
The results from this study showed sequence variation of the HVR1 predominant vims 
population during the natural course of infection in all three renal dialysis patients. The 
substitution rate of HVR1 was found to vary between the three patients and between 
different sampling points within the same patient. The substitution rate represents the 
degree of nucleotide difference between the predominant virus populations obtained at 
different time intervals. The substitution rates displayed by patient KR ranged from 
0.21 to 7.9 x 10' 2 nucleotide change/site/year. Those for patient SF ranged from 0.29 
to 6.3 x 10"2 nucleotide change/site/year. For patient FAL the substitution rate 
calculated for between March 1988 and April 1991 was 4.4 x 10-2  nucleotide 
change/site/year, and that between April 1991 and November 1991 was 1.4 x 10'2. 
These substitution rates are lower than those reported by Kurosaki et al. (1993). They 
found substitution rates ranging from 1.54 to 2.24 x 10_1 nucleotide change/site/year 
for patients displaying fluctuations in their ALT levels ("flare-up" type patients). In 
patients whose ALT levels remained within normal limits with little or no fluctuation 
("quiescent" type patients) substitution rates ranged from 0.13 to 1.21 x 10_1 nucleotide 
change/site/year. The difference in substitution rate between these two groups was 
significant according to the Mann-Whitney U test (p<0.01).
Adopting the categorisation method of Kurosaki et al. (1993) patient KR would 
be classified as having “flare-up” type hepatitis and patient SF as having “quiescent” 
type hepatitis. However, no significant difference was found in substitution rates 
between these two patients, according to the Mann-Whitney U test (p=0.05). This 
discrepancy in results between this study and those of Kurosaki et al is probably due to
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sampling differences. Kurosaki et al examined four patients with “flare-up” type 
hepatitis and eight with “quiescent” type hepatitis. Each patient was examined at two 
time points, the time interval between samples ranging from 38 to 50 weeks. Although 
only one patient from each of the above mentioned categories was examined in the 
study presented here, each patient was sampled at several time points. The time between 
samples ranged from 4 to 44 weeks for patient KR and from 4 to 56 weeks for patient 
SF. A larger sample size examined at several time points would be necessary to confirm 
that the substitution rate between patients displaying fluctuating ALTs and those 
displaying normal or near normal ALTs is not significantly different. Differences in the 
substitution rate of the HVR1 domain amongst patients in the acute phase of infection 
have also been observed; rates ranged from 0.14 to 0.91 nucleotide change/site/year 
(Sakamoto et al., 1994). These authors suggested substitution rates increased with 
progression of infection. However, the findings of this study and those of Kurosaki et 
al. (1993) are contrary to this suggestion.
The data from this study show that during the chronic stage of infection the 
substitution rate varies. Periods of variation are interspersed with periods of no change, 
lasting up to several months. Not only does the substitution rate for the HVR1 differ 
between patients and isolates but other regions of the genome mutate at different rates 
(Ogata et al., 1991; Okamoto et al., 1992b). The differences in substitution rate 
between patients and different regions of the viral genome may reflect different error 
rates of the HCV RNA-dependent RNA polymerase or different selective pressures. It 
is interesting that analysis of part of the NS5a gene showed the substitution rate to 
range from 0.12 to 1.62 x 10-2 to 2.68 to 3.11 x 10-2 nucleotide change/site/year for 
patients KR and FAL, respectively for three isolates (Data for the NS5 gene were 
kindly given by Dr June Munro).
The low transition to transversion ratio and the preference for nonsynonymous 
substitutions in all three patients examined suggests that the HCV HVR1 domain is 
under selective pressure to mutate. Nucleotide variation occurred predominantly in the 
first and second codon positions. The majority of nucleotide changes resulted in a
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change in the deduced amino acid sequence. The average ratio of synonymous to 
nonsynonymous substitutions for patients KR, SF and FAL are 0.05, 1.43 and 0.28, 
respectively (results are summarised in Table 4.7). These are comparable to those 
found by Kurosaki et al. (1993) who found values between 0 and 0.86 for “flare-up” 
type hepatitis patients and between 0.41 and 1.43 for “quiescent” type hepatitis 
patients. These values are comparable with the value of 0.67 found for the gpl20 V3 
domain of the HIV-1 (Simmonds etal., 1990b). A low ratio implies selective pressure 
for change. Overall, mutations in the HVR1 which survive result in a change in amino 
acid. The ratio of transitions to transversions was 1.1 for patient KR and 1.8 and 1.6, 
respectively for patients SF and FAL. Tanaka et al. (1992) also found the ratio of 
transitions to transversions to be low in the HVR1, less than 1.0. Normally transitions 
are much more frequent than transversions, between closely related sequences 
transition to transversion ratios of 5 and 6  were observed for the El and NS5B regions 
of the genome, respectively (Smith et al., 1997). The low transition to transversion 
ratio also suggests increased infidelity of the RNA polymerase at this region during 
replication, the HVR1 domain may fold in such a way that the RNA polymerase cannot 
read across it and so jumping occurs. The E2 HVR1 domain may be under no structural 
constraints to remain conserved since envelope proteins are on the surface of the virus. 
Thus, nucleotide changes within this region are more likely to be tolerated. In patients 
KR and SF the majority of amino acid changes are equivalent in terms of shape and 
charge of the amino acid. However, there are some which are not. In patient KR 
between samples C and D, three of the eight amino acid changes resulted in a change in 
charge, one resulted in the replacement of a larger amino acid with a smaller one (Ala- 
393 to Gly) and one (Ala-400 to Thr) resulted in the replacement of a hydrophobic 
amino acid with a hydrophilic amino acid. Unlike hydrophobic amino acids, 
hydrophilic amino acids are found at the surface of the protein, where they can form 
binding sites for charged molecules. In patient SF amino acid position 405 is variable 
among isolates. The amino acid changes which occur at this position are Thr to Thr/Ile 
to Ala to Thr/Pro to Pro to Thr to Pro. Unlike all other amino acids proline has a cyclic
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ring structure, which creates a kink in the polypeptide chain. Using computer analysis 
packages Taniguchi et al. (1993) predicted the secondary structure of the E2 protein. 
Change in the secondary structure of the HVR1 domain was found to occur during 
infection, no change in secondary structure occurred in the remainder of the E2 protein 
despite amino acid substitutions.
A specific viral protein or domain of a protein may tolerate substitutions more 
than others for several reasons. The substitutions may be equivalent in terms of shape 
and charge of the amino acid or the protein may require the amino acid only as a spacer. 
Thus, the substitution does not affect the overall conformation or function of the 
protein. Alternatively, the substitutions may be beneficial. They may allow escape from 
immune recognition or they may confer an advantage on the virus by changing a feature 
of the protein, which in turn may result in the virus persisting in the host.
The results from patient KR show the possible creation of a new potential N- 
linked glycosylation site in sample M (April 1994) at amino acid position 414 just 
outside HVR1. Since a mixture of two bases is observed at this position it is necessary 
that either cloning or limiting dilution be performed on this sample. This will allow the 
base that predominates at this position to be determined with a degree of clarity. Surface 
proteins, like the E2 of HCV, are normally glycosylated. The glycosyl groups may be 
important for physical properties of the protein such as solubility or they may be 
involved in interactions with other cells, immunoglobulins or cell surface receptors. In 
the case of HCV, the creation of new potential glycosylation sites could be one 
mechanism by which the virus persists. The attachment of a glycosyl group to a protein 
may result in the masking of an HVR1 epitope by preventing the binding of a host 
neutralising antibody.
On initial infection with HCV in July 1990, patient KR displayed a rise in ALT 
which subsequently declined to within normal limits only to rise again in October. It is 
possible that this second elevation in ALT coincides with the recognition of the virus by 
the patient’s immune system, since antibody to HCV first became detectable in October. 
It is possible that on infection the virus population is relatively homogenous, becoming
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heterogeneous after seroconversion. This has been shown for HIV-1. On infection with 
HIV-1 and until seroconversion the virus population appears to be relatively 
homogenous in the V3 domain of the envelope protein gpl20. Strong selective pressure 
is believed to account for this homogeneity (Simmonds et al., 1990b; Zhang et al., 
1993). Unfortunately the HVR1 from 1990 to 1991 sera could not be amplified to test 
this hypothesis, despite the 5'NCR having been amplified in earlier testing by a 
previous worker in 1992. Difficulty in amplifying other regions of the HCV genome 
extracted from these samples was also experienced. The reasons for this are not 
known. It was originally thought that serum storage conditions may have affected the 
stability of HCV RNA but the results of work described in Chapter 5 make this 
unlikely.
The data show periods during which the predominant strain of HCV remains 
unchanged i.e. no sequence variant emerges. This is most notable in patient SF. No 
change in the HVR1 predominant sequence was detected over a 25 month period (June 
1988 to July 1990). This suggests that HVR1 sequence variation is not necessary for 
persistence, as had previously been noted by Kumar et al. (1994) and van Doom et al. 
(1995). However, in contrast to these studies, in patient SF, such persistence was 
noted in the presence of a detectable humoral immune response. Kumar et a l examined 
the HVR1 domain of an agammaglobulinemic patient infected with chronic hepatitis C 
at three time points over a 30 month period. No changes were detected in the 
predominant HVR1 sequence. In the study by van Doom et al., the HVR1 predominant 
sequence from a chronically infected chimpanzee remained unchanged for six years. 
During this period the chimpanzee was negative for HCV antibodies. With the 
appearance of anti-HCV antibody a HVR1 sequence variant emerged. The conclusion 
drawn from these studies was that the lack of sequence change in the HVR1 domain 
was associated with the absence of a humoral immune response. Therefore, sequence 
variation of the HVR1 is driven by humoral immune selection pressure. However, 
patient SF displayed a period of no change in the HVR1 predominant sequence 
comparable to that found by Kumar et a l This observation in an immunocompetent
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individual casts doubt on their conclusion that the selective pressure driving HVR1 
variation is the host’s humoral immune response, and indeed, several studies discussed 
in the next section have documented variation in the absence of immune selection.
4.9.3 Variation in the absence of immune selection
Antigenic variation and the emergence of immunological escape mutants as a strategy 
for viral persistence, has been proposed for a several viruses, notably influenza virus 
and the lentiviruses. Influenza A virus has the ability to undergo both antigenic shift 
and drift resulting in the emergence of distinct viruses which are not recognised by a 
previously infected host. Mutations in the surface proteins haemagglutinin (HA) and 
neuraminidase (NA) appear to account for this antigenic variability. Antigenic shift is 
responsible for influenza virus pandemics. A new influenza virus appears in the 
population with different surface antigens. The first influenza A virus isolated in 1933 
was of the subtype H1N1, in 1957 a new subtype H2N2 (Asian flu) emerged and in 
1968 a third subtype H3N2 (Hong Kong flu) emerged, with the subtype H1N1 
(Russian flu) reappearing in 1977. Antigenic drift is the result of accumulation of point 
mutations in the viral surface antigens (HA and NA) and appears to be due to immune 
antibody selection (reviewed by Wiley & Skehel., 1987; Webster et al., 1992).
Similar findings to those of influenza virus have been reported for the 
lentiviruses, Visna virus, equine infectious anaemia virus (EIAV) and HIV-1 (reviewed 
by Clements et al., 1988). The emergence of variants of these viruses occurs in a single 
host rather than in a population. EIAV infection is characterised by sequential episodes 
of viraemia associated with haemolytic crises during persistent infection. Neutralisation 
assay studies have demonstrated that virus isolates recovered from different episodes of 
viraemia were not susceptible to neutralisation by serum samples taken prior to their 
appearance. Each episode of viraemia was associated with a unique predominant virus 
population (Salinovich et al., 1986). The extensive sequence variation displayed by 
HIV-1 may also be the result of immune selection pressure exerted by the host against
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the V3 domain of gpl20. This is supported by the generation of neutralisation escape 
mutants of HIV-1 (Nara et al., 1990; Montefiori etal., 1991).
However, evidence now exists from several systems suggesting antigenic 
variation is not necessarily the result of immune selection. Immunological escape 
mutants can occur in the absence of immune pressure. This was first demonstrated by 
work on foot-and-mouth disease (FMVD) (Diez et al., 1989; Borrego et al., 1993; 
Domingo et al., 1993) Serial passage of plaque purified FMDV in BHK-21 cells 
resulted in the emergence of viruses with amino acid substitutions in antigenically 
important sites, as revealed by its altered reactivity with monoclonal antibodies (mAb). 
Since the virus was propagated in the absence of anti-FMDV antibodies, antigenic 
variation of FMDV occurred in the absence of immune selection (Diez et al., 1989). 
This work was extended by Borrego et al. (1993). The same FMDV variants were 
passaged in the presence of a limited amount of neutralising polyclonal antibodies 
directed to the major antigenic sites of FMDV. Substitution of antigenically critical 
amino acids resulting in the loss of several epitopes within site A of the capsid protein 
VP1 was only observed in FMDV passaged in the presence of antibody. In the 
presence of neutralising antibody there is selection of a variant in the viral quasispecies 
with antigenically critical amino acid substitutions because it confers a selective 
advantage, however, in the absence of immune selection pressure such a variant would 
have a selective disadvantage and so would be kept at low levels in the quasispecies. 
Antigenic variation in the absence of immune selection pressure arises randomly by the 
selection of variants with substitutions in an antigenic site for properties unrelated to 
their antigenicity. The results suggest that antigenic variants of FMDV can emerge in 
the presence or absence of immune selection pressure.
The emergence of antigenic variants in the absence of immune selection pressure 
has not only been observed in FMDV. Serial passage of HIV-1 in cell culture in the 
absence of anti-HIV-1 antibodies resulted in amino acid substitutions in the V3 domain 
(Sanchez-Palomino et al., 1993). Similarly, sequential influenza type A virus isolates 
recovered from a severe combined immunodeficient (SCID) child persistently infected
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with the virus, revealed multiple point mutations in the HA1 domain of the HA 
glycoprotein. The observed amino acid changes in this domain occurred in or close to 
antigenic sites (Rocha et al., 1991). Such observations mean that the emergence of an 
experimentally identifiable escape variant is not evidence per se of humoral selection 
pressure. This is further supported by the observation in EIAV that the sequential 
appearance of two antigenically distinct viral isolates was independent of the 
development of variant-specific neutralising antibody (Carpenter et al., 1987). EIAV 
variation may be the result of cellular or nonimmunological selection pressures rather 
then humoral immune pressure. Therefore, it is possible that this may also be true for 
HCV variation.
4.9.4 Evidence for immune selection of HCV
The low transition to transversion ratio and nonsynonymous to synonymous ratio 
observed in the HVR1 of chronically infected HCV renal dialysis patients suggest this 
region of the genome is under pressure to mutate. If so, then what pressure is driving 
this change ? Several groups have suggested humoral immune selection pressure 
(Weiner et al., 1992; Kato et al., 1993a, 1994; Taniguchi et al., 1993; Kojima et al., 
1994; van Doom et al., 1995), but the results from patient SF suggest that other 
selection pressures may be responsible. Patient SF was sampled at eleven time points 
over a six year period from 1988-1994. The majority of other studies have examined 
only about three samples over a similar period, therefore, periods of no change may 
have gone undetected. According to the immune selection hypothesis, antibodies to 
epitopes contained in the HVR1 of E2 cause positive selection of escape mutants. An 
antibody escape mutant would be expected to be a variant which emerges in the viral 
population and is then maintained in the absence of antibodies which recognise that 
particular sequence.
The HVR1 has been shown to contain linear B-cell epitopes, in particular between 
amino acids 394 and 407. Evidence for antibody escape mutants has come from studies
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showing that antibodies present in patient sera to a specific HVR1 predominant variant 
early in the course of HCV infection, fail to bind to the HVR1 variant which 
subsequently emerges as the predominant viral population (Weiner et al., 1992; 
Lesniewski et al., 1993; Taniguchi et al., 1993; van Doom et al., 1995). All these 
studies have used solid-phase HVR1-peptide binding assays because of the relative 
ease with which antibody reactivity to them can be determined. It is possible that the 
peptide may bind to the plate in such a way that key antigenic amino acids at the plate- 
peptide interface are no longer recognised by antibodies present in patient sera. Indeed, 
studies with HIV-1 have revealed limitations in use of such assays. It was found that 
reactivity of antibody to a solid-phase V3-peptide does not ensure reactivity to that V3 
sequence in its native structure either because binding is blocked or the peptide 
sequence assumes a nonreactive conformation in the native form. Conversely, 
antibodies that react to conformation-dependent epitopes may not react to the 
corresponding linear peptide (Moore et al., 1994). For these reasons the results from 
solid-phase peptide binding assays using HCV HVR1 derived peptides on their own 
cannot be considered as conclusive evidence in favour of humoral immune selection. 
Moreover, data from studies in which a branched peptide based solid-phase binding 
assay was employed provide evidence that sequence variants which arise during HIV-1 
and HCV infection may not represent antibody escape mutants. All the afore mentioned 
studies used monomeric peptides for their assay.
Work performed by Dr Carol Robertson (Ph.D.thesis) and Dr Howard Marsden, 
Institute of Virology, using a branched peptide based assay showed that high titres of 
antibody were found against most of the V3 sequence variants that emerged in an HIV- 
1 infected haemophiliac patient before the variant was detected in the viral population. 
Despite the presence of antibodies that recognised the sequence of V3 variants, the 
variants were found to persist within the patient. If the V3 variants which emerged 
during infection represented antibody escape mutants, one would expect antibody 
against them to be present only in sera taken after they emerged. This has now also 
been observed for HCV (Scarselli et al., 1995). Using a branched peptide based assay,
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antibodies recognising a specific HVR1 sequence variant which emerged in a 
chronically infected individual were found to precede its appearance. Coexistence in the 
bloodstream of the variant in the presence of increasing amounts of specific antibodies 
for seven months was also observed. Unfortunately, due to problems experienced in 
amplifying the HVR1 from HCV RNA extracted from patient sera, there was 
insufficient time to undertake a similar study using a branched peptide based assay with 
regards to examining the HVR1 sequence variants which emerged during natural 
infection in the three renal dialysis patients described here. Such a study would give a 
better indication of the role of humoral immune selection in HVR1 sequence variation 
because it would allow more samples to be looked at.
A different approach was adopted by Kato et a l (1993a, 1994) to examine the 
humoral immune response to HVR1. They examined the reactivities of anti-HVRl 
antibodies in an infected patient to substituted amino acids sequences within two B-cell 
epitopes. They found that HVR1 variants in both epitopes identified within the HVR1 
escaped from anti-HVRl antibodies that were pre-existing in the patient’s serum. To 
test for reactivities of anti-HVRl antibodies, an expression plasmid was constructed 
and used to express a fusion protein with HVR1 variants and the dihydrofolate 
reductase gene derived from Escherichia coli by in vitro transcription and translation. 
Immunoprecipitation of the expression fusion proteins with patient sera collected at 
various times was then performed. The expression system used does not allow for 
post-translational modification of the protein, which can have a major effect on the 
structure or immunogenicity of the protein. Therefore, the expressed HVR1 domain 
may not show antigenicity similar to that in the native E2 protein. It could be argued 
that because the HVR1 domain itself does not appear to contain potential glycosylation 
sites and lacks conserved secondary structure motifs, change may not interfere with 
conformation (Taniguchi et al., 1993). So, the expression solely of the HVR1 domain 
is adequate to test for reactivities of anti-HVRl antibodies. However, secondary 
structure predictions using computer programs may not take into account the effect of 
post-translational modifications or contacts made with other proteins (or as dimers,
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trimers or other polyproteins). Studies on HIV-1 have shown that antigenicity of the 
oligomeric viral envelope protein are distinct from the monomer (Broder et al., 1994). 
In its native form, the E2 protein may adopt a conformation that prevents the binding of 
antibodies to epitopes in the HVR1 domain which are seen to bind to the HVR1 when it 
is expressed as a “bare” polypeptide. The optimal way to demonstrate that variation in 
the HVR1 is the result of selection by the humoral immune system would be to detect 
the presence of antibodies using as the antigen E1/E2 protein complexes containing the 
appropriate variations of HVR1 and processed in an appropriate system, reflecting what 
would occur in an infected hepatocyte. To determine the antibody binding sites on the 
E1/E2 proteins, a series of expressed proteins increasing in size should be generated.
Kojima et al. (1994) studied the influence of humoral immune selection on the 
emergence of HVR1 sequence by passaging a human plasma infected with HCV 
through eight chimpanzees in three generations and examining the HVR1 in acute-phase 
plasma from each chimpanzee. They found that one clone (clone A) detected in the 
original inoculum was selected for in chimpanzees during three passages. Antibody to 
clone A was detected in only one chimpanzee, whereas antibody to clones B and C 
were detected in two chimpanzees. Plasma from all three infected chimps was pooled to 
create inoculum three, which contained antibody to all three clones. In the two 
chimpanzees who received this inoculum only clone A was found. The authors suggest 
that because antibody to clone A was not present in sufficient levels to neutralise it, 
clone A was selected, indicating positive selection by the humoral immune system. 
However, it is possible that clone A was selected because it was stable on passage of 
the virus. During passage, mutations in other regions of the genome may render the 
other clones in the viral population avirulent. This could explain why they were not 
detected in the two chimpanzees infected on the third passage.
Such studies as those discussed above do not directly prove the variation 
observed in the HVR1 domain is driven by humoral immune selection or that the 
sequence variants which emerge represent antibody escape mutants. Moreover the 
study by Scarselli et al. provides evidence in support of the hypothesis that HVR1
82
Chapter 4
sequence variants do not represent antibody escape mutants. Further studies will need 
to be conducted to settle this contentious issue.
4.9.5 Mechanisms of liver damage and persistence in chronic hepatitis C
The mechanisms responsible for liver damage in chronic hepatitis C are unclear. The 
virus may be directly cytopathic or hepatocyte damage may be immune mediated. If 
damage is due to a direct cytopathic action of the virus, a new genetic variant would 
emerge before an elevation in ALT. Alternatively, if damage was as a result of the 
destruction of infected hepatocytes by the host’s immune system, a new genetic variant 
would appear some time after an elevation in ALT.
Throughout the period of observation patient KR's ALT levels fluctuated 
markedly and new genetic variants were seen to emerge. The first HVR1 sequence 
variant to be detected was in sample B (March 1991), which emerged during a period 
when the ALT levels were elevated (> 196U/L). In contrast the sequence variants 
detected in samples C (October 1991) and D (August 1992) emerged during periods 
when the ALT levels were within normal limits. The sequence variant detected in 
sample G (January 1993) emerged after an elevation in ALT in October/November 
1992 (>97U/L) whereas those detected in samples J (October 1993) and K (November 
1993) emerged before an elevation in ALT in December 1993 (124U/L). The results 
from patients SF and FAL are similar. In patient SF the sequence variant detected in 
sample E (July 1990) emerged during an elevation in ALT (99U/L). After the elevation 
in ALT in July 1991 a sequence variant was detected in sample G (October 1991). 
Apart from these two sequence variants all the others are detected during periods when 
the ALT levels are within normal limits. It is possible that the sequence variant detected 
in sample A (March 1988) from patient FAL is a new genetic variant which has 
emerged before the elevation in ALT in May 1988 (8 6 U/L). The sequence variants 
detected in samples G (April 1991) and I (November 1991) emerge before and after a 
small elevation in ALT (62U/L), respectively. However, it is possible that the
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predominant sequence detected in these two samples is the same. HCV isolates from 
patient FAL proved difficult to sequence by the direct method used here so only three 
isolates were analysed. The sequence ambiguities detected in the gels from patient FAL 
and also from patients KR and SF, may be resolved by performing SSCP 
electrophoresis or limiting dilution on the amplified products.
The sequencing gels of patient FAL suggest that within the quasispecies 
population there exists one which contains a deletion(s) or insertion(s). This could 
result in the generation of a defective genome. Cocirculation of defective viral genomes 
in HCV infection has been documented (Martell et al., 1992; Higashi et al., 1993). This 
may be another mechanism utilised by HCV to allow persistence within the host since 
defective viruses are usually poorly cytopathic. Alternatively, the presence of a 
insertion and /or deletion may result in a frame shift mutation being generated, the result 
of which is an antigenic escape variant. Antigenic escape mutants in the G protein of 
respiratory syncytical virus, which is involved in virus binding to target cells, have 
been shown to arise by frame shift mutations (Garcia-Barreno et al., 1994).
In the study presented here, no direct association could be demonstrated between 
the emergence of new sequence variants and either mechanism of liver damage. The 
results from patient KR show that new genetic variants were detected before, during 
and after elevations in ALT. They also showed that variants emerged during periods 
when the ALT level was within normal limits. Patient SF in particular displayed this. 
By using ALT levels as a predictor of liver damage it is difficult to predict from the 
results whether the direct cytopathic nature of the virus or the host immune response to 
it is the mechanism responsible for liver damage. Indeed, the results suggest that the 
emergence of variants may not be related to a period of liver disease on the basis of 
using ALT levels as a marker of damage. However, it is possible that ALT levels are 
not a satisfactory predictor of liver damage.
If damage is due to a direct cytopathic nature of the virus, a high titre of 
neutralising antibodies (those that inactivate the virus and thus arrest the disease 
process) against the virus would be expected to be found to prevent infection of
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hepatocytes. HCV infection has been shown to elicit neutralising antibodies in both 
humans and chimpanzees (Farci e ta l, 1994; Shimizu et al., 1994). Since in many viral 
infections neutralising antibodies are directed against envelope proteins, it is presumed 
that the type specificity of the neutralising antibodies may be directed against the HVR1 
domain. In one study addressing this point antibodies specific to HVR1 variants were 
shown to block viral attachment to cells in an in vitro binding assay (Zibert et al., 
1995). Because the neutralisation assay employed in this study was based on the use of 
HVR1 specific fusion proteins expressed in Escherichia coli and the detection of bound 
virus by PCR (PCR was also employed by Shimizu et a l), careful consideration must 
be given to the results, since PCR is a technique subject to variability within and 
between runs. A recent study has shown that neutralising antibodies directed towards 
regions of E2 protein result in protection from infection in vaccinated chimpanzees. 
Antibodies directed towards the HVR1 domain are found to be neutralising but are not 
necessary for protection. No difference in titre of neutralising antibodies was found 
between chronically infected patients and “healthy seropositives”. Thus, HCV infection 
appears to elicit no or only a low titre of neutralising antibody (Rosa et al., 1996). 
These findings question whether neutralisation antibody constitute a strong selection 
pressure. Thus, the HCV sequence variation, especially in the HVR1 domain, may not 
be driven by the humoral immune system of the host. They also suggest that liver 
damage in HCV infection may be due to the host’s cellular immune response. Because 
neutralising antibodies are not produced or are only produced in low numbers, 
hepatocytes will not be protected from infection. Once the virus has infected the cell, it 
is immune to attack from antibodies but not from cytotoxic T-lymphocytes (CTLs). 
Persistence of the virus may be due to CTL escape mutants and not antibody escape 
mutants.
HCV-specific CTL within the liver lymphocytes of individuals infected with 
chronic hepatitis C have been observed (Battegay etal., 1995; Shirai et al., 1995). The 
CTL responses observed in chronic HCV infection are recognised in the context of 
multiple human leukocyte antigens (HLAs). CTLs are restricted by distinct HLAs,
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therefore, they recognise different epitopes. CTL response is multi-specific, involving 
epitopes in most viral proteins that are presented by class I major histocompatability 
complex (MHC) allotypes. There appears to be no particular clustering of epitopes 
within a given protein. CTL epitopes been identified in core, E l, E2, NS2, NS3 and 
NS5b regions (reviewed by Walker, 1996). Yet, despite strong CTL activity, persistent 
infection can occur. It is possible that CTLs are not present in high enough numbers to 
eliminate HCV but are capable of causing damage via lysis of hepatocytes expressing 
HCV proteins, or CTL escape variants exist. Mutations within crucial CTL epitopes 
may affect MHC binding or T-cell antigen receptor (TCR) recognition. A CTL escape 
variant has been observed in a chronically infected chimpanzee. CTLs in the 
chimpanzee liver were able to recognise a conserved epitope in the NS3 protein. The 
same CTLs did not recognise the HCV quasispecies present at 16 weeks post-infection 
or at later time points. An aspartic to glutamic acid substitution at amino acid 1449 
abrogated recognition (Weiner et al., 1995). CTL escape may be important in 
persistence since the virus cannot integrate into the host genome. Direct evidence for the 
emergence of CTL escape mutants in humans infected with HCV is still lacking. CTL 
escape has been documented in HIV infection. Sequence variation in HIV gag CTL 
epitopes in HIV positive haemophiliac donors was found to lead to loss of CTL 
recognition (Phillips et al., 1991). However, the emergence of CTL escape variants 
alone may not be sufficient to sustain HCV persistence. They may be of limited 
importance for persistence because CTL response is often directed against multiple 
epitopes in both variable and conserved regions of the viral protein. It is possible that 
suppression of presentation of MHC class I molecules may be involved in persistence, 
a mechanism of persistence employed by adenovirus (Oldstone, 1989).
Alternatively, cytokine unresponsiveness would be a more effective mechanism 
by which the virus could escape the host’s immune response, since it would abolish the 
effect of the entire CTL population instead of just the effect of the CTL response 
generated against an individual CTL epitope. Recognition of the antigen/MHC class I 
complex is not sufficient to generate a T-cell response, cytokines are needed to induce
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and amplify the T-cell response. If an antigen is presented to CTL by MHC class I 
molecules but the receptor for cytokines are not or are inefficiently expressed then T- 
cells are not able to proliferate, instead they will be unresponsive and so, the virus will 
be allowed to persist. In two patients with chronic HBV infection, the virus was found 
to mutate in such a way that it could still bind to the MHC class I molecule and the CTL 
but failed to activate the T-cell and thus, did not induce lysis of the infected hepatocyte 
(Bertoletti et al., 1994). This has also been documented for HIV (Klenerman et al., 
1994; Meier et al., 1995). Such mutations occur within epitopes which result in an 
alteration in the TCR contact residue on the infected cell. The variant epitopes can also 
act as TCR antagonists by inhibiting the CTL response to the wild-type epitope, since 
they retain the ability to bind to CTLs.
The results from patient SF and those of other studies suggest more than one 
mechanism may be involved in the persistence of HCV within the host. The viral 
envelope proteins, El and E2 of HCV are heavily glycosylated. Viral glycosylation 
sites have been shown to be conserved among different isolates despite mutation of 
surrounding sites (Ogataetal., 1992; Okamoto et al., 1992b). It is possible the heavy 
glycosylation of the envelope proteins masks the viral epitopes thus inhibiting the 
binding of host antibody. Site-specific antibodies to a peptide sequence of the influenza 
virus HA molecule containing a site of glycosylation improved in reactivity after 
removal of the carbohydrate moiety (Alexander & Elder, 1984). Thus, the carbohydrate 
portion of the glycoprotein can effectively block the interaction of antibodies with the 
underlying polypeptide regions. Alternatively, the association of HCV with low density 
lipoprotein (LDL) (Thomssen et al., 1992, 1993) may inhibit or delay binding of host 
antibodies. Since HCV is an enveloped virus, one presumes that it buds from the liver 
cell during its life cycle, so it is possible that on budding from the liver cell some host 
LDL is incorporated into the virus envelope. Thus, the host immune system recognises 
the virus as "self" and does not mount an immune response, which may account for the 
low levels of neutralising antibodies in HCV infection. HCV density gradient analysis 
has shown circulating HCV in chronically infected patients to be found in both a low
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and high density fraction. The low density fraction contains free infectious virus while 
the high density fraction contains virus complexed to antibody (Kanto et al., 1995). 
With progression of liver disease there appears to be a shift from low to high density 
dominance. Such virus/antibody complexes may be a consequence of HCV 
neutralisation. Alternatively, such vims/antibody complexes may represent binding of 
the virus to non-neutralising antibodies. This would prevent the binding of neutralising 
antibodies and allow persistence of the virus. In a persistent infection such 
virus/antibody complexes may deposit over a long period of time producing chronic 
inflammation.
4.9.6 Serum ALT levels as a marker of liver damage
How "good" a marker at predicting liver damage are serum ALT levels ? A limitation in 
using serum ALT levels as a predicator of liver damage due to HCV is that an elevation 
in ALT is not a specific marker of HCV infection. ALT levels are a marker of liver 
damage in general and thus an elevation may occur for several reasons. Studies have 
shown that not all HCV infected individuals have elevated ALTs, many individuals 
displaying normal ALT levels have chronic hepatitis C (Bruno et al., 1994; Prieto et al., 
1995; Shindo et al., 1995). More than half of all viraemic patients have normal ALT 
levels, so the normalisation of ALT levels does not necessarily mean that no liver 
damage is occurring. Serum ALT levels are also poor markers of the severity of liver 
disease associated with chronic HCV infection. At present performing a liver biopsy is 
the only way to evaluate the severity of liver disease (Lemon & Brown, 1995). Due to 
the associated risks associated with liver biopsies it is not feasible to perform sequential 
liver biopsies to monitor liver damage. None of the three patients used in the study 
presented here had liver biopsies.
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4 . 9 . 7  Future Studies
To provide clear evidence that sequence variants that arise in the HVR1 domain do not 
represent antibody escape mutants and that variation is not driven by humoral immune 
selection, it is important that this study be extended to examine the humoral immune 
response of the three patients. The study should also be extended to examine a larger 
cohort of patients. Before the humoral immune response of the patients can be 
examined, minor vims populations and the frequency at which they are detected at each 
time point will need to be determined either by SSCP or limiting dilution analysis. After 
this has been performed branched peptides corresponding to the HVR1 variants found 
during the natural course of infection in each patient can be synthesised to test the 
hypothesis that the sequence variation in the E2 HVR1 is driven by humoral immune 
selection. Alternatively, the humoral immune response to the E2 protein could be 
determined by developing an ELISA system which uses E2 protein which has retained 
its native form and contains the appropriate sequence variations of HVR1 as the 
antigen. To do this would require the envelope protein to be expressed in a system 
reflecting what occurs in an infected hepatocyte. By doing this antibodies to 
conformational as well as linear epitopes would be detected.
It is possible that sequence variation in the HVR1 domain is accompanied by 
variation in other regions of the E2 protein and possibly the El protein also, and that 
interaction with other regions of the protein are important for immune recognition. To 
investigate this, it would be necessary to sequence, clone and express the entire El and 
E2 proteins from each individual viral isolate and test it against autologous sera.
The amino acid changes observed in the HVR1 domain in each of the three 
patients could represent mutants escaping from CTL responses or such mutants could 
affect the MHC binding or TCR contact sites, thereby inhibiting CTL function. Indeed 
the HVR1 domain contains CTL epitopes (reviewed by Walker., 1996). Therefore, it is 
important not only to investigate the humoral response of each patient but also the CTL
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response. To do this would require the generation of CTL lines from the liver of 
infected individuals.
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Chapter 5 Results: Section 2
The Effect of Serum Storage Conditions on the Detection o f  
Hepatitis C Virus by the Polymerase Chain Reaction.
The currently available commercial assays for detection of HCV rely on detecting 
antibodies to recombinant cloned antigens. First-generation assays detected antibodies 
to the c l00-3, a fusion polypeptide representing nearly all of the NS4 region of the 
HCV genome (Kuo et al., 1989). The presence of antibodies to C l00 proved to be a 
marker of infection (Alter et al., 1989) but it became evident that this assay lacked 
specificity and sensitivity. False-positive results were common when screening low 
risk groups (McFarlane etal., 1990) The development of second- and third-generation 
assays, which have incorporated HCV recombinant antigens representing other regions 
of the genome, have increased the specificity and sensitivity of these serological assays 
but limitations in their use still exist. These assays are unable to distinguish between an 
ongoing or a resolved infection and there exists a considerable period of time between 
infection with the virus and appearance of detectable anti-HCV antibodies (Alter et al., 
1989; Farci et al., 1991). Since no universally successful ELISA to detect HCV 
antigens has yet been developed, detection of the virus itself is based upon detection of 
HCV RNA.
The direct detection of HCV RNA in serum or plasma is the most sensitive and 
specific marker for HCV infection in both symptomatic and asymptomatic patients. 
HCV RNA can be detected in the blood within a few days of infection, weeks before 
an increase in liver enzyme levels or viral antibody levels are detected (Shimizu et al., 
1990). Because of the low titre of HCV in blood (102-107 particles per ml) (Simmonds 
et al., 1990; Ulrich et al., 1990) amplification of HCV RNA is necessary by the 
reverse transcription-polymerase chain reaction (RT-PCR). However, RNA is easily
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degraded by contaminating RNases and therefore handling of specimens could greatly 
influence the results obtained by RT-PCR.
The ability to identify HCV infection by anti-HCV assays and detection of HCV 
RNA has resulted in numerous studies to evaluate the natural course of HCV infection. 
Most published studies are retrospective, relying on stored sera but few authors 
comment on the storage conditions. Problems experienced in attempting to amplify the 
hypervariable region of HCV from patient sera suggested that the storage conditions, 
especially the number of freeze-thaw cycles, may have affected the stability of the 
HCV RNA and hence the sensitivity of detection. The aim of this work was to study 
the effect of serum storage conditions on the detection of HCV RNA by RT-PCR.
5 .1  Processing of serum  samples
Fresh blood samples were collected from a known HCV positive renal transplant 
patient, infected with the virus since the early 1980's and an individual repeatedly 
negative for HCV RNA and anti-HCV antibodies. The blood was allowed to clot for 
2hrs at 4°C before being centrifuged at room temperature. The serum was removed 
and aliquoted into 800pl volumes into three tubes. Tube 1 was placed at 4°C, tube 2 at 
-20°C and tube 3 was further aliquoted into lOOjil volumes which were stored at - 
20°C for use in future experiments. Total time from collection of blood samples to 
obtaining serum was 2 hours 45 minutes. To estimate the titre of HCV RNA present, 
serial 10-fold dilutions of the serum in PBS were performed. RNA was extracted from 
lOOjal of sera using the acid guanidium thiocyanate method described in Chapter 3, 
section 3.5. Tube 1 was sampled at 14, 17, 19, 25 and 27 weeks and tube 2 after 1, 3, 
5, 7 and 10 successive freeze-thaw cycles (-20°C to room temperature).
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5 .2  HCV RNA RT-PCR Analysis
The extracted HCV RNA was reversed transcribed using random primer (pd(N)6 ) at 
25°C for 10 minutes, followed by 37°C for 55 minutes, with a final 95°C incubation 
for 5 minutes to inactivate the reverse transcriptase enzyme. A 'nested' PCR reaction 
was performed, using two primer pairs from the highly conserved 5' non coding 
region of the HCV genome (outer pair, HCV21 and EHCV24 and inner pair, HCV23 
and NCR4). Table 5.1 shows the sequence and position of the primers selected. 
Negative and positive controls were included in each round. Amplification was 
performed with an initial denaturation step of 4 minutes at 94°C, followed by 30 cycles 
of denaturation for 30 seconds at 94°C, annealing of primers for 45 seconds at 55°C 
and extension for 2.5 minutes at 70°C, followed by a final extension for 7 minutes at 
70°C. Amplified products were viewed under UV light on a 2% (w/v) agarose gel, 
stained with ethidium bromide.
5 .3  Effect of serum storage conditions on the detection of HCV RNA
To assess the effect of storage at 4°C and successive freeze-thawing of serum on the 
detection of HCV RNA, serial 10-fold dilutions of serum were performed and the viral 
RNA titre detectable by RT-PCR was determined. In the case of serum stored at 4°C 
the titre of viral RNA detectable was determined after only one run because the amount 
of serum stored was insufficient to perform a second run. For serum stored at -20°C 
and subjected to successive freeze-thawing the titre of viral RNA detectable was 
determined after two runs. Table 5.2 shows the results for the serum stored at 4°C. 
The titre of viral RNA detectable after 14, 17 and 27 weeks was 10'3, 10-2  and >10-2 
respectively, a 10-fold reduction in titre of HCV RNA detectable having occurred 
between 14 and 17 weeks, as shown in Figure 5.1. The detection of HCV RNA at a 
titre of >10-2  after 27 weeks was unexpected, so the serum was left for a further 30
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Table 5.2 HCV RNA Titres of serum samples stored at 4°C.
Storage time at 4°C Titre
14 weeks lO’3
17 weeks 1 0 '2
19 weeks 1 0 -2
25 weeks* > 1 0 -2
27 weeks* > 1 0 -2
57 weeks* UD
* Denotes sample was not tested at a dilution higher than 10' 2 because serum samples
- 3
stored at 4°C for 17 and 19 weeks tested negative for HCV RNA at 10 . In  hindsight
- 2  - 3such samples should have been tested at dilutions between 1 0  and 1 0  to determine 
the end-point dilution titre.
UD denotes undiluted serum sample.
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Chapter 5
weeks. HCV RNA in this serum sample, stored at 4°C for a total period of 57 weeks 
could be detected only in the undiluted sample (Figure 5.2), a 100-fold reduction in 
titre. In contrast a titre of 10~3 was detectable in a serum sample stored at -20°C for 57 
weeks, a 1000-fold difference in titre (Figure 5.2).
Each dilution of the serum stored at -20°C and subjected to successive freeze-thaw 
cycles was performed in duplicate (i.e. two separate, extraction and RT-PCR runs 
were performed). Table 5.3 shows the titre of RNA detectable after 1, 3, 5, 7 and 10 
freeze-thaw cycles. The titre detectable after 10 cycles was >10-2. An indeterminate 
result (positive/negative) was observed for the dilution of 1 0 -4 after one freeze-thaw 
cycle (Figure 5.3). Serum from tube 3 (which had not been previously thawed) was 
therefore diluted 1:100, 1:250, 1:500, 1:750 and 1:1000 and subjected to 1 and 10 
successive freeze-thaw cycles. Figure 5.4 shows the results of this work. The 
endpoint dilution after 10 freeze-thaw cycles was found to be 1:500 (approximately 10_ 
2-3). Thus, there is at least a 2-fold reduction in titre between the first and tenth freeze- 
thaw cycle.
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Table 5.3 HCV RNA Titres of serum samples subjected to 
freeze-thawing.
No. Freeze-Thaw  Cycles +/+
PCR Results 
+ /- -/- T itre
1 1 0 -3 1 0 -4 1 0 -5 10-3-10-4
3 1 0 -2 NS IO-3 1 0 -2
5 1 0 -2 NS 10-3 1 0 -2
7 * 10 -2 ND ND > 1 0 -2
1 0 * 1 0 -2 ND ND > 1 0 -2
* Denotes sample was not tested at a dilution higher than 10"2 because serum samples
.3
tested negative for HCV RNA at 10 after 3 and 5 freeze-thaw cycles. In hindsight
- 2  - 3such samples should have been tested at dilutions between 1 0  and 1 0  to determine 
the end-point dilution titre.
+/+ indicates both samples positive; +/-, one sample positive and the other negative;
-/- both samples negative.
NS denotes not seen.
ND denotes not done.
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F i g u r e  5 . 4  Gel electrophoresis of PCR amplified cDNA from the 5 ’NCR of 
serum subjected in duplicate to one freeze-thaw cycle (A) and 10 freeze-thaw 
cycles ( B ) .  HCV RNA was extracted from serially diluted serum, reverse
transcribed and amplified by PCR. lOpl of each product was run on a 2%
agarose gel. Lanes: (1,2) serum diluted 1:100; (3,4) serum diluted 1:250; (5, 10) 
extraction carry-over control; (6,7) serum diluted 1:500; (8, 9) serum diluted 
1:750; (11, 12) serum diluted 1:1000; (13) negative serum control; (14) positive 
serum control (15) negative control for reverse transcription reaction; (16, 17) 
negative control for first and second round PCR reactions. M, molecular weight 
marker (Boehringer Mannheim DNA molecular weight marker VI). Arrow 
denotes size of product. Mis-loading of product occurred in lanes 1 and 2 ( B ) .
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5.4 Discussion
The work presented in this chapter was undertaken to assess the effect of serum 
storage conditions on the detection of HCV RNA by RT-PCR. The storage conditions 
used in this study are common in diagnostic laboratories. It is therefore important to 
assess how such conditions affect the stability of HCV RNA. Unfortunately, there 
were several flaws in the study design and since it took more than a year, there was 
insufficient time to repeat it. Only one serum obtained from a single chronic HCV 
infected patient was used. Originally, blood from two chronic HCV infected patients 
was received but HCV RNA could not be consistently amplified from serum obtained 
from the second patient. From the work presented in this chapter, the actual loss in 
detectable levels of HCV RNA due to serum storage conditions cannot be fully 
assessed. No steps were taken to avoid possible bacterial contamination of the stored 
serum, which could influence the results obtained by RT-PCR. An inhibitor of 
bacterial growth such as sodium azide should have been added to the serum. The end­
point dilution titre of the serum should have been determined before the serum was 
stored at either 4°C or -20°C and at all sampling points. Due to an insufficient amount 
of serum stored at 4°C each dilution could not be performed in duplicate. In hindsight, 
titration of the cDNA could have been done to make up for the insufficient amount of 
serum.
The results of the study presented in this chapter, are in agreement with those of 
Busch et al. (1992), Cuypers et al. (1992), Wang et al. (1992) and Fong et al. (1993), 
with minimal loss in the level of HCV RNA detected in serum stored at 4°C, at -20°C 
and subjected to repeated freeze-thawing. The longest period of time sera were stored 
at 4°C in the aforementioned studies was 14 days when the end-point dilutions were 
1 0 -3.3 t 0  io ~5 (Cuypers et al., 1992). In the study presented here, semm was stored at 
4°C for 14 weeks before being sampled and the end-point dilution detectable by RT- 
PCR was 10-3. This indicates HCV RNA is relatively stable when serum is stored at 
4°C. However, over 57 weeks the end-point dilution detectable declined to 10°
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compared to 10' 3 for serum stored at -20°C over the same time period. Therefore, for 
long term storage, sera should be kept at -20°C. Minimal or no reduction in the level of 
HCV RNA detectable following serum storage at 4°C for 48 hours, 5 days and 7 days 
was observed in studies by Wang et al. (1992), Fong et a l (1993) and Busch et al.
(1992), respectively. In the study by Wang et al. all sera had been stored at -70°C 
prior to use, therefore the effect of storage conditions was not compared to freshly 
extracted RNA samples and in that by Busch et al. it is unclear if freshly extracted 
RNA from serum was used.
Repeated freeze-thawing of serum does not appear to affect the stability of HCV 
RNA. The detectable HCV RNA titre after 10 freeze-thaw cycles was 10-2 -7 
approximately (1:500 dilution) compared to 10' 3 (1:1000 dilution) after one-freeze- 
thaw cycle, a two-fold reduction in titre. The indeterminate result observed at 10"4 after 
one freeze-thaw cycle could have been followed up by testing serial dilutions between 
1:1000 and 1:10000 to obtain a more accurate end-point. The results obtained are in 
agreement with those of Fong et al (1993) who observed end-point dilutions of 10_1 
to 10‘3 in five sets of patient sera subjected to five freeze-thaw cycles. An end-point 
dilution of 1 0 -2 was observed after five freeze-thaw cycles in the study presented here. 
Despite methodological problems in this study, it is clear HCV RNA appears to be 
stable despite repeated freeze-thawing.
Serum stored continuously at -20°C had a HCV RNA titre of between 10-3 to 10_ 
4. Titres of 10_1 to 10-4 were detected by Fong et al. (1993).
The effect on the stability of HCV RNA when serum is stored at room 
temperature was not addressed. Busch et a l (1992) found a reduction in detectable 
HCV RNA titre of 2 log units in serum stored at room temperature for 7 days. A 3 to 4 
log unit reduction was found in serum and whole EDTA-blood stored at room 
temperature after 8  to 14 days by Cuypers et a l (1992). In contrast to these two 
studies, Wang et al. (1992) and Fong et a l (1993) observed no reduction in HCV 
RNA titre after storage at room temperature for 48 hours and 5 days, respectively. The 
results of a study by Davis et a l (1994) using the branched-DNA (b-DNA) assay,
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which determines quantitatively levels of HCV RNA present in serum, to assess the 
optimal conditions for storage agree with those of Busch et a l and Cuypers et a l Their 
results showed a 4.1 % and 6.9% loss of HCV RNA from serum stored for 2 hours at 
room temperature and 4°C, respectively. After storage for 12 hours at room 
temperature this loss increased to 16.6% but no additional loss was observed at 4°C.
The results of this study and those from other research groups show that the 
sensitivity of RT-PCR is not significantly affected by serum storage conditions. 
Repeated freeze-thawing of serum or storage at 4°C does not result in a substantial 
reduction in HCV RNA levels detectable by RT-PCR compared to continuous storage 
at -20°C, indicating that HCV RNA present in serum is relatively resistant to 
degradation. But it is important to resolve the differences observed in studies 
concerning storage of serum at room temperature. Any reduction in detection of HCV 
RNA by RT-PCR must be considered when interpreting results from studies using 
stored serum where the investigators failed to state whether all samples were handled 
and stored under uniform conditions. Qualitatively, samples with a low HCV RNA 
titre may be more sensitive to serum storage conditions. Therefore, serum samples 
collected for confirmation of HCV infection or to be stored for future research 
purposes should be separated within 2-3 hours of blood collection and stored at -20°C.
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Chapter 6 Results: Section 3
Construction of a control HCV RNA transcript for  
quantitative analysis of HCV infection.
The technique of RT-PCR is the method of choice for the amplification of HCV RNA, 
since it requires only small amounts of nucleic acid. However, PCR is qualitative not 
quantitative, indicating the presence or absence of target sequence only. Because the 
amount of PCR product increases exponentially with each cycle of amplification until it 
reaches a plateau, a difference in any of the variables that effect the efficiency of 
amplification no matter how small, can dramatically alter product yield. The need to 
measure the level of HCV RNA present is important for studies on the relationship 
between HCV RNA levels present in serum, plasma or liver tissue and the natural 
course of acute and chronic HCV infection and for evaluation of response of HCV 
infected individuals to anti-HCV therapies.
At present quantitation of HCV RNA is done either by limiting dilution analysis 
or competitive PCR. Limiting dilution analysis determines the end point titre of HCV 
RNA by performing RT-PCR on serial dilutions of extracted HCV RNA. To exclude 
variation in sensitivity between RT-PCR assays, calibration of each assay with a 
purified and quantitated control sample is performed (Kobayashi et al., 1993). With 
competitive PCR, the amount of HCV RNA in serum or plasma is quantitated in a RT- 
PCR assay by co-amplification of the target HCV RNA with known amounts of 
synthetic control HCV RNA (Kaneko et al., 1992; Hagiwara et al., 1993; Kato et al., 
1993b; Naito et al., 1994). The synthetic control HCV RNA differs in some way from 
the target sequence; it may differ in length, contain a unique restriction enzyme site or 
unique sequence to distinguish it from the target HCV RNA. The same primers are 
used to amplify the target and synthetic control HCV RNA allowing both target and 
synthetic control HCV RNA to be amplified with equal efficiency, therefore the ratio of
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the amplified products reflects the initial amount of target HCV RNA versus that of the 
known added amount of synthetic control HCV RNA.
The work described in this chapter was undertaken to provide control HCV RNA 
to allow quantitative analysis to be performed. This control HCV RNA would allow 
the sensitivity and efficiency of the RNA extraction, RT and PCR methods employed 
in our laboratory to be calculated and studies on the natural course of HCV infection in 
renal dialysis patients to be undertaken. To synthesise the control HCV RNA, PCR 
products amplified from the 5' non coding and core region of HCV were used as 
template to introduce a unique 28 nucleotide scramble sequence between nucleotide 
position -194 to -171, numbering according to Choo et al. (1991), using PCR. This 
region of the virus was chosen because it is highly conserved among HCV isolates. 
The primers Econll and Econl2 were designed with a unique sequence of bases 
towards the 5' end of each primer, see Figure 6.1. Within the unique sequence an 
EcoRl restriction enzyme site was incorporated. The first 10 bases of the unique 
sequence of primer Econl 1 is complementary to the first 10 bases of Econl2 to allow 
products amplified with Econll and Econl2 to anneal together during amplification, 
resulting in amplification of a product incorporating the unique sequence of bases, 
Figure 6.2 outlines how the control HCV RNA would be synthesised. The resultant 
PCR product would then be purified to remove PCR reaction components, primers and 
other artefacts. A subsequent round of PCR would then be performed using primers 
containing bacteriophage T7 promoter sequences, to incorporate the T7 promoter 
sequences into the PCR product. Internal control HCV RNA would then be 
transcribed.
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Figure 6.2 Schematic diagram outlining the method used to construct control 
HCV RNA transcripts.
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6 .1 Oligonucleotide primers
Oligonucleotide primers were derived from the 5' non coding and core region of the 
HCV isolate HCV-1 (Choo et a l ., 1991). The following primers were used: HCV21 
(sense; 5'-CGACACTCCACCATGAATCAC-3'; -322 to -302 nts.); HCV22 (anti­
sense; 5'-GAGGTTTAGGATTCTGCTCATG-3'; -1 to 22 nts.); EPT1 (sense; 5'- 
GGCGTTAGTATGAGTGTCGT-3'; -255 to -236 nts.); SF3AS (antisense; 5'- 
AGG A AG AT AG AG AAAG AGC AAC-3'; 512 to 533 nts.); CPU (antisense; 5'- 
GAAGATAGAGAAAGAGCAACCA-3'; 510 to 531 nts.); Econll (sense; 5'- 
AGGAATTCGCCAGGCGTCCAGGACGACCGGGT-3': -180 to -151nts.) and 
Econ 12 (antisense; 5 '-GCGAATTCCTCTGGCCTTAACGACCACTATGGCTC- 
TC-3'; -209 to -173nts.), numbering according to Choo et a l . (1991). The sequences 
in bold in Econl 1 and Econ 12 are the unique sequence of bases and those underlined 
are the 10 complementary bases. Primers were synthesised and purified as described 
Chapter 3 section 3.1. The concentration of each primer was determined by its optical 
density at 260nm. Primers were used at a concentration of 40 pmol per PCR reaction.
6 .2  PCR amplification
To synthesise control HCV RNA, first round PCR products previously amplified with 
primer pairs HCV21 and HCV22, product one, and EPT1 and SF3AS, product two, 
were used to introduce the unique 28 nucleotide scramble sequence. Two PCR 
reactions were performed, product one was used as template for primer pair HCV21 
and Econ 12 and product two for primer pair Econll and CPU. Amplification was 
performed with an initial denaturation step of 4 minutes at 94°C followed by 2 cycles 
of denaturation for 30 seconds at 94°C, annealing of primers for 40 seconds at 45°C 
and extension for 2.5 minutes at 70°C, followed by 28 cycles of amplification with 
annealing of primers occurring at 55°C for 40 seconds and a final extension step of 7
100
Chapter 6
minutes at 70°C. Two products the correct size were generated (Figure 6.3). The 
product generated by primer pair Econl 1 and CPI 1 (715 base pairs) produced a strong 
band of DNA when lOjil of PCR product was run on EtBr stained 2% low melting 
point agarose gel and visualised under longwave UV light. This product band was 
excised from the gel. However, the smaller product generated by HCV21 and Econ 12 
(151 base pairs) was very faint, suggesting that this primer combination did not work 
well under the PCR conditions used. Since equal amounts of both products was 
needed, the PCR using primers HCV21 and Econ 12 was repeated, only this time 5 
cycles of amplification were performed with an annealing temperature of 45°C instead 
of 2 cycles. This made no difference to the amount of product generated. Problems 
with plasmid contamination in the laboratory had limited the choice of primers that 
could be used. Primer HCV21 was the outer sense primer of choice in the laboratory to 
amplify the 5' non coding region of HCV. In synthesising the control HCV RNA, it 
was important that it too could be amplified with HCV21, therefore finding an 
alternative sense primer to use with Econ 12 was not feasible. Therefore, to obtain 
equal amounts of the two PCR products, the technique of ‘hot start’ PCR was used, 
with several PCR reactions using HCV21 and Econ 12 being performed. The resulting 
products were run on a 2 % low melting point agarose gel, the product band excised 
and the DNA extracted and re-amplified. To check that equal amounts of each PCR 
reaction product was being added, lOjil of each PCR product was run out on a 2% low 
melting point agarose gel and the intensity of each product band was visualised under 
longwave UV light . The product bands from both PCR reactions were excised from 
the gel, added to the one eppendorf tube, melted and vortexed to mix to be used as 
template in a further round of amplification involving the primers HCV21 and CPI 1.
To amplify the agarose gel template, the appropriate amount of PCR buffer, 
dNTPs, distilled water and Taq polymerase were added to a 0.5ml eppendorf, to 
which a wax gem was added and melted by heating the tube for 10 minutes at 70°C. 
2jl1 of melted agarose products, were then added. Denaturation for 4 minutes at 94°C 
was performed, followed by 3 cycles of denaturation at 94°C for 30 seconds,
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Chapter 6
annealing at 45°C for 40 seconds and extension at 70°C for 2.5 minutes, to allow the 
two products to anneal together at the region where they were complementary to one 
another, after which the primers HCV21 and CPU were added and 25 cycles of 
amplification were performed using the PCR conditions described above, except 
annealing occurred at 55°C and there was a final extension step of 7 minutes at 70°C. 
The resulting PCR product is shown in Figure 6.4. A product the correct size, 854 
bases, was produced but smaller products were also generated. The correct size 
product band was excised and the product reamplified. An EcoRl restriction digest 
was then performed on the amplified product to check for the 28 nucleotide scramble 
sequence (Figure 6.5). A plasmid with known EcoRl sites was included as a control 
to confirm complete digestion had taken place. There was no digestion of the amplified 
product suggesting that the 28 nucleotide scramble sequence had not been 
incorporated. However, the size of products generated by PCR was all correct 
suggesting incorporation had taken place. To resolve this issue, the product generated 
by the primer pair HCV21/CP11 was nucleotide sequenced.
6 .3  Single stranded sequencing of PCR product with unique scramble 
sequence of bases
Single stranded sequencing of the product amplified by primer pair HCV21/CP11 was 
performed using Dynabead method, as described in Chapter 3 sections 3.9.2 and 3.10. 
The biotin labelled primers used to generate single stranded DNA were HCV23 (sense; 
5 '-T C ACT CCCCTGTG AGG A ACT-3'; -305 to -286 nts.) and NCR4 (antisense; 5'- 
GCACCCTATCAGGCAGT-31; -54 to -37 nts.), (numbering according to Choo et al.
(1991). Figure 6 .6  shows the resulting autoradiograph. Up to and after the point 
where incorporation of the 28bp unique scramble sequence of bases should occur the 
sequence obtained is correct for the 5'NCR of HCV (Figure 6.7). However, at each 
nucleotide position (between -194 and -171) where the scramble sequence (5*-
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Figure 6.4 Agarose gel electrophoresis of the PCR product generated by 
amplifying the Econl 1 /CP 11 and HCV21/Econl2 generated PCR fragments 
with the primers Econl 1 and Econ 12. Lane 1, the resultant Econl 1/Econ 12 
amplified fragment; lane 2, negative control for the PCR reaction. M, 
molecular weight marker (Boehringer Mannheim DNA molecular weight 
marker VI).
Figure 6.5 Agarose gel electrophoresis of Econ 11/Econ 12 PCR 
product EcoRl restriction digest. Lane 1, digested Econ 11/Econ 12 
fragment; lane2, undigested Econl 1 /Econ 12 fragment; lane3, digested 
control plasmid; lane4, undigested control plasmid. M, molecular 
weight marker (Gibco, BRL lOObp DNA ladder).
Figure 6.6 Direct DNA sequencing of the Econl l/Econl2 amplified PCR 
product. Both the sense and antisense sequencing direction are shown. The arrows 
indicate the incorporation site of the 28bp unique scramble sequence.
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GTTAAGGCCAGAGGAATTCGCCAGGCGT-3 ’) should have been incorporated, 
two bases are present (Figure 6.7). The sequence of the mixed base positions appears 
to indicate the presence of both control and native HCV DNA in the final PCR product. 
The sequence of native HCV between the primers Econ 12 and Econll is 5’- 
TGCGCAACCGGTGAGTACACCGGAATTG-3’, suggesting that at some stage 
during the synthesis of the PCR product “contamination” with native HCV DNA has 
occurred. If time had permitted, one could resolve this by cloning the PCR product and 
selecting clones with the desired insert.
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1 46
TAGCCATGGCGTTAGTATGAGTGTCGTACAGCCTCCAGGACCCCCC
47 90
CTCCCGGGAGAGCCATAGTGGTCNNNNNNNNNNNNNNNNNNNNN
91 136
NNNNNNNCCAGGACGACCGGGTCCTTTCTTGGATAAAACCCGCTCA
137 177
ATGCCTGGAGATTTGGGCGTGCCCCCGCAAGACTGCTRGCC
Figure 6.7 Sequence of PCR product (primers HCV21/CP11). The sequence in 
blue and red type face denotes the HCV sequence of primers Econl2 (antisense) 
and Econl 1 (sense), respectively.
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6.4 Discussion
The work presented in this chapter was undertaken to provide control HCV-RNA 
transcripts for quantitative competitive RNA PCR analysis. Several authors have used 
either internal control cDNA or HCV RNA to quantitiate HCV RNA levels (Kaneko et 
a l,  1992; Hagiwara et a l, 1993; Kato et a l, 1993). In the study by Kaneko et al.
(1992) competitive PCR was used to analyse serial changes in serum HCV RNA levels 
from patients with chronic hepatitis C who had received a-interferon treatment. A 
deletion mutant HCV cDNA plasmid was used as the internal control for competitive 
PCR. The control plasmid was constructed by cloning a fragment of HCV cDNA into 
a pGEM vector and performing restriction digests on the cloned HCV cDNA. The 
resultant subclone contained the same primer sites as target cDNA but it was 106 base 
pairs shorter. Target HCV cDNA, reverse transcribed from HCV RNA extracted from 
patient sera, was co-amplified with known amounts of the deletion mutant HCV- 
cDNA. The PCR products were visualised by UV fluorescence after electrophoresis. 
Two product bands were seen, the smaller corresponding to the internal control HCV. 
At the point where the amount of target HCV and internal control HCV concentrations 
are equivalent (i.e. 1:1 ratio), the PCR product bands were of equal intensity.
Performing competitive PCR using HCV cDNA as an internal control does not 
take into account the efficiency of the RNA extraction method or reverse transcription 
reaction. To overcome this, control HCV RNA transcripts are produced which can be 
added in known amounts to patient serum or plasma and hence be co- extracted, 
reverse transcribed and amplified. Studies by Hagiwara et al. (1993) and Kato et a l 
(1993b) used control HCV RNA transcripts to quantitate HCV RNA levels. Both 
groups used site-directed mutagenesis by RT-PCR and in vitro transcription to produce 
control HCV RNA transcripts. The resultant product was cloned into a vector with a 
promoter to generate the RNA transcripts.
The method described in this chapter to produce control HCV RNA transcripts, 
with a unique 28 base sequence and EcoRl restriction site (Figure. 6.2), was designed
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to avoid cloning the PCR product into a vector containing a T7 promoter to produce 
RNA transcripts, thus avoiding the risk of PCR contamination in the laboratory. 
Unfortunately, “contamination” appears to have occurred at some stage during the 
synthesis of the PCR product which was to be used to produce the control HCV RNA 
transcripts, which resulted in a heterogeneous product. The sequencing result suggests 
“contamination” with native HCV cDNA rather than mis-annealing of the two 
products. If mis-annealing had occurred, the two strands would not overlap by 10 
bases every time resulting in a product of fixed length but one would expect mixed 
base positions outwith nucleotide positions -194 to -171 and products of varying 
length. This is not what is observed. The contamination with native HCV cDNA 
probably occurred during amplification of template DNA with the primer combinations 
HCV21/Econl2 and E conll/C P ll. Although during amplification the shorter cDNA 
copies, with both ends defined by the primer sequences, are amplified, the original 
full-length template DNA will remain, resulting in copies of native HCV cDNA being 
present. In addition, there may have been mispriming upstream. Since the primer 
combination Econl 1/CPI 1 produced a more diffuse PCR product band than the primer 
combination HCV21/Econl2, it is more likely that the Econl 1/CPI 1 PCR reaction was 
the source of contamination. The size of the “short product” DNA and original full- 
length template DNA produced by the primer combination Econll/C Pll are 715 and 
787 base pairs, respectively. Because the original full-length template DNA differs in 
size from the “short product” DNA by only 72 base pairs, it is possible it was excised 
along with the “short product” from the low melting point agarose gel. If both native 
and control HCV cDNA are present, why did the restriction digest with EcoRl not cut 
the control HCV cDNA present ? Perhaps it did but the amount of resultant product 
was present in insufficient quantities to be detected by gel electrophoresis. To prove 
the presence of native HCV DNA in the PCR product, the product would need to be 
cloned into bacteria and the resultant clones sequenced. This could also allow selection 
of clones with the desired insert to act as template for control RNA production.
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In a paper by Gretch et al. (1994) reporting the relationship between HCV RNA 
levels and HCV pathogenesis, internal control HCV RNA was synthesised using a 
similar technique to the one described in this chapter. A 60 base pair Salmonella 
typhimurium DNA insert was introduced into a PCR product amplified from the HCV 
5’ NCR. Instead of 10 base pairs of overlapping sequence between the two internal 
primers used to introduce the DNA insert into the PCR product, Gretch et al. (1994) 
synthesised two internal primers JHC160 (sense) and JHC161 (antisense), with 60 
base pairs of overlapping S.typhimurium sequence. However, after performing two 
separate PCR reactions with the primers JHC160 and JHC51 (HCV specific antisense 
primer) and JHC161 and JHC93 (HCV specific sense primer), the resultant double 
stranded DNA products were digested with lambda exonuclease to produce single 
stranded DNA. The single stranded DNA products were then purified before being 
reamplified with the primers JHC93 and JHC51. A further round of PCR was then 
performed with primers containing bacteriophage T7 promoter sequences to allow in 
vitro transcription. If the method described by Gretch et al. (1994) had been followed, 
the problem of contamination with native HCV DNA may not have occurred. Also, 
after each round of PCR, the amplified DNA should have been purified, thereby 
removing any PCR reaction primers and non-specific products which may interfere 
with the subsequent round of amplification. Another factor to be considered if 
repeating the work presented here, would be to quantitiate the HCV21/Econl2 and 
E conll/C Pll PCR product DNA by measuring the optical density of the DNA at 
260nm, quantitating the products using this method would perhaps be more accurate. 
Thus, the actual amount of each product present before they are co-amplified together 
is known.
106
Chapter 6
6 . 4 . 1  Future Studies
The ability to measure the level of HCV RNA present in serum or plasma from infected 
persons is important in understanding the pathogenesis of HCV infection, deciding 
when to administer anti-viral therapy and assessing treatment efficacy. The findings of 
Gretch et al. (1994) and Naito et al. (1994) indicate that high levels of HCV RNA may 
correlate with the progression of liver disease. It would therefore, be of interest to 
measure the HCV RNA levels present in the three renal dialysis patients, studied in 
Chapter 4, to assess the relationship between the level of HCV RNA and the 
emergence of new genetic variants.
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Hepatocyte damage in HCV infected individuals may result from direct cytopathic 
action of the virus or may be the result of the host’s immune response. RNA viruses 
are noted for their variability in genome sequence, as has been shown in vivo for HCV 
(Martell et al., 1992). Aspects of genetic variation of HCV which could influence 
pathogenesis are (i) antigenic variation and (ii) variants that differ in virulence. 
Antigenic variation can lead to escape from the host’s humoral and cell-mediated 
immune responses. If damage is due to a direct cytopathic action of the virus, a new 
genetic variant would be expected to emerge at any time. Alternatively, if damage was 
as a result of the destruction of infected hepatocytes by the host’s immune system, a 
new genetic variant would appear after an elevation in ALT. It is widely believed that 
variation in the HVR1 domain in E2 is driven by immune selection pressure. The 
findings of the study described in Chapter 4 showed sequence variation of the E2 
HVR1 domain in the predominant virus population to occur during the natural course 
of hepatitis C infection in renal dialysis patients. Unfortunately, the results of this 
study did not show an association between the emergence of new sequence variants 
and either mechanism of liver damage, based on ALT levels as a measurement of liver 
damage. At present, liver biopsies are the only way to evaluate accurately the severity 
of liver disease but performing biopsies frequently to monitor liver dysfunction is not 
feasible and since there is no alternative biochemical marker, ALT levels are 
monitored.
It is possible that sequence variants play another role which is selectively 
advantageous for the virus. Genetic mutation of the virus may result in the generation 
of variants that differ in virulence. This may affect the severity and progression of 
disease. The HVR1 may be important for cell tropism, the formation of virus/antibody 
complexes or viral entry. It is also possible that the HVR1 domain itself has no role in 
viral persistence. Before understanding what role, if any, HVR1 variants play in
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persistence of HCV within the host, several issues will have to be addressed. These 
are: (1) the biological function of HVR1; (2) whether antibodies to epitopes in the 
HVR1 are neutralising; (3) whether cytotoxic T-cells against HCV provide a protective 
response against the virus; (4) the structure of the envelope glycoproteins. Rosa et al. 
(1996) have recently provided evidence that although antibodies to the HVR1 domain 
are neutralising, the protection induced by vaccination with recombinant envelope 
proteins is not dependent on them.
The structure of the HCV envelope proteins may be similar to those of alpha- and 
flaviviruses. Like the two envelope glycoproteins (El and E2) of Semliki Forest virus 
(SFV), an alphavirus, the El and E2 proteins of HCV appear to form a complex 
(Grakoui et al., 1993a; Ralston et al., 1993). Indeed chimpanzees vaccinated with 
recombinant E1/E2 protein were shown to be protected upon challenge with the virus 
(Choo etal., 1994). The El and E2 proteins of SFV form a heterohexameric complex 
that projects out from the surface. Although, structurally different from the influenza 
HA protein, a solid trimer, SFV also undergoes a pH-induced conformational change 
to allow the fusion protein to associate with the plasma membrane of the cell. The 
fusion protein (El) is brought to the surface in the form of a homotrimer (Helenius, 
1995). Alternatively, the structure adopted by the HCV envelope proteins may be 
similar to the major envelope protein of the flavivirus tick-borne encephalitis (TBE) 
virus. Unlike SFV, influenza and HIV membrane proteins, the major envelope protein 
of TBE is a flat, elongated homodimer extending laterally along and parallel to the 
membrane surface. TBE, like influenza and alphaviruses, enters the cell via an 
endosome and a low pH-conformational change occurs. Rey et al. (1995) has 
suggested that this conformational change allows the protein to protrude from the 
surface i.e. stand up and interact with the cell to allow fusion. It is possible that the 
structure adopted by the HCV envelope proteins is such that HVR1 domain is not 
exposed on the surface of the virion and therefore, not exposed to immune selection 
pressure. It has been suggested that the gpl20 in HIV exists as a tetrameric protein 
with the V3 loop being in the middle of it unexposed to the host immune system and
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under no structural constraints, therefore it can mutate at will (Howard Marsden, 
personal communication). One could speculate that the sequence variation displayed by 
HVR1 arises because this region is under no structural constraint to remain conserved.
A modified, non-pathogenic strain of an infectious virus, able to stimulate the 
host’s immune system but whose replication and spread is impaired compared to the 
wild type virus, may be considered an ideal vaccine. The favoured type of vaccine 
against viruses in the past has been live attenuated virus. Vaccines of this nature are 
able to stimulate both arms of the immune system. The live attenuated virus will 
encounter the same cells of the host’s immune system as the wild type virus and so 
stimulate them to respond in a similar manner to that seen in a natural infection. 
Antibodies and T-cells are produced to a large number of epitopes that give rise to a 
large population of memory cells and a high level of neutralising antibody. However, 
the disadvantage of attenuated virus vaccines is the possibility of reversion to a virulent 
form. For many viral vaccines, surface antigens of the virus are among the most 
important to elicit neutralising antibodies. In the case of HCV, the envelope 
glycoproteins El and E2 are likely to be the targets of the host’s humoral immune 
response. Neutralising antibodies against the envelope proteins of HCV would prevent 
the virus from infecting hepatocytes. The findings of Choo et al. (1994) demonstrated 
that chimpanzees vaccinated with recombinant E1/E2 protein were protected from 
infection. However, by mutating the genes encoding the El and E2 proteins the virus 
could evade the host’s humoral immune response. The E2 HVR1 domain in particular 
is highly variable and appears to contain neutralising epitope(s) (Zibert et al., 1995). If 
the HVR1 domain were to contain the only neutralising epitope(s) of the virus, 
neutralising antibodies induced by vaccination may not afford protection from infection 
because of the sequence variation displayed by this region between different HCV 
variants. In terms of developing an effective vaccine against HCV it will be important 
to identify a region of the genome which contains conserved epitopes, so that the 
response elicited will protect against infection from all strains. Recent evidence 
suggests that at least two neutralising epitopes are present on the E2 protein, one of
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which may be conserved in some infected individuals (Rosa et al., 1996). Yet, despite 
this finding it may prove difficult to develop a multivalent vaccine against HCV which 
elicits a neutralising antibody titre which is high enough to protect against infection, 
since HCV infection elicits low or no neutralising antibody titres and chimpanzees can 
be reinfected with same homologous strain (Farci et al., 1992; Rosa et al., 1996). 
Thus, in the case of HCV a vaccine capable of stimulating a good cell-mediated 
immune response may be of more importance, especially it’s ability to stimulate a CTL 
response in the vaccinee.
A new approach to immunisation is the use of DNA vaccines. Such vaccines are 
plasmids that contain the gene(s) for the antigenic portion of the target virus. By 
injecting naked DNA into a person both humoral and cell-mediated responses are 
induced but naked DNA appears, in animals models at least, to stimulate cell-mediated 
immunity more efficiently than a live attenuated vaccine (McDonnell & Askari, 1996). 
The naked DNA enters the host cell, where it is expressed and the corresponding 
protein is synthesised inside the cell, allowing the viral protein to enter the MHC class 
I pathway and stimulate a CTL response. One advantage a DNA vaccine has over a 
standard live attenuated vaccine is that genes from several different strains could be 
included on the same plasmid and a multivalent response could be elicited. This could 
prove useful if no one conserved epitope(s) exists between all HCV variants.
The second part of the work presented in this thesis was aimed at determining 
whether serum storage conditions could affect the detection of HCV RNA by RT- 
PCR. As a result of difficulties experienced in amplifying the HVR1 region from 
stored patient sera, it was important to consider what effect, if any, storage conditions 
had on the stability of HCV RNA. The study described in Chapter 4 of this thesis like 
many other published studies was retrospective. The results of the work described in 
Chapter 5 showed that HCV RNA was relatively stable despite prolonged storage at 
4°C or successive freeze-thaw cycles. The results of this work are also important from 
a diagnostic viewpoint. When a person becomes infected with HCV it may be several 
weeks or months before seroconversion occurs. If so, then it is important to be able to
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go back and test sera which may have been taken from the patient before 
seroconversion for the presence of HCV RNA so that the time of infection may be 
known.
The need to measure the level of HCV RNA is important for studies on the 
relationship between HCV RNA levels in serum or liver tissue and the evaluation of 
response of HCV infected individuals to anti-HCV therapies. It is also important in 
studying the natural course of acute and chronic infection. For these reasons I 
attempted to construct control HCV RNA transcripts for quantitative analysis of the 
HCV RNA levels in patient serum, notably that of the three renal dialysis patients 
studied in Chapter 4, to assess the relationship between the level of HCV RNA in 
patient serum and the emergence of HVR1 genetic variants. Unfortunately, a problem 
with contamination prevented the construction of control PCR products. Cloning of the 
resultant product would allow the control cDNA to be selected, from which RNA 
transcripts could be synthesised.
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